The role of nitric oxide in hindlimb remote ischaemic preconditioning of the liver by Abu-Amara, M.
 1 
 
The Role of Nitric Oxide in Hindlimb Remote  
Ischaemic Preconditioning of the Liver 
 
 
Mahmoud Abu-Amara 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
University College London 
 
 
 
 
 
 
University Department of Surgery 
University College Medical School, Royal Free Campus 
University College London 
 
 2 
I, Mahmoud Abu-Amara confirm that the work presented in this thesis is my own. 
Help and contribution of others to this work is specified in the acknowledgement 
section. Where information has been derived from other sources, I confirm that this 
has been indicated in the thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
This thesis is dedicated to my wife Lubna and our children Ameen, Yousef, and 
Mariam, for their support and understanding. I also dedicate this thesis to my mother 
and late father, who have been a guiding light throughout my education and career. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
Abstract 
 Ischaemia reperfusion (IR) injury is a major contributor to morbidity and mortality 
following liver resection and transplantation. Hindlimb remote ischaemic 
preconditioning (RIPC) reduces liver IR injury but the mechanisms underlying this 
protection are unknown. This thesis evaluated the effects of RIPC on the early phase 
of liver IR injury in a new mouse model. This model was used to assess the role of 
the nitric oxide (NO) pathway in mediating the protective effects of RIPC on liver 
IR injury.  
 
In the initial experiments wild type C57BL/6 mice were used to establish a new 
model of hindlimb RIPC that protects against liver IR injury. The new experimental 
model hindlimb protocol consisted of 6 cycles of 4 minutes of femoral vessel 
clamping followed by 4 minutes of reperfusion. The IR protocol consisted of a well-
described 40 minutes of lobar liver (70%) ischaemia followed by 2 hours 
reperfusion. This hindlimb RIPC model resulted in significant reductions in liver IR 
injury, as evaluated by plasma liver transaminases levels, histopathological scores, 
and ultrastructural assessment of cellular damage in the liver. In addition hindlimb 
RIPC preserved the hepatic microcirculatory blood flow (MBF) in livers subjected 
to IR.  
 
In subsequent experiments administration of the selective NO scavenger C-PTIO to 
wild type mice abrogated the protective effects of limb RIPC on liver IR injury. In 
addition the RIPC-induced preservation of hepatic MBF was attenuated by C-PTIO 
administration. In contrast to the protective effects of limb RIPC on liver IR injury 
in wild type mice; mice lacking the constitutively expressed NO synthase (eNOS-/-) 
 5 
enzyme were not protected against liver IR injury by hindlimb RIPC, and MBF 
measurements in these mice showed no benefit of RIPC on the microcirculation. In 
wild type mice hepatic and limb eNOS protein expression was similar among 
preconditioned and non-preconditioned animals. In comparison expression of the 
inducible NOS (iNOS) isoform was only seen in preconditioned animals.    
 
In order to elicit the pathway through which RIPC-derived NO protects against liver 
IR injury, plasma nitrite and nitrate (NOx) levels were quantified in wild type 
animals and shown to be significantly elevated in preconditioned compared to non-
preconditioned animals. However, intravenous administration of exogenous nitrite to 
eNOS-/- mice undergoing liver IR injury failed to mimic the protective effects of 
RIPC-derived endogenous NOx in wild types. Administration of the soluble 
guanylyl cyclase (sGC) inhibitor ODQ showed a trend indicating reversal of the 
protective effects of RIPC on liver IR injury but this did not reach statistical 
significance. ODQ significantly annulled the protective effects of limb RIPC on 
hepatic MBF during liver reperfusion. Measurement of hepatic cyclic GMP levels in 
wild type animals showed a significant increase in animals subjected to limb RIPC 
only compared to sham. However there was no difference in the cGMP levels in the 
RIPC + IR compared to the IR group.   
 
In conclusion this thesis has described a new mouse model of limb RIPC that 
protects against liver IR injury. It was also shown that NO and eNOS are essential in 
mediating the protective effects of limb RIPC on liver IR injury. Endogenous NOx 
metabolites of NO play a crucial role in RIPC induced protection. The hepatic sGC-
cGMP pathway is at least partially involved in RIPC-induced liver protection.          
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1.1 Clinical importance of liver ischaemia reperfusion injury 
Ischaemia reperfusion (IR) injury results from a prolonged ischaemic insult followed 
by restoration of blood perfusion. It affects all oxygen dependent cells that rely on 
an uninterrupted blood supply. These aerobic cells require mitochondrial oxidative 
phosphorylation for their energy supply. Consequently all aerobically metabolising 
tissues and organs (central nervous system, intra-thoracic, and intra-abdominal 
organs; as well as blood vessels, skeletal muscle, and adipo-cutaneous tissues) are 
potential targets of IR injury (1).   
 
Significant liver IR injury during surgical resection is commonly a consequence of 
prolonged portal triad clamping followed by reperfusion, performed as an elective 
pre-planned procedure or as an emergent manoeuvre, to control excessive bleeding 
from the cut hepatic surface (2). Transplantation of the liver can also lead to IR 
injury. Here, the damage is sustained during cold preservation of the liver following 
explantation from the donor, and during subsequent warm reperfusion at 
implantation into the recipient (3). In non-heart beating transplantation there is 
additional warm ischaemic damage until hepatic cold perfusion is commenced. 
Importantly however, liver dysfunction in IR injury is not solely dependent on blood 
flow interruption, but is also seen with excessive handling and mobilisation of the 
liver during resection or procurement in transplantation, even without blood supply 
interruption in the former and regardless of its duration in the latter (4). This is 
mostly due to hepatic microcirculatory disturbances, and in some cases to hepatic 
artery vasospasm (4). Systemic low flow states and hypoxia such as is encountered 
in haemorrhage (5), sepsis, congestive cardiac failure, trauma, and respiratory failure 
may also lead to liver IR injury (6).  
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The degree of IR injury sustained is dependent on the length and method of 
ischaemia applied to the liver, as well as the background liver condition. Patients 
that undergo short intermittent periods of ischaemia sustain less liver dysfunction 
compared to those receiving a continuous period of ischaemia (7). This is especially 
the case in patients with underlying cirrhosis or steatosis (7). Animal studies also 
support the notion that the background liver parenchymal condition significantly 
determines the degree of tolerance to IR. Animal models of steatosis and cirrhosis 
exhibit worse liver damage when subjected to IR compared to those with normal 
livers (8,9). Other determinants of liver susceptibility to IR injury include: age – 
older livers exhibit more damage compared to young ones (10), and gender – in 
animal models males tolerate ischaemic insults less than females, however there is 
insufficient evidence for a firm clinical recommendation on the role of gender in 
liver IR injury (11). Systemic and localised neo-adjuvant chemotherapy is 
increasingly being used to down stage liver tumours prior to surgical resection. 
There is increasing evidence that, contrary to instinctive beliefs, neo-adjuvant 
chemotherapy does not increase liver susceptibility to IR injury (12-14). In fact, 
through suppression of inflammatory pathways, chemotherapy may attenuate the IR 
injury (12-14).  
 
In the mildest form of IR injury sustained during liver resections, liver transaminase 
enzymes are elevated in the circulation. More severe insults lead to clinical liver 
dysfunction and progressive failure. Direct IR to the liver can also result in distant 
organ dysfunction due to remote IR injury. Lungs (15), heart (16), kidneys (17), and 
blood vessels (18) have all been shown to sustain remote dysfunction secondary to 
direct liver IR. Humoral factors such as reactive free radicals and cytokines released 
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from kupffer cells are the main mediators of liver – induced remote IR injury (19-
22). Substantial IR injury sustained during liver transplantations increase the 
incidence of primary graft non-function, primary graft dysfunction, and biliary 
strictures (23,24). Hepatic non-function and intra-hepatic biliary strictures in 
transplantation, and failure of the remnant liver in resectional surgery usually 
necessitate transplantation, placing an even greater pressure on the limited number 
of donor livers.         
 
1.2 Pathophysiology of liver IR injury  
Liver IR injury is a complex process involving numerous cell types and molecular 
mediators in various pathways. The cellular damage occurs during both the 
ischaemic and reperfusion phases. The end result is cellular death via a combination 
of apoptosis and necrosis. Warm ischaemic damage arises when the blood supply to 
the liver is interrupted at normal body temperature as is the case during liver 
resections. Cold ischaemic damage arises during cold perfusion and storage of livers 
in transplantation. The following is an up to date review of the mechanisms of liver 
IR injury. The discussion begins by reviewing the function of each of the main 
cellular types within the liver, which participate in IR injury. This is followed by a 
description of the role of platelets, complement, cytokines, endogenous initiators of 
inflammation, and mitochondria in liver IR injury.  
 
1.2.1 Cellular contributors 
During the ischaemic phase as a result of glycogen consumption and lack of oxygen 
(O2) supply, kupffer cells, sinusoidal endothelial cells (SEC), and hepatocytes suffer 
with lack of adenosine triphosphate (ATP) production (25,26). The lack of ATP 
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leads to failure of the sodium / potassium ATP-dependent plasma membrane pump 
(Na+ / K+ ATPase) and subsequent intracellular Na+ accumulation, oedema, and 
swelling. Kupffer cell and SEC swelling combined with an increase in the 
vasoconstrictors endothelin (27) and thromboxane A2 (28) and a decrease in the 
vasodilator nitric oxide (29) lead to sinusoidal narrowing. In addition on reperfusion 
there is increased adhesion and aggregation of neutrophils and platelets in the 
sinusoids. The end result is significant reduction of microcirculatory blood flow on  
reperfusion, including some areas with complete absence of blood flow which is 
known as “no-reflow” (30) (figure 1.1).     
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The pathophysiology of the decreased microcirculatory blood flow 
(MBF) seen on reperfusion of the ischaemic liver. Multiple factors contribute to 
sinusoidal narrowing with subsequent reduction in MBF. NO, nitric oxide; SEC, 
sinusoidal endothelial swelling; MBF, microcirculatory blood flow.  
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Kupffer cells are the liver resident macrophages. They play a key role in initiating 
and propagating cellular damage and death in IR injury (31). Kupffer cells are 
activated during the ischaemic phase and even more so on reperfusion. On activation 
they produce reactive free radicals, specifically reactive oxygen species (ROS) (32), 
and pro-inflammatory cytokines including tumour necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), and IL-1α (22,33). These ROS and cytokines have 
widespread effects in the initiation and propagation of IR injury. Their main role is 
to recruit and activate circulating neutrophils on reperfusion (34). In addition they 
induce remote IR injury in distant organs (22), recruit and activate CD4+ T-
lymphocytes (35), activate SEC leading to expression of cell – surface adhesion 
molecules and contribute to their damage (35,36), stimulate hepatocytes to produce 
ROS and contribute to their damage (37,38), and stimulate platelet adhesion to SEC 
(39). Kupffer cells are mainly activated as a direct consequence of IR causing 
disruption of mitochondria and ATP production, they are also activated indirectly 
via the complement system (40,41) (figure 1.2). 
 
Activated SEC, hepatocytes, and neutrophils express cell-surface adhesion 
molecules. On neutrophils L-selectin and β2-integrins (CD11b/CD18) adhere to 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 
(VCAM-1) on the surface of SEC and hepatocytes (42,43) (figure 1.2). In liver IR 
injury however, early neutrophil accumulation in the sinusoids mainly results from 
mechanical trapping by the swollen, constricted, platelet-adhering sinusoids (44). In 
response to chemokines from activated and injured hepatocytes, sinusoidally-
accumulated neutrophils use the surface-expressed adhesion molecules to bind their 
SEC’s counterpart and migrate across the endothelium into the parenchyma. The 
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binding of CD11b/CD18 on the neutrophils to ICAM-1 and VCAM-1 on the 
hepatocytes triggers an enhancement of ROS production through the NADPH 
oxidase system as well as degranulation of cytoplasmic vesicles containing various 
enzymes that assist in the degradation of the extracellular matrix and dead 
hepatocytes, and damage viable hepatocytes (42).  
 
The liver contains all the subtypes of lymphocytes as resident cells. These comprise 
B-cells, CD8+ and CD4+ T-cells (conventional T-lymphocytes), natural killer T 
(NKT) cells and γδ T-cells (unconventional T-lymphocytes) (45). CD4+ and to a 
lesser extent NKT lymphocytes play a key role in liver IR injury. CD4+ cells 
accumulate in the liver within one hour of reperfusion following IR, preceding any 
neutrophil accumulation (46,47). They are recruited to the liver and activated, by 
various kupffer cell-derived products (figure 1.2). These include chemokines 
(CXCL9, CXCL10 (IP-10), CXCL11), ROS, cytokines (TNFα, IL-6), and matrix 
metalloproteinase 9 (35,48,49). CD4+ cells have been shown to be important 
contributors in neutrophil recruitment into the post ischaemic liver which is 
supported by experiments demonstrating significantly reduced liver neutrophil 
accumulation in CD4-/- mice and in CD4+ mice administered anti-CD4+ antibodies 
(46,47). CD4+ lymphocytes stimulate neutrophil accumulation through production 
of the chemotactic agent IL-17 (46). Furthermore the CD4+ cells produce interferon-
γ (IFN-γ) that activates kupffer cells to produce TNF-α and IL-1, and hepatocytes to 
produce chemokines (50). Thus CD4+ T-lymphocytes and kupffer cells reciprocally 
activate one another (35). The end result of hepatic CD4+ cell recruitment and 
activation post ischaemia, is hepatocyte and SEC damage with microvascular 
perfusion defects (47,51). NKT cells are recruited and activated into the post 
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ischaemic liver on a time scale similar to CD4+ cells (46). NKT cell activation is 
dependent on interaction with CD1d antigen presenting molecules, expressed on 
hepatocytes and antigen presenting cells within the liver (52,53). CD1d presents 
either self or foreign glycolipid antigens to NKT cells. Activated NKT cells are  
capable of damaging the liver directly and of producing IFN-γ with subsequent 
kupffer cell and hepatocyte activation (52,53).                
 
 
 
 
Figure 1.2. Cellular and humoral factors in liver IR injury. The figure illustrates the 
activation of immune cells, and damage to hepatocytes and SEC, by humoral 
factors. Note the humoral factors are themselves produced by the same group of 
cells that they activate. *NKT cells are activated by CD1d antigen presenting 
molecules expressed on hepatocytes and antigen presenting cells. #NKT and CD4+ 
T cells can directly damage hepatocytes and SECs. IFN-γ, interferon-γ; IL-17, 
interleukin-17; NKT, natural killer T; ROS, reactive oxygen species; SEC, sinusoidal 
endothelial cells.          
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1.2.2 Platelets 
Platelet adhesion and aggregation within the sinusoids contributes to neutrophil 
accumulation, SEC apoptosis, and sinusoidal perfusion failure during the post 
ischaemic period (39,54,55). The IR-induced damaging effects of kupffer cells, 
neutrophils, and platelets are interdependent. Each of these acts synergistically with 
the other, resulting in a degree of IR damage that is greater than the damage 
sustained if one of these cell types is missing (56,57). In contrast, platelets may also 
play a beneficial role in postoperative liver regeneration. Platelet-derived serotonin 
has recently been shown to be an important factor in liver regeneration, and more 
specifically hepatocyte proliferation, as mice deficient in this effector fail to 
regenerate their livers (58).  
 
1.2.3 Complement 
The complement system comprises approximately 30 soluble and membrane-bound 
proteins. Hepatocytes manufacture 90% of plasma complement components (59). 
The majority of published studies used either a complement component-specific 
transgenic mouse strain or selective complement component inhibitors to elucidate 
the role of complement in liver IR injury. Three distinct pathways are known to 
activate the complement cascade, the classical, alternative, and mannose-binding 
lectin pathways. All three pathways are likely contributors to complement activation 
in liver IR (60). Once activated in IR injury, complement leads to liver damage 
either directly by lysing liver cells through the formation of a membrane attack 
complex in the plasma membrane (61), or by recruiting neutrophils and activating 
both neutrophils and kupffer cells (41) (figure 1.2). Therefore complement 
activation during liver IR injury leads to accentuation of the inflammatory cascade 
 35 
and subsequent cellular death (62). Complement activation has also been implicated 
in the pathogenesis of remote IR injury. For example in rodents, bilateral hindlimb 
IR injury leads to remote liver IR injury by activation of kupffer cells via 
complement factor C5a (40,63). Direct liver IR injury on the other hand, results in 
remote endothelial damage in the lungs and small bowel in the mouse, that is 
significantly attenuated by mice transgenically over expressing the physiologically 
occurring complement inhibitor called C1 inhibitor (64). C1 inhibitor inhibits 
complement factor C1 and therefore the classical pathway of complement activation. 
These observations implicate C1 (classical pathway) as a mediator of liver IR injury-
induced remote organ injury (64).        
 
1.2.4 Cytokines 
Cytokines are a diverse group of signalling molecules that may act in an autocrine, 
paracrine, or endocrine manner. They are important messengers between the cellular 
players in both direct and remote IR injury. Cytokines exert their effect by binding 
to cell surface receptors on target cells, and may play a pro- or an anti-inflammatory 
role. An extensive volume of literature is available on the function of a large number 
of cytokines in liver IR injury. In this review the action of three key (IL-12, IL-23, 
TNF-α) cytokines involved in liver IR injury modulation is described in detail. The 
actions of a further ten important (aFGF, bFGF, HGF, IFN-γ, IL-1β, IL-6, IL-10, IL-
13, IL-18, VEGF) cytokines is summarised.     
 
1.2.4a IL-12 and IL-23 
IL-12 and IL-23 are heterodimeric cytokines. Each is made of a common p40 
subunit, and a second cytokine-specific subunit. In the case of IL-12 this is p35, and 
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in the case of IL-23 it is p19 (65). Within the liver these cytokines are produced by 
hepatocytes and kupffer cells (65,66). IL-12 discovery preceded that of IL-23 by 
many years (65) and preliminary work showing that IL-12 was one of the key 
molecules in initiating a pro-inflammatory cytokine cascade in liver IR injury (66), 
was later re-examined and could have been due to either IL-12 or indeed IL-23 (67). 
This is because the two techniques used to illicit the role of IL-12 relied on the use 
of anti-p40 antibodies and p40-/- mice. Nevertheless, these studies indicated that IL-
12 / IL-23 production occurs during the ischaemic phase and first hour of 
reperfusion. One or both of these cytokines is a prerequisite for the induction of 
TNF-α., the central component of the pro-inflammatory cytokine cascade in liver IR 
injury (66,67). The mechanisms through which this is achieved have not been 
resolved, but the transcription factors NF-κB and STAT-4 have been suggested as 
possible regulators of IL-12 / IL-23’s effects on TNF-α expression (68).Other effects 
of IL-12 include leukocyte infiltration, kupffer cell activation, and cell-surface 
adhesion molecule expression (69); and of IL-23 include stimulation of CD4+ cells 
to produce IL-17 which stimulates neutrophil accumulation in the post ischaemic 
liver (70).       
 
1.2.4b TNF-α 
TNF-α is the central cytokine mediator of the pro-inflammatory cascade in liver IR 
injury. TNF-α is produced by kupffer cells and acts both locally in a paracrine 
fashion, and remotely as an endocrine mediator. It is a crucial effecter of remote 
organ damage following hepatic IR injury (71). A large number of endogenous pro- 
or anti-inflammatory molecules either stimulate or inhibit the expression of TNF-α 
respectively. These are summarised in table 1.1. TNF-α up-regulation in liver IR 
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injury leads to liver damage. TNF-α binds to specific TNF-receptors (TNF-R) on the 
surface of hepatocytes. This results in increased production of the chemokine 
epithelial neutrophil activating protein-78 (ENA-78) and ROS; as well as activation 
of NF-κB and the mitogen activated protein kinase (MAPK) C-Jun N-terminal 
kinase (JNK) (72-75). In addition, TNF-α up-regulates expression of the adhesion 
molecules ICAM-1 and P-selectin (71,76). Through various mechanisms, all these 
molecules are able to recruit and activate neutrophils into the post ischaemic liver. 
Furthermore, JNK and ROS are capable of direct cellular damage within the liver 
(75).   
 
Table 1.1 Stimulators and inhibitors of TNF-α expression in hepatic IR injury. 
Molecule Reference Effect on TNF-
α expression 
Transcription 
factor intermediate 
bFGF (77) decreased Not provided 
IL-1 (78) increased Not provided 
IL-4 (79) decreased Activates STAT-6 
IL-6 (80-83) decreased Activates STAT-3# 
IL-10 (84-86) decreased Inhibits NF-κB 
IL-13 (87-90) decreased Activates STAT-6 
ANP (91) decreased Inhibits NF-κB 
PGE2 (92) decreased Not provided 
PAF (93) increased Not provided 
NO (33) decreased Not provided 
NO (94) decreased Not provided 
ROS (73,75) increased Activates JNK* 
#IL-6 has been shown to decrease TNF-α and activate STAT-3 in separate experiments. 
*JNK is not a transcription factor, but an intracellular transduction pathway that phosphorylates 
transcription factors, amongst other functions. 
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1.2.4c Other cytokines 
The role of other important cytokines in liver IR injury is summarised in table 1.2. 
The expression of these cytokines is under the control of a variable group of 
upstream regulators. Downstream, the cytokines influence the expression of various 
molecules that ultimately lead to either protection from, or exacerbation of liver IR 
injury. Each of these molecules belongs to a group that shares similar functions. 
There are transcription factors (AP-1, HSF, NF-κB, STAT-3, STAT-6), antioxidants 
(SOD, GSH), adhesion molecules (ICAM-1, E-selectin), inflammation – stimulated 
inducible enzymes (COX-2, iNOS, and HO-1), Intracellular signalling molecules 
(Akt), anti-apoptotic proteins (Bcl-2 / Bcl-x exert their effect by altering the 
mitochondrial membrane permeability), and chemokines (CINC, ENA-78, IP-10, 
MCP-1, MIG, MIP-2). The latter are chemotactic cytokines that direct and regulate 
the accumulation of neutrophils, monocytes / macrophages, and T-lymphocytes into 
the post ischaemic liver. 
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Table 1.2 The role of important cytokines in liver IR injury. 
Cytokine Reference (s) Cellular source Upstream regulator Down stream 
mediator(s) of effect 
Summary effect on 
liver  
Acidic and basic 
fibroblast growth 
factors (aFGF and 
bFGF) 
(77,95-98) T-lymphocytes, 
hepatocytes, hepatic 
stellate cells 
Not provided *↑ expression of NO 
and SOD; ↓markers 
of oxidative stress 
Reduces hepatic IR 
injury 
Hepatocyte growth 
factor (HGF) 
(99-101) Non-parenchymal 
liver cells, mainly 
kupffer cells 
Not provided ↑ hepatocyte DNA 
synthesis and 
hepatocyte 
proliferation; ↑ GSH 
expression, ↓ markers 
of oxidative stress; ↓ 
ICAM-1 expression 
on SEC; ↓ CINC, ↓ 
neutrophil infiltration 
Reduces hepatic IR 
injury and pro-
proliferative 
Interferon-γ (IFN-γ) (66,85,90,102-108) T-lymphocytes, NKT 
cells, hepatocytes 
TLR-4 activation & 
IL-12 stimulate IFN-γ 
production; A2A 
adenosine receptor 
activation, IL-10, IL-
13, STAT-6, & 
VEGF inhibit IFN-γ 
production 
Dual action:  
1. Physiological 
doses: ↑neutrophil 
recruitment & 
activation. 
2. Pharmacological 
doses: ↑IP-10, ↑MIG, 
↑neutrophil 
recruitment; ↓CINC, 
↓MIP-2, ↓ENA-78, 
↓neutrophil activation 
Dual action: 
1. Physiological 
doses: increase 
hepatic IR injury 
2. Pharmacological 
doses: reduce hepatic 
IR injury 
Interleukin-1β (IL-1β) (33,109-114) Kupffer cells IP-10 stimulates IL-
1β production; PGE1, 
↑ hepatocyte NO 
production via Akt, 
Increases hepatic IR 
injury 
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NO, IL-10, & A2A 
adenosine receptor 
activation, all inhibit 
IL-1β production 
NF-κB, & iNOS; ↑ 
ROS production; ↑ 
leukocyte recruitment 
& adhesion via 
activation of NF-κB 
& MIP-2 
IL-6 (80-83,115) Kupffer cells NF-κB & HSF 
stimulate IL-6 
production 
Activates STAT-3; ↑ 
GSH expression, ↓ 
markers of oxidative 
stress 
Reduces hepatic IR 
injury and pro-
proliferative 
IL-10 (84-86,104,114,116-
119) 
Kupffer cells, T 
lymphocytes 
COX-2-derived 
prostanoids & IP-10 
inhibit IL-10 
production 
↑HO-1; ↑Bcl-2/Bcl-x; 
↓NF-κB; ↓IL-1β; ↓IL-
2; ↓IFN-γ; ↓MIP-2; 
↓CINC; ↓E-selectin; ↓ 
neutrophil 
accumulation 
Reduces hepatic IR 
injury and pro-
proliferative 
IL-13 (87-90,120) Kupffer cells, T 
lymphocytes 
Not provided Inactivates TLR-4;  
activates STAT-6; 
↑HO-1; ↑Bcl-2/Bcl-x; 
↑IL-4; ↓IL-1β; ↓IL-2; 
↓IFN-γ; ↓MIP-2; ↓E-
selectin; ↓neutrophil 
accumulation 
Reduces hepatic IR 
injury 
IL-18 (103,121) Kupffer cells A2A adenosine 
receptor activation 
inhibits IL-18 
production 
Activates NF-κB & 
AP-1; ↓activation of 
STAT-6; ↑MIP-2; 
↓IL-4; ↓IL-10; 
↑neutrophil 
accumulation  
Increases hepatic 
injury 
Vascular endothelial (108,122-125) Kupffer cells, T CD154-CD40 co- Dual action: Dual action:  
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growth factor 
(VEGF) 
lymphocytes, SEC, 
hepatocytes 
stimulation 1. Endogenous 
expression with 
hepatic IR injury: 
activation of VEGF 
receptor and cytosolic 
SRC tyrosine kinases, 
↑ expression of TNF-
α, IFN-γ, MCP-1, & 
E-selectin leading to 
hepatic accumulation 
of T-cells, 
macrophages, and 
neutrophils. 
2. Exogenous 
administration: iNOS 
up-regulation. 
1. Endogenous 
expression increases 
hepatic IR injury. 
2. Exogenous 
administration 
reduces hepatic IR 
injury. 
*Only the downstream mediators of bFGF were given. No downstream pathways were provided for aFGF. 
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1.2.5 Endogenous mediators of inflammation 
1.2.5a Danger associated molecular patterns 
Danger associated molecular patterns (DAMPs) are normal physiological molecular 
constituents of cells or the extracellular environment, that are passively released by 
necrotic cells or the damaged extracellular matrix; or actively secreted by stressed 
and  injured cells. These molecules have the ability to initiate and propagate the 
inflammatory response in an analogous manner to the pathogen associated molecular 
patterns (PAMPs). PAMPs are conserved molecular motifs found in various 
prokaryotic pathogens but not in mammals, and are therefore recognised as foreign 
by the cells of the innate immune system in the host, leading to the initiation of an 
immune response (126). Examples of PAMPs include lipopolysaccharide from 
Gram negative bacteria, lipoteichoic acid from Gram positive bacteria, and double-
stranded RNA from viruses (127). Examples of DAMPs released during liver IR 
injury include the nuclear transcription factor high mobility group box-1 (HMGB-1) 
(128,129), the cytoplasmic Ca2+ regulator S100 (130), the cell matrix component 
hyaluronic acid (131), urate and ATP (132). It is also important to note that DAMPs 
are released during both, infectious states such as severe sepsis or localised purulent 
infections; and during sterile inflammatory conditions other than IR injury, such as 
arthritis, burns, and cancer (126). Both DAMPs and PAMPs exert their effects by 
binding to pattern recognition receptors either on the surface of or in the cytoplasm 
of mammalian cells.    
  
1.2.5b Pattern recognition receptors (PRRs) 
PRRs are constitutively expressed on cells of the innate immune system and 
function to immediately recognise invading microorganisms by binding to their 
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associated PAMPs without the need to involve the adaptive immune system. PRRs 
have the essential function of sensing tissue damage through the recognition of 
DAMPs on dead and injured host cells. Different PRRs recognise specific PAMPs 
and DAMPs, show distinct cellular expression patterns, and activate specific 
signalling pathways culminating in the initiation and propagation of the 
inflammatory response (133). Broadly speaking, two classes of PRRs have been 
shown to initiate and propagate the inflammatory responses in liver IR injury; the 
most extensively studied of these are the toll-like receptors (TLRs) specifically 
TLR-4. The receptor for advanced glycation end products (RAGE) is the second 
family of PRRs that has been shown to mediate hepatic IR injury. 
 
TLRs are type 1 transmembrane proteins containing an extracellular amino terminus 
and an intracellular carboxy terminal domain. The latter includes an IL-1 and an IL-
18 receptor – like signalling motif called Toll – IL-1 receptor (TIR) homology 
domain (134). TLRs that detect DAMPs released during sterile inflammatory 
conditions of the liver provide an important link between liver parenchymal damage 
and the activation of the immune system. Eleven human TLRs (TLR-1 to TLR-11) 
have been identified. An agreed general model of TLR mechanism of action 
involves engagement of a TLR by its ligand(s) which triggers an intracellular 
signalling cascade that culminates in the up-regulation of pro-inflammatory 
cytokines, chemokines, and other mediators of inflammation (134). The cascade 
begins with the TIR domain on the cytoplasmic portion of the TLR recruiting and 
activating one or more TIR – containing intracellular adaptors. The type of adaptor 
recruited broadly defines the subsequent intracellular signalling pathway involved. 
The adaptor recruited maybe the myeloid differentiation factor 88 (MyD88 – 
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dependent) which is common to all human TLRs except TLR-3; or non-MyD88 
(MyD88 – independent) adaptors. The latter includes TIR domain-containing 
adaptor protein (TIRAP), TIR domain-containing adaptor inducing interferon β 
(TRIF), and TRIF-related adaptor molecule (TRAM) (135).  
 
In MyD88-dependent signalling and as a consequence of TLR-2 or TLR-4 
activation, TIRAP is recruited to the TLR-MyD88 complex. The TLR-MyD88-
TIRAP complex recruits and phosphorylates IL-1 receptor-associated kinase 4 
(IRAK4), which then recruits and phosphorylates IRAK1. The activated IRAK1 
then dissociates from the MyD88 receptor complex and interacts with TNF receptor-
associated factor-6 (TRAF-6), which in turn activates a complex composed of the 
MAPK kinase kinase transforming growth factor β-activated kinase-1 (TAK-1) and 
TAK1-binding proteins-1, -2, and -3 (TAB-1, TAB-2, TAB-3). This TAK1-
TAB1/2/3 complex leads to the activation of IκB kinase (IKK) and eventually NF-
κB nuclear translocation. In addition one or more of the MAPK family members is 
activated leading to the eventual activation of the transcription factor activator 
protein 1 (AP-1). The end result is pro-inflammatory cytokine and chemokine gene 
transcription (133,135). TLR-3 and TLR-4 can transduce their activation through 
MyD88-independent signalling pathways, culminating in activation of the 
transcription factors interferon regulatory factors-3 or -2 (IRF-3 or IRF-2), or NF-
κB. This leads to the production of type 1 IFN (133,135). Moreover, activation of 
TLR-7, TLR-8, and TLR-9 also leads to induction of type 1 IFN. Figure 1.3 
summarises the MyD88-dependent and –independent signalling pathways 
downstream of TLR-4 activation. For TLRs that are capable of transducing their 
signal through more than one pathway such as TLR-4, the factor that determines 
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which pathway is recruited every time the TLR is activated is the cell type. For 
example MyD88 signalling exclusively transduces TLR-4 activation in the 
endothelium since these cells lack TRAM expression (134). However, within a 
defined cell type the specificity of TLR mediated signalling is determined by a 
combination of the TLR, the intracellular adaptor, and the intracellular signalling 
pathway (133).           
            
1.2.5c DAMPs and PRRs in liver IR injury 
Only endogenous DAMP signals rather than exogenous PAMP signals are involved 
in PRR activation in liver IR injury (129,136). The most extensively studied DAMP 
in liver IR injury is HMGB-1. Liver IR results in a significant increase in serum and 
hepatic HMGB-1 levels that contribute to hepatocellular damage (129,137). 
Physiologically, HMGB-1 acts as a regulator of DNA transcription, organisation, 
and repair. All nucleated cells posses HMGB-1 and will release it passively upon 
necrosis. In addition, monocytes, macrophages, and dendritic cells can secrete 
HMGB-1 actively (126). A further function of HMGB-1 involves mediating the 
increased expression of TLR-4s that is observed in liver IR injury and that leads to 
hepatocellular damage (138,139). This is at least partially achieved by HMGB-1 
acting on liver dendritic cells (140). During the ischaemic phase of liver IR the 
active secretion of HMGB-1 has been shown to involve TLR4-dependent ROS 
production and calcium / calmodulin kinase-mediated signalling (141). In a positive 
feedback cycle, HMGB-1 released during liver IR, binds to and activates TLR-4 
receptors (129). Downstream of this DAMP-TLR4 interaction, at least three separate 
signalling pathways maybe recruited (figure 1.3): 1. NF-κB (142,143); 2. p38 
MAPK, JNK, and ERK (114,129,142,143); 3. the sequential activation of IRF-
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3→type 1 IFN (e.g. IFN-β)→STAT-1→IP-10 (114,138,144,145). All three of the 
MAPK families maybe activated by HMGB-1 (129), whilst IP-10 exclusively 
activates ERK (114). Whatever signalling pathway is utilized, increased production 
of pro-inflammatory cytokines (TNF-α, IL-1β, IL-12β) and chemokines (IP-10) is 
the final result (114,129,142,144). TLR-4 receptors on none parenchymal liver cells 
that are derived from the bone marrow (kupffer and dendritic cells) are preferentially 
activated in liver IR injury and result in hepatocellular damage (140,143). The 
hepatocytes do not undergo TLR-4 activation directly by DAMPS but respond to 
inflammatory mediators produced from the non-parenchymal cells that are directly 
stimulated by DAMPs (146). The signalling pathway utilising IRF3-type 1 IFN in 
hepatic IR is down-regulated by HO-1. HO-1 induction blocks the expression of 
type 1 IFN, the subsequent activation of STAT-1, and the expression of downstream 
IP-10 (138,144). Furthermore, HO-1 even leads to a reduction in TLR-4 protein 
levels (147). The mechanisms described hitherto have all been elucidated in direct 
liver IR models. However in a haemorrhagic shock followed by resuscitation animal 
model, which is synonymous with systemic IR injury, serum and liver HMGB-1 
levels are significantly elevated causing activation of TLR-4s on circulating 
polymorphonucleocytes. Activated TLR-4s increase ROS production through the 
NADPH oxidase system. This is achieved through the sequential activation of 
MyD88-IRAK4-p38 MAPK or MyD88-IRAK4-Akt downstream of TLR-4 (148). In 
addition, trauma haemorrhage followed by resuscitation results in engagement of 
TLR-2, TLR-4, and TLR-9 in kupffer cells with subsequent p38 and JNK activation 
(149). Thus, in hepatic IR injury the signalling pathway(s) mediating the activation 
of a PRR will at least be partly dependent on the mechanism of the IR.    
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Figure 1.3. General and liver IR injury-related TLR-4 signalling. In non-liver IR 
injury, ligand engagement of TLR-4 leads to signal transducton through one of two 
pathways that are known to mediate TLR-4 signalling, a MyD88-dependent and an –
independent pathway. The molecules highlighted with blue have been shown to 
mediate TLR-4 signalling in liver IR injury models. Those highlighted with yellow 
have been shown to mediate liver injury in haemorrhagic shock followed by 
resuscitation models, which are synonymous with systemic IR injury. The 
culmination of either pathway is propagation of liver injury. HO-1 down-regulates 
TLR-4 expression and blocks various parts of the MyD88-independent pathway. IP-
10 activates ERK (dashed red line) and therefore provides a linkage between the 
MyD88-independent and MyD88-dependent pathways which forms a positive 
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feedback loop to enhance liver injury through the up-regulation of pro-inflammatory 
cytokines. Akt, protein kinase B; AP-1, activator protein 1; DAMP, danger 
associated molecular pattern; ERK, extracellular signal regulated kinase; HMGB-1, 
high mobility group box 1; HO-1, hemoxygenase-1; IFN-1, interferon-1; IKK, IκB 
kinase; IL-1B/-12B, interleukin-1B/12B; IP-10, inducible protein-10; IRAK-1/-4, IL-
1 receptor-associated kinase; IRF-2/-3, interferon regulatory factor-2/-3; JNK, C-Jun 
N-terminal kinase; MyD88, myeloid differentiation factor 88; NAD(P)H, reduced 
nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor kappa B; 
PAMP, pathogen associated molecular pattern; P38, P38 mitogen activated protein 
kinase; ROS, reactive oxygen species; STAT-1, signal transducer and activator of 
transcription-1; TAB-1/-2/-3, TAK1-binding proteins-1/-2/-3; TAK-1, transforming 
growth factor B-activated kinase-1; TIRAP, TIR domain-containing adaptor protein; 
TLR-4, toll-like receptor-4; TNF-α, tumour necrosis factor-α; TRAF-6, TNF 
receptor-associated factor-6; TRAM, TRIF-related adaptor molecule; TRIF, TIR 
domain-containing adaptor inducing interferon B.    
 
The receptor for advanced glycation end products (RAGE) is the second family of 
PRRs that is involved in liver IR injury. Within the liver RAGE is mainly expressed 
on dendritic cells and to a lesser extent kupffer cells (150,151). Hepatic IR leads to 
increased expression of RAGE and engagement of these receptors by endogenous 
DAMPs such as HMGB-1 with consequent hepatocellular injury (150,151). HMGB-
1 binding to RAGE in the setting of liver IR leads to a signalling cascade involving 
the activation of JNK / ERK, which increase the expression and activation of the 
inducible transcription factor early growth response-1 (Egr-1). Egr-1 acts as a 
coordinating up-regulator of divergent gene families affected by stress, that in the 
setting of hepatic IR includes MIP-2 that functions to recruit immune cells into the 
post ischaemic liver (151). Engagement of RAGE by other DAMPs results in the 
activation of other intracellular mediators of inflammation such as p38 MAPK, and 
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the transcription factors STAT-3 and AP-1, with a consequent increase in pro-
inflammatory cytokines such as TNF-α (150) (figure 1.4).  
 
 
Figure 1.4. RAGE signalling in liver IR injury. Engagement of RAGE by one of its 
ligands leads to signal transduction through one of two pathways. The end result of 
both pathways is activation of transcription factors that increase expression of the 
chemokine MIP-2 and the cytokine TNF-α. These two mediators are pro-
inflammatory and act to propagate the liver injury further. AP-1, activator protein-1; 
DAMP, danger associated molecular pattern; Egr-1, early growth response-1; ERK, 
extracellular signal regulated kinase; HMGB-1, high mobility group box-1; JNK, C-
Jun N-terminal kinase; MIP-2, macrophage inflammatory protein-2; P38 MAPK, 
P38 mitogen activated protein kinase; RAGE, receptor for advanced glycation end 
products; STAT-3, signal transducer and activator of transcription-3; TNF-α, tumour 
necrosis factor-α.        
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1.2.6 Mitochondria 
Physiologically, the primary function of the mitochondria is maintenance of a 
continuous supply of ATP to meet the cell’s energy requirements. In addition, the 
mitochondria is involved in numerous other physiological processes, such as steroid 
and lipid synthesis, metabolic control of cell-cycle progression, intracellular ions 
regulation, cellular growth and differentiation, signalling, cytokine production, and 
embryonic development (152). In IR injury, the mitochondrion participates in 
various pathophysiological processes. There is failure of ATP production as a 
consequence of disruption of oxidative phosphorylation caused by the generation of 
and damage by ROS, RNS, and free radicals. Cytosolic ionic ([Ca2+] [Na+] [H+]) 
disturbances lead to mitochondrial ionic disturbances, and vice versa, with 
consequent plasma and mitochondrial membrane damage, including the formation of 
mitochondrial permeability transition (MPT) pores.  
 
1.2.6a ROS, RNS, and free radicals 
Reactive oxygen species (ROS) are molecules or ions formed by the incomplete 
one-electron reduction of oxygen. Reactive nitrogen species (RNS) are nitrogenous 
products of nitric oxide synthase. A free radical is any atom or molecule with 
unpaired electrons in one or more valence shells (153). The terms ROS and RNS 
encompass free radicals. The physiopathologically important ROS include O2
.-
 
(superoxide anion), H2O2 (hydrogen peroxide), 
.
OH (hydroxyl radical), and HCLO 
(hypochlorous acid). The equivalent biologically important RNS include NO (nitric 
oxide), NO2 (nitrogen dioxide), N2O3 (dinitrogen trioxide), and ONOO
-
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(peroxynitrite). Out of these, O2
.-
, 
.
OH, NO, and NO2 constitute the free radical 
species (153,154).  
 
The main intracellular mechanisms for producing ROS are the xanthine oxidase, 
mitochondrial respiratory chain, and NADPH oxidase systems. Xanthine 
dehydrogenase (XD) is a dehydrogenase enzyme, meaning it uses the co-enzyme 
nicotinamide adenine dinucleotide (NAD+) as an electron acceptor during its normal 
function of oxidising hypoxanthine and xanthine to uric acid. However, during 
ischaemia intracellular proteases are activated, leading to proteolytic modification of 
XD to yield xanthine oxidase (XO). XO does not bind NAD+ and therefore electrons 
are transferred to O2 with subsequent production of O2
.-
 (155). The mitochondrial 
respiratory chain is involved in the production of ROS via various pathways. 
Physiologically, a small fraction of the electrons entering the respiratory chain are 
passed onto O2 from ubisemiquinone to form O2
.-
. Some of the O2
.-
 is dismutated 
into H2O2 by the antioxidant superoxide dismutase present in the mitochondrial 
matrix (MnSOD). H2O2 is able to diffuse out of the mitochondria to participate in 
intra- and intercellular signalling. In addition H2O2 directly oxidises protein thiols 
and mediates the formation of disulfide bonds. Similarly, complexes I and III are 
also involved in physiological ROS production within the mitochondria. Following 
cytochrome C inhibition by mitochondrial NO, complexes I and III are reduced 
which subsequently act as reducing agents of O2 to generate O2
.- (154). During IR 
injury mitochondrial KATP channel opening increases O2.- generation by complex I 
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(156). Furthermore, ‘ROS-induced ROS release’ or RIRR is a recently described 
phenomenon involving the mitochondria. When ROS production reaches a threshold 
level, the MPT pore or the inner membrane anion channels, or both, are opened 
leading to loss of mitochondrial membrane potential with subsequent cessation of 
electron flow in the respiratory chain and increased ROS production by complexes I-
III (157). With a disrupted mitochondrial membrane a large amount of ROS is 
released into the cytosol that may induce RIRR in adjacent mitochondria. Thus, this 
mechanism of ROS production may act as a self-perpetuating cycle leading to 
mitochondrial and cellular destruction (157).  The NADPH oxidase system is a 
membrane-associated enzyme complex which normally functions to produce ROS to 
kill invading microbes. It is the predominant ROS – generating system in 
neutrophils and kupffer cells. This system generates O2
.-
 from NADPH oxidase 
itself, H2O2 from SOD, and HCLO from the enzyme myeloperoxidase (155,158). 
All three systems (XO, mitochondrial respiratory chain, NADPH oxidase) of 
intracellular ROS production are utilized by the remaining cell types found in the 
liver, namely SEC and hepatocytes, to generate ROS (155). Other ROS species such 
as the 
.
OH radical is produced when O2
.-
 or H2O2 interact with certain transition 
metals, for example iron or copper. Additionally, ROS may also interact with haem 
proteins, for example haemoglobin or the cytochromes to produce the porphyrin 
cationic radical (+.HP-Fe4+) (158).             
 
NO is produced by the enzyme nitric oxide synthase (NOS) which has three 
isoforms. Endothelial NOS (eNOS) is a constitutive enzyme expressed in vascular 
endothelial cells. The expression of the inducible NOS (iNOS) isoform is up-
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regulated in inflammatory conditions, including IR injury, and is expressed by all 
nucleated cells. The neuronal NOS (nNOS) is a constitutive isoform, the expression 
of which is mostly restricted to the nervous tissue and few other tissues. NO reacts 
with superoxide and molecular oxygen to produce the remaining biologically 
important RNS species in the following reactions (159):  
 
 NO + O2
.-
 → ONOO
-
  
2NO + O2 → 2NO2 
NO2 + NO → N2O3 
A further mechanism which increases NO and therefore RNS production involves 
ROS. Superoxide radicals have been shown to increase iNOS gene expression in IL-
1β – treated hepatocytes. This effect is mediated by a redox-sensitive response 
element, termed antioxidant response element (ARE), located in the iNOS gene 
promoter (160). ARE has been shown to bind a redox-sensitive nuclear protein, that 
has not yet been characterised (160).        
 
ROS and RNS play a dual role in liver IR injury. They may contribute to the injury 
of the various cell types found in the liver, leading to both apoptotic and necrotic 
cell death. Alternatively they may function to protect the liver from the deleterious 
effects of IR injury by the process of preconditioning. Their exact role is likely to be 
dependent on multiple factors, including the length of the ischaemic and reperfusion 
periods, in vitro versus in vivo experimental models, and exogenous versus 
endogenous sources of ROS or RNS. ROS contribute to liver IR injury by multiple 
mechanisms. ROS cause oxidative damage to membrane lipids (lipid peroxidation), 
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especially polyunsaturated fatty acids, which result in disturbances in ion 
homeostasis, cell swelling and death (155). The damage sustained is not limited to 
the plasma membrane but also extends into the intracellular compartment to 
encompass all membrane-bound organelles; for example the mitochondrion and the 
nucleus. In addition, within the mitochondria, ROS can cause oxidative damage to 
the enzyme complexes of the respiratory chain leading to failure of ATP production 
and release of cytochrome C into the cytosol triggering apoptosis (161,162), and 
within the nucleus the DNA can be oxidatively damaged resulting in failure of 
protein transcription and translation (163). Antiproteases can also sustain ROS 
damage leading to their inactivation which allows inappropriate activation of 
proteases to inflict cellular damage. Kupffer cells and neutrophils generate ROS into 
the extracellular space through the antimicrobial NADPH oxidase system. Some of 
these ROS species such as hydrogen peroxide and hypochlorous acid are capable of 
diffusing through the plasma membrane of hepatocytes and SEC to inflict 
intracellular oxidative damage. ROS can also activate the redox-sensitive 
transcription factors, namely NF-κB and AP-1 (75,164). Amongst their functions 
NF-κB up-regulates pro-inflammatory cytokines like TNF-α (165), and AP-1 
promotes hepatocyte apoptosis through cytochrome C release and caspase-3 
activation (75). RNS inflict their damage by any of the mechanisms described for 
ROS, and in addition they cause post translational protein modifications that may 
result in the inactivation or introduction of a new function to a protein (166,167). A 
detailed discussion of the molecular biology of RNS and their redox reactions is 
beyond the scope of this review but can be found elsewhere (168,169).   
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1.2.6b Ionic disturbances 
Intracellular Ca2+ plays an important physiological role in regulating the 
hepatocyte’s function in response to extracellular signals such as hormones and 
growth factors. Ca2+ is mainly found in three cellular compartments, the cytosol, the 
mitochondria, and the endoplasmic reticulum (ER). The interplay of Ca2+ movement 
across the membranes of these structures determines the temporal and spatial 
distribution of [Ca2+] in the three compartments. Within each of these compartments 
Ca2+ has various functions. That of the cytosol is by far the most diverse ranging 
from cellular contraction to proliferation to modulation of numerous intracellular 
signalling pathways (170). The ER Ca2+ stores represent a mechanism to regulate 
[Ca2+]cytosol. Mitochondrial Ca2+ has three main functions: regulation of metabolism 
(ATP production), stimulation of apoptosis, and regulation of [Ca2+]cytosol (171). In 
order to understand the pathological disturbances of Ca2+ homeostasis in liver IR 
injury, it is important to have a good comprehension of the various mechanisms that 
control Ca2+ movement across the membranes of the three Ca2+-regulating cellular 
compartments (summarised in table 1.3).    
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Table 1.3 Physiological Ca2+ pathways in the plasma, mitochondrial, and ER membranes of hepatocytes. 
Ca2+ pathway Membrane 
location 
Main regulating signal(s) of Ca2+ movement Direction of Ca2+ 
movement 
Ref. Role 
in IR 
Ligand gated Ca2+ 
channels 
Plasma Extracellular signalling molecule (e.g. hormone, growth factor) 
binds to receptor on extracellular domain of Ca2+ channel 
From extracellular 
space to cytosol 
(172,1
73) 
√ 
Store operated Ca2+ 
(SOC) channels 
Plasma Activated by a decrease in [Ca2+] in ER From extracellular 
space to cytosol 
(172) √ 
Receptor activated 
Ca2+ channels 
Plasma Extracellular signalling molecule (e.g. hormone, growth factor) 
binds to G-protein or tyrosine kinase coupled receptor, leading 
to generation of second messengers that bind to the cytoplasmic 
domain of the Ca2+ channel that is separate from the receptor 
From extracellular 
space to cytosol 
(172,1
73) 
√ 
Stretch activated 
Ca2+ channels 
Plasma Mechanical force applied to hepatocytes leads directly to Ca2+ 
channel opening   
From extracellular 
space to cytosol 
(172) √ 
Ca2+ ATPase Plasma Inhibited by low [Ca2+]cytosol and by hormones (vasopressin, 
epinephrine, angiotensin II, PTH, calcitonin, endothelin B) 
through a mechanism that involves activation of G-proteins 
From cytosol to 
extracellular space  
(174) √ 
Na+ / Ca2+ exchanger Plasma The Na+ and Ca+ gradients across the plasma membrane. In the 
heart, the Na+ / Ca+ exchanger is regulated by phosphorylation 
by protein kinase A (PKA) and C (PKC), which in turn are 
activated by numerous extracellular signals (e.g. hormones) 
Normally extrudes 
Ca+ into 
extracellular space 
but may act in 
reverse if Na+ / 
Ca+ gradient is 
altered, e.g. if 
[Na+]extracellular is 
decreased 
massively 
(175,1
76) 
 
Ca2+ ATPase ER SOC stimulation and raised [Ca2+]cytosol From cytosol into 
lumen of ER 
(174) √ 
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Inositol triphosphate 
(IP3) and Ryanodine 
receptors 
ER Extracellular signalling molecule (e.g. vassopressin, ADP, 
angiotensin II, noradrenalin) binds to plasma membrane G-
protein coupled receptor leading to production of phospholipase 
C (PLC). PLC produces IP3 and  diacylglycerol (DAG) which 
stimulate IP3 and ryanodine receptors, resulting in Ca2+release 
into the cytosol 
From ER to 
cytosol 
(174,1
77) 
√ 
Na+ / Ca2+ exchanger Inner 
mitochondrial 
Mitochondrial transmembrane potential across the inner 
membrane (m∆Ψ), and cytosolic [Na] and [Ca2+]. Other cations 
either stimulate (K+) or inhibit (Mg2+, Ba2+, Ni2+) the activity of 
the exchanger 
Extrudes Ca2+ into 
the cytosol from 
mitochondrial 
matrix in exchange 
for cytosolic Na+. 
Can act in reverse 
if mitochondrial 
membrane potential 
is depolarised 
(178,1
79) 
 
H+ / Ca2+ exchanger Inner 
mitochondrial 
Mitochondrial transmembrane chemical (pH) gradient, and 
[Ca2+]cytosol 
Extrudes Ca2+ into 
the cytosol from 
mitochondrial 
matrix 
(179)  
Ca2+ uniporter 
channel 
Inner 
mitochondrial 
Cytosolic [Ca2+] and m∆Ψ. Mitochondrial purinergic – like 
(mP2Y) receptors regulate Ca2+ flow through the uniporter. 
Specifically mP2Y1 are activated by ADP and AMP and lead to 
increased mCa2+ uptake; mP2Y2 are activated by ATP and leads 
to inhibition of mCa2+ uptake. Both P2Y receptors use PLC to 
regulate mCa2+ uptake through the uniporter   
From cytosol to 
mitochondrial 
matrix 
(180-
182)3 
√ 
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Liver IR injury leads to disturbances in the Ca2+ regulating mechanisms in the 
plasma, ER, and inner mitochondrial membranes (figure 3). The consequence is 
Ca2+ overload in the cytosol and mitochondrial matrix (183-185). The rise in 
cytosolic [Ca2+] results from a combination of increased Ca2+ entry across the 
plasma membrane as well as Ca2+ release from ER stores. This is brought about by 
the activation of SOC channels in the plasma membrane and ryanodine receptors in 
the ER membrane (186,187). How these channels and receptors are activated is not 
clear. However, there is evidence that ROS and RNS can activate some Ca2+-
permeable non-selective cation channels – the so called transient receptor potential 
(TRP) channels (188). TRP channels include some ligand gated, receptor activated, 
and stretch activated Ca2+ channels (see table 1.3) (172). Specifically the TRPM7 
channel subtype is found in liver cells, and ROS and RNS can activate these 
channels leading to Ca2+ influx from the extracellular space into the cytosol 
(188,189). In addition, cold ischaemic injury inhibits both the plasma membrane and 
ER Ca2+ ATPases, which normally function to extrude cytosolic Ca2+ into the 
extracellular space and ER lumen respectively, thereby compounding the rise in 
[Ca2+]cytosol (185).               
 
The rise in cytosolic Ca2+ during liver IR injury leads to a secondary rise in 
mitochondrial Ca2+ (mCa2+) (183). This is a consequence of stimulation of the 
mitochondrial Ca2+ uniporter (190,191). How these Ca2+-selective channels are 
activated in IR injury hasn’t been fully elucidated but probably involves the PLC – 
dependent mP2Y – like receptors that regulate Ca2+ flow through the mCa2+ 
uniporter (192,193). mP2Y1 are activated by ADP and AMP and lead to stimulation 
of  Ca2+ uptake by the uniporter. mP2Y2 are activated by ATP, ADP, and AMP and 
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lead to the inhibition of the uniporter.  During the ischaemic phase of IR injury, 
there is a relative decrease in [ATP]cytosol and an increase in [AMP and ADP]cytosol 
resulting in an overall increase in the activity of the Ca2+ uniporter and therefore in 
mitochondrial [Ca2+]  (181). This increase in mitochondrial [Ca2+] results in a 
reduction of the mitochondrial transmembrane potential (m∆Ψ). In response, and in 
order to maintain m∆Ψ, ATP-synthase reverses its activity and hydrolyses ATP to 
provide energy for the various ionic pumps in the mitochondrial membrane that 
maintain the mitochondrial potential. This results in partial restoration of m∆Ψ, 
which in turn leads to a further increase of Ca2+ inflow through the mCa2+ uniporter. 
Therefore a cycle of increasing mCa2+ overload and ATP depletion (as the 
mitochondria become a net consumer of ATP during ischaemia as a consequence of 
the reversed activity of ATP synthase) is established (183). The mCa2+ overload 
leads to Bax translocation from the cytosol to the mitochondria and subsequent MPT 
pore formation, cytochrome C release, and cellular death (190,194). 
 
Sodium (Na+) and hydrogen (H+) ions also have important functions in determining 
the liver’s response to IR insults. Hepatic ischaemia results in intracellular acidosis 
through anaerobic respiration (195,196). To restore intracellular pH towards normal, 
the liver cells activate the Na+ / H+ exchanger (NHE) and the Na+ / HCO3- 
cotransporter (NHCT) (197) (figure 1.5). The NHE extrudes H+ into the extracellular 
space in exchange for Na+ inflow into the cell. The NHCT transports Na+ and HCO3- 
intracellularly. Both these mechanisms of correcting the ischaemically-induced 
intracellular acidotic pH result in intracellular Na+ accumulation. It is the increase in 
intracellular [Na+] ([Na+]i) secondary to intracellular acidosis that contributes to 
cellular death. Intracellular acidosis per se is actually cytoprotective (198,199). 
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Support for this finding comes from five experimental observations. Firstly, 
blocking the function of the NHE and the NHCT protects against hepatic IR injury 
(195,200). Secondly, in vitro experiments using Na+-free incubation buffers results 
in hepatocyte and SEC  protection by inhibiting the rise in [Na+]i (198,199). Thirdly, 
IPC protects hepatocytes by the activation of vacuolar (H+)-ATPase (V-ATPase) 
which lead to H+ extrusion from the cells, with a subsequent decrease in intracellular 
[Na+] (201). Fourthly, maintenance of an acidotic pH at reperfusion, results in a 
decrease in [Na+]i and cellular protection, a phenomenon known as the ‘pH paradox’ 
(199,200,202). Fifthly, ischaemia – induced hepatocyte death is a result of ATP 
depletion with subsequent inhibition of the Na+ / K+ ATPase and an increase in 
[Na+]i (197,200). The question as to how increased [Na+]i promotes, and decreased 
[H+]i inhibit cellular death in liver IR injury is not fully resolved. Two experimental 
observations have been reported that shed light on this. The first is that [Na+]i 
accumulation does not lead to hepatocyte death by promoting cellular swelling 
(198); and the second is that maintenance of an acidotic pH at reperfusion prevents 
the formation of MPT pores (196,199). Further research is needed to fully explain 
how [Na+]i and [H+]i mediate their respective action in hepatic IR injury.     
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Figure 1.5. Ionic disturbances in liver IR injury. The perturbations of membrane-
associated ion channels, pumps, and carriers results in an increase in cytosolic 
[Ca2+] and [Na+], and mitochondrial [Ca2+] that have important consequences in 
promoting cellular injury – see  main text. AMP / ADP / ATP, adenosine mono / di / 
tri-phosphate; Ca2+, calcium ions; ER, endoplasmic reticulum; H+, hydrogen ions; 
HCO3-, bicarbonate; mP2Y, mitochondrial purinergic-like receptors; Na+, sodium 
ions; NHCT, Na+/HCO3- cotransporter; NHE, Na+/H+ exchanger; PLC, 
phospholipase C; RNS, reactive nitrogen species; ROS, reactive oxygen species; 
SOC, store operated Ca2+; TRP, transient receptor potential.   
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1.2.6c Mitochondrial permeability transition  
The mitochondria is surrounded by a double membrane. The outer mitochondrial 
membrane (OMM) is significantly more permeable than the inner mitochondrial 
membrane (IMM). This is due to the presence of voltage-dependent anion channels 
(VDAC) in the OMM that non-selectively permit the passage of solutes up to 5 kDa. 
Under normal physiological conditions the IMM is permeable to solutes only 
through specific exchangers, channels, and transporters. However, under certain 
circumstances such as IR injury, the IMM becomes non-selectively permeable to 
molecules up to 1500 Da, resulting in mitochondrial depolarization and collapse of 
the m∆Ψ, uncoupling of oxidative phosporylation, and mitochondrial swelling due 
to colloid osmotic forces that lead to the release of pro-apoptotic factors such as 
cytochrome C. These changes are known as the MPT (196). The MPT is due to the 
formation and opening of pores, with an average diameter of 3 nm when fully 
opened, through the IMM. It used to be thought that these pores are formed from 
VDAC in the OMM, adenine nucleotide transporter (ANT – responsible for 
exchanging ADP/ATP across the IMM) in the IMM, and cycolphilin D (CycD – a 
mitochondrial matrix protein) in the matrix. However this model did not explain 
experimental observations such as why ANT knockout mice still undergo MPT 
(203). The current prevailing hypothesis is that the MPT is formed from integral 
mitochondrial membrane proteins, that as a consequence of modifications by ROS 
and by reactive chemicals, lead to exposure of hydrophilic residues in the protein to 
the hydrophobic membrane environment, and as a result the proteins aggregate at 
these hydrophilic residues to form channels that conduct aqueous solutes (204,205) 
(figure 1.6). The identity of proteins in the MPT pores is not known for certain but is 
thought to include misfolded ANT and anion transporters such as aspartate-
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glutamate and phosphate carriers (206). The MPT pore protein composition is not 
consistent but depends on the relative abundance of the misfolded proteins. 
Therefore even in ANT deficient mitochondria, MPT pore formation can still occur 
(206). Moreover, two conductance modes of MPT pores are thought to be 
operational depending on the number of misfolded proteins and therefore on the 
number of pores formed. In the regulated conductance mode the MPT pores 
associate with chaperone-like proteins, including CycD on the inner surface of the 
IMM (figure 1.6). These proteins serve to inhibit conductance through the MPT 
pores. When the number of newly formed MPT pores exceeds the number of 
chaperones available then unregulated pore opening occurs (207). CycD confers 
Ca2+, ROS, and cyclosporine A sensitivity on pore conductance (208). A rise in 
matrix [Ca2+] increases, and cyclosporine A inhibits pore opening. Many other 
factors influence opening of and therefore conductance through the pores (209). 
Aside from Ca2+, other divalent cations such as Mg2+, Sr2+, and Mn2+ inhibit pore 
opening. H+ (and therefore acidotic pH) inhibit pore opening by the reversible 
protonation of histidyl residues, thereby explaining why maintenance of acidosis at 
reperfusion of ischaemic hepatocytes significantly decreases cellular death (199). 
ROS induce pore opening. Inorganic phosphate (Pi) plays a dual role in regulating 
MPT pore opening. In the mitochondrial matrix Pi binds H+ and Mg2+ blocking their 
pore – inhibitory effect, and resulting in pore opening. On the other hand Pi can bind 
to MPT pores directly leading to inhibition of pore opening only when CycD has 
been ablated or in the presence of cyclosporine A which inhibits CycD activity. This 
is because it is thought that active CycD normally binds to the Pi – binding sites on 
the MPT pores thereby preventing Pi binding. In the absence or inactivation of 
CycD, Pi binds to and inhibits the opening of MPT pores (209).  
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Figure 1.6. Current model of MPT pore structure and function. A cross section of 
the mitochondrial double membrane illustrating damaged integral mitochondrial 
membrane proteins that misfold and aggregate at their hydrophilic residues to form 
aqueous pores through the IMM. The conductance through the pores is inhibited by 
CycD and other chaperone proteins. These are in turn regulated by other ions and 
molecules as described in the figure. The fenestrations in the OMM denotes the high 
physiological conductivity of this membrane. Ca2+, calcium ions; CycD, 
cyclophilin D; H+, hydrogen ions; IMM, inner mitochondrial membrane; Mg2+, 
magnesium ions; Mn2+, manganese ions; MPT, mitochondrial permeability 
transition; OMM, outer mitochondrial protein; Pi, inorganic phosphate; ROS, 
reactive oxygen species; Sr2+, strontium ions.       
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The end result of MPT depends on the number of mitochondria affected and 
therefore cellular ATP levels. When mitochondria within a hepatocyte are afflicted 
by MPT then these mitochondria are depolarised and are permanently damaged. 
When the number of these dysfunctional mitochondria is small then the hepatocyte 
removes these by the process of mitophagy (210). Mitophagy is the process of 
sequestration of mitochondria into autophagosomes and their delivery to lysosomes 
for degradation. This is an important process for cells, as damaged mitochondria are 
a source of accelerated ROS production and ATP consumption (211,212). As the 
number of mitochondria undergoing MPT rises, with relative preservation of cellular 
ATP levels, apoptotic cell death occurs due to cytochrome C release and subsequent 
formation of the ATP – dependent apoptosome (213). As the majority of the 
hepatocyte’s mitochondria undergo MPT, the ATP levels plummet, causing cell 
death by necrosis (196,214,215). In summary, with an increasing number of 
mitochondria undergoing MPT the hepatocyte’s graded response is:  
Mitophagy → Apoptosis → Necrosis 
Whilst in the preceding discussion, the majority of the experimental data supports 
the observation that IR resulting in MPT leads to mitophagy, there has also been 
recent work showing that on the contrary, anoxia / reoxgenation of cultured 
hepatocytes which results in MPT does not cause mitophagy but leads to 
accumulation of dysfunctional mitochondria (216) that are the source of increased 
ROS production and subsequent mitochondrial damage, including mitochondrial 
DNA damage (212). The discrepancy in whether IR with subsequent MPT formation 
results in mitophagy maybe due to differences in the models used such as in vitro 
versus in vivo settings. This discrepancy along with the fact that the molecular 
constituents of the MPT pores have not been discovered, seek to highlight the need 
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for much more research in this field to better characterise the main players and their 
interrelationships in MPT pore formation and control of conductance.   
 
1.2.7 Conclusions and future directions 
Despite two decades of research into the pathophysiological basis of liver IR, many 
questions remain unanswered. The complex interactions woven by each of the 
cellular contributors is only just beginning to be mapped. The function of different 
TLRs and their respective DAMPs is a relatively new field of research about which 
little is known. The detrimental means by which disturbances of the homeostatic 
concentrations of Ca2+, Na+, and H+ arise, and the pathways mediating the 
consequences of these disturbances are incompletely understood. The structure and 
regulation of conductance of MPT pores in liver IR injury is poorly characterised 
and warrants further research. Only by understanding the action of these factors and 
how they interact with each other will it be possible to design therapeutic strategies 
to ameliorate liver IR injury.    
 
1.3 Strategies to reduce liver IR injury   
Over the past two decades extensive research has gone into attempting to better 
understand the molecular pathophysiology that underlies both the ischaemic and 
reperfusion phases of liver IR injury and that culminate in cellular death. 
Understanding these processes will pave the way for the development of new 
therapeutic strategies to ameliorate the effects of IR. The current strategies, albeit 
mostly limited to experimental settings, revolve around three methods: in situ 
cooling, pharmacological interventions, and ischaemic preconditioning (IPC). The 
first two of these strategies, in situ cooling and pharmacological preconditioning, are 
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beyond the scope of this thesis and will not be discussed here in detail. Suffice to 
say that in situ cooling, which is performed when total vascular exclusion (TVE) of 
the liver is required during surgical resection, has been shown clinically and 
experimentally, to significantly reduce liver IR injury compared to resections 
performed under TVE without in situ cooling (217-220). A large number of 
pharmacological agents have been investigated and shown to ameliorate liver IR 
injury in experimental settings, summarised by Iniguez et al (221). However, 
systematic reviews and meta-analysis of human randomised clinical trials of 
pharmacological interventions in liver resections performed under vascular 
occlusion have failed to show clear benefits for any pharmacological agent in 
reducing clinical liver IR injury (222,223).  
 
IPC involves subjecting an organ to brief ischaemic stimuli that afford the same 
organ, protection against subsequent prolonged ischaemic insults. IPC has been 
shown to be beneficial in many organs including the liver, heart, brain, kidneys, 
intestine, and skeletal muscle (224,225). IPC is the only strategy that has reached 
clinical practice in some centres. A variation on IPC is remote IPC (RIPC) which 
involves a brief ischaemic stimulus to one organ that affords protection against a 
subsequent sustained ischaemic insult to a second organ that is at a distance from the 
first organ. RIPC is known to exist across multiple organ combinations. The 
following two subsections will summarise our current understanding of 
preconditioning non-liver organs that subsequently protect the liver against IR injury 
(subsection 1.3.1), and the evidence that nitric oxide plays a role in mediating the 
beneficial effects of RIPC of one organ against IR injury of a second distant organ 
(subsection 1.3.2).  
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1.3.1 Mechanisms of remote ischaemic preconditioning protection 
against liver IR injury 
Four publications have evaluated the mechanisms underlying the protective effects 
of RIPC on liver IR injury. The findings of each of these studies will now be 
discussed in turn.  
 
Wang et al (226) applied an elastic band around the thigh for 10 minutes to induce 
hindlimb ischaemia followed by 10 minutes reperfusion in a mouse model. The liver 
IR protocol consisted of 1 hour partial hepatic ischaemia and up to 4 hours of 
reperfusion. Their results demonstrated significant reductions in liver IR injury in 
the RIPC + IR compared to the IR alone group. The mechanisms underlying the 
protection afforded by RIPC were further explored in this study, and through the use 
of transgenic mice expressing mutant TLR-4 receptors, they were able to 
demonstrate that hindlimb RIPC require functional TLR-4 receptors to exert its 
protective effect. Moreover, HMGB-1 levels increase following RIPC; injection of 
HMGB-1 into mice with functional but not into mice with mutant TLR-4 receptors 
protected against liver IR; and injection of anti-HMGB-1 antibodies prior to RIPC 
reversed its protective effects (226). The conclusion of this study was RIPC reduces 
liver IR injury through the release of HMGB-1 that act on TLR-4 receptors.   
 
The work described by Kanoria et al (227) consisted of a rabbit model with 
hindlimb RIPC achieved through the use of a tourniquet to induce 3 cycles of 10 
minutes ischaemia followed by 10 minutes reperfusion. Liver IR consisted of total 
hepatic inflow occlusion for 25 minutes followed by 2 hours reperfusion. The RIPC 
+ IR group had significant improvements in liver IR injury compared to the IR alone 
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group. This study evaluated the effect of RIPC on the haemodynamics and showed 
RIPC + IR preserves total hepatic blood flow at the end of the 2 hour reperfusion 
period compared to IR. Similarly the RIPC + IR group had significantly higher mean 
arterial pressure and peripheral oxygen saturation at the end of 2 hours liver 
reperfusion compared to IR alone (227). The conclusion from this work is that RIPC 
offers liver protection, at least partially, through preservation of haemodynamic 
parameters.        
 
The experiments by Lai et al (228) described hindlimb RIPC consisting of 4 cycles 
of 10 minutes femoral artery clamping followed by 10 minutes reperfusion. The 
liver IR protocol consisted of partial liver ischaemia for 45 minutes followed by 4 
hours reperfusion. RIPC + IR group had significantly less liver IR injury compared 
to the IR alone group. Hindlimb RIPC also resulted in a significant increase in the 
expression and activity of hepatic HO-1 with no increase in circulating lymphocyte 
HO-1 expression. Zinc protoporphyrin IX (a specific inhibitor of HO enzymatic 
activity) reversed the effects of RIPC on liver IR injury and enzymatic activity 
(228). The conclusion being that the protective signal from the RIPC site acts 
through the HO-1 pathway within the liver.   
 
The final study by Tapuria et al (229) used a specially designed tourniquet to induce 
4 cycles of 5 minutes ischaemia followed by 5 minutes reperfusion in the rat 
hindlimb. Liver IR consisted of 45 minutes of partial hepatic ischaemia and 3 hours 
reperfusion. This RIPC protocol resulted in a significant reduction of liver IR injury 
in the RIPC + IR compared to the IR alone group. Whilst this study did not 
investigate the signal that transmits the protective effects from the RIPC site to the 
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liver, it did evaluate the intrahepatic consequences of hindlimb RIPC. The study 
demonstrated RIPC + IR had significantly higher hepatic sinusoidal RBC velocity, 
sinusoidal blood flow, and sinusoidal perfusion compared to the IR group. 
Moreover, sinusoidal neutrophil adhesion and hepatocellular death were 
significantly less in the RIPC + IR compared to the IR group (229). The conclusion 
from these results was that hindlimb RIPC modulates the hepatic microcirculation to 
reduce the effects of hepatic IR injury.  
 
1.3.2 Nitric oxide as a mediator of the beneficial effects of remote 
ischaemic preconditioning on IR injury  
A summary of the published studies that have evaluated the capacity of NO to act as 
an important facilitator of the protective effects of RIPC is provided in table 1.4. All 
these studies with the exception of one (230) have indicated NO could be an 
important molecule in the beneficial effects of RIPC. The results of four of these 
studies (227,230-232) need further corroboration as each of these only used a single 
technique to evaluate the role of NO (table 1.4). The study by Kanoria et al (227) is 
the only one to allude to the effects of NO in ameliorating liver IR injury by RIPC; 
however, the only pertinent endpoint measured by the investigators was the plasma 
NOx levels, and therefore more research is needed not only to substantiate these 
results, but also to assess how NO generated by RIPC attenuates liver IR injury.    
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Table 1.4 A summary of the actions of NO in RIPC.  
Ref. species RIPC site and 
protocol 
IR site and 
protocol 
Effect of RIPC on endpoints 
of IR injury 
Assessment of nitric oxide’s 
involvement in mediating 
effects of RIPC 
Conclusions 
(233) Rats Bilateral 
femoral arteries 
ischaemia (I.) 
for 15 min 
followed by 2 
hrs reperfusion 
(R.)  
Left anterior 
descending 
(LAD) 
coronary artery 
I. for 30 min 
followed by 2 
hrs R. 
↓myocardial infarct size; 
↑maximal rate of rise of LV 
pressure; ↓Left ventricular end 
diastolic pressure (LVEDP);  
↓serum CK-MB and LDH levels  
Administration of L-NAME prior 
to RIPC + IR abolished protective 
effects of RIPC on all endpoints of 
IR injury. Administration of L-
arginine before IR protected 
against IR injury 
NO is a mediator of 
protective effects of 
RIPC 
(232) Rats Contralateral 
hindlimb I. for 
10 min 
followed by 30 
min R. 
Abdominal 
adipocutaneous 
flaps raised on 
superficial 
epigastric 
artery I. for 3 
hrs followed by 
up to  5 days R. 
↑flap survival; ↑p38 MAP kinase 
phosphorylation in flaps (30 min 
after RIPC but not following 3 
hrs of ischaemia)  
Administration of L-NAME prior 
to RIPC + IR abolished flap 
survival advantage conferred by 
RIPC, and diminished 
phosphorylation of p38 MAP 
kinase 
NO mediates increased 
tissue survival following 
IR through 
phosphorylation of p38 
MAP kinase 
(230) Rabbits Two cycles of 
left renal artery 
I. for 5 min 
followed by 15 
min R. 
Spinal cord 
(through aortic) 
I. for 40 min 
followed by 48 
hrs R.  
↑(improved) neurological score; 
↑viability index; ↓inflammatory 
response; ↓neuron-specific 
enolase measured at 2 hrs post 
reperfusion (marker of ischaemic 
neuronal injury) 
Measurement of serum NOx levels 
at 2 and 48 hrs post reperfusion 
showed no significant differences 
between RIPC + IR and IR alone 
group 
NO does not mediate 
effects of RIPC  
(231) Rats Four cycles of 
bilateral 
hindlimbs I. for 
5 min followed 
by 5 min R. 
LAD coronary 
artery I. for 30 
min followed 
by 2 hrs R. 
↓myocardial infarct size  Administration of L-NAME prior 
to RIPC + IR abolished protective 
effects of RIPC on myocardial 
infarct size 
NO is a mediator of 
protective effects of 
RIPC  
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(234) Mice Six cycles of 
bilateral 
hindlimb I. for 
5 min followed 
by 5. min R. 
24 hrs 
following 
RIPC, hearts 
were 
langendorff-
perfused, and 
subjected to 40 
min of global I. 
followed by 60 
min R. 
↓myocardial infarct size; ↑Left 
ventricular developed pressure 
(LVDP); ↓LVEDP  
↑cardiac iNOS levels post RIPC. 
iNOS-/- mice lost protective effects 
of RIPC on infarct size, LVDP, 
and LVEDP  
iNOS-derived NO is a 
mediator of protective 
effects of RIPC  
(235,236) Rats Right hindlimb 
or right fem. 
artery and vein 
I. for 10 
minutes 
followed by 30 
min R.  
Epigastric 
adipocutaneous 
flaps raised on 
left superficial 
epigastric 
artery I. for 3 
hrs followed by 
5 days R. 
↓mean flap necrosis area Administration of L-NAME prior 
to RIPC + IR abolished protective 
effects of RIPC on mean flap 
necrosis area. I.V. administration 
of NO donor Sper/NO prior to IR 
simulated the effects of RIPC  
NO is a mediator of 
protective effects of 
RIPC 
(237,238) Rats Hindlimb I. for 
10 min 
followed by 30 
min R. 
Cremaster 
muscle flap I. 
for 2 hrs 
followed by 1 
hr R. 
↑RBV in arterioles and 
capillaries; ↑capillary flow; 
↓number of leukocytes adherent 
to endothelium of venules.  
Administration of L-NAME prior 
to RIPC + IR abolished protective 
effects of RIPC on RBV, capillary 
flow, and number of adherent 
leukocytes. I.V. administration of 
NO donor Sper/NO prior to IR 
simulated the effects of RIPC 
NO is a mediator of 
protective effects of 
RIPC 
(227) Rabbits Three cycles of 
hindlimb I. for 
10 min 
followed by 10 
min R. 
Total liver I. 
for 25 min 
followed by 2 
hrs R. 
↓serum ALT, AST, and LDH; 
↑total hepatic blood flow 
Measurement of plasma NOx 
showed higher levels in the 
RIPC+IR compared to IR 
NO is a mediator of 
protective effects of 
RIPC 
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1.4 Thesis hypothesis 
The foregoing review on the mechanisms of liver IR injury, and our knowledge base 
of the therapeutic strategies to ameliorate liver IR injury specifically through the 
actions of NO (chapter 2), resulted in the following hypothesis (summarised in 
figure 1.7):  
 
Liver IR injury in the mouse is ameliorated by hindlimb preconditioning through the 
production of NO from eNOS (and iNOS). This NO is transported in the circulation 
as nitrite and nitrate to reach the liver where it provides hepatic protection against 
IR injury through the sGC-cGMP pathway which acts to preserve the hepatic 
microcirculation.         
   
1.5 Objectives of the thesis 
1. To investigate if hindlimb RIPC affords protection against liver IR injury in 
the mouse. 
2. To investigate the putative beneficial role of NO in mediating the protection 
afforded by hindlimb RIPC on liver IR injury.     
 
The next chapter reviews the literature with regards to the beneficial effects of NO 
in IR injury and in mediating organ protection afforded by IPC.  
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Figure 1.7. Thesis hypothesis. Mouse hindlimb preconditioning leads to the release 
of NO from both eNOS and iNOS. NO is then oxidised to nitrite and nitrate that 
travel in the circulation and reach the post-ischaemic hypoxic and acidotic liver. 
Under these conditions the nitrite and nitrate are reduced to NO which acts locally 
through the sGC-cGMP pathway to preserve the hepatic microcirculation and 
ultimately attenuate live IR injury. cGMP, cyclic 3’, 5’ guanosine monophosphate; 
eNOS and iNOS, endothelial and inducible nitric oxide synthase respectively; NO, 
nitric oxide; sGC, soluble guanylyl cyclase.  
 
 
mouse hindlimb 
preconditioning 
NO (from eNOS / iNOS) 
Nitrite / nitrate 
(hypoxic / acidotic liver) 
(NO) 
sGC 
cGMP 
Amelioration of  
liver IR injury 
Preservation of hepatic microcirculation 
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The mechanisms of nitric oxide  
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2.1 Introduction 
Nitric oxide (NO) is a gas with a molecular mass of 30.0 daltons. It is a free radical 
due to the presence of an unpaired electron in its valence shell. This structural 
configuration results in NO being highly reactive, with a consequent half life in the 
order of 5-10 seconds. In vivo synthesis of NO is catalysed by the enzyme nitric 
oxide synthase, which has three isoforms (section 2.2).  The effects of NO 
production in liver IR may be harmful or beneficial, or a combination of both. The 
determining factors are the length of the ischaemic insult and the NOS source of 
NO. This concise review focuses on the hepato-protective mechanisms of action of 
NO in liver IR injury. Specifically, three core areas are discussed: nitric oxide 
synthase, arginine, and the soluble guanylyl cyclase-cyclic GMP-protein kinase G 
pathway.    
 
2.2 Nitric oxide synthase 
The synthesis of NO is catalysed by nitric oxide synthase, an enzyme with three 
isoforms of distinct tissue distribution. Neuronal NOS (nNOS) is found in neural 
tissue and will not be discussed further. Endothelial NOS (eNOS) is Ca2+ / 
calmodulin dependent and catalyses the electron transfer reactions during the 
synthesis of NO from L-arginine. This electron transfer requires eNOS binds 
calmodulin, a process that is in turn dependent on the cellular concentrations of Ca2+ 
(239). eNOS is constitutively expressed in many cell types, including sinusoidal 
endothelial cells and hepatocytes (240-243). Inducible NOS (iNOS) is Ca2+  
independent as it is tightly bound to calmodulin at all cellular concentrations of Ca2+ 
(244). iNOS is not expressed under normal circumstances, but is up-regulated in 
various nucleated cell types in inflammatory conditions, including hepatocytes, 
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neutrophils, T-lymphocytes, endothelial, biliary, and kupffer cells in liver ischaemia 
reperfusion (IR) injury (245-249). NOS catalyses NO formation in a two-step 
oxidation of L-arginine to L-citrulline and NO (250,251):  
 
L-arginine                       Nῶ-hydroxy-L-arginine                     L-citrulline + NO 
 
The reaction also requires the co-factors tetrahydrobiopterin, flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) (250,251).  
 
Experimental evidence indicates that eNOS-derived NO is hepato-protective against 
liver IR injury. This has been demonstrated using various animal models and 
experimental techniques. eNOS knockout (eNOS-/-) mice exhibit significantly 
greater liver injury following warm IR compared to wild type (WT) counterparts 
(94,252-254). Similarly, eNOS-/- mice demonstrate more severe liver injury 
following cold preservation (cold ischaemic injury) and warm reperfusion in a 
mouse orthotopic liver transplantation (OLT) model (255). It is not just the baseline 
constitutive eNOS-derived NO that is protective, but mice with transgenic 
overexpression of eNOS show greatly reduced liver IR injury compared to WT 
animals (256). The protective effects of eNOS overexpression would raise the 
possibility that IR injury may act by down-regulating the expression of eNOS. This 
has indeed been shown in mouse and rat liver IR models (240,257).   
     
The role of iNOS-derived NO in liver IR injury is much less clear than that of 
eNOS. However, there is some evidence that the effects of iNOS expression on liver 
IR injury maybe be dependent on the length of ischaemia the liver is subjected to. 
1 NADPH 1 NADPH 
O2     H2O   O2     H2O 
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Animal experiments with relatively short ischaemic insults of less than 60 minutes 
show either exacerbation of (254), or no effect (253,258) of iNOS expression on the 
degree of liver injury. These seemingly incongruent results could be a consequence 
of the specific methods used to ascertain the functions of iNOS in liver IR injury. 
For example, Hines et al (258) described a significant increase in liver IR injury in 
iNOS-/- mice with 45 minutes ischaemia followed by 3 hours of reperfusion 
compared to WT animals. However, using exactly the same ischaemic protocol, 
whilst varying the reperfusion period length, they could not illicit a difference 
between iNOS-/- and WT animals with either 1 or 6 hours of reperfusion (258). The 
investigators also showed a time-dependent increase of liver IR injury in WT mice, 
but without an increase in iNOS expression. Moreover, administration of the relative 
iNOS inhibitor L-NIL to WT animals did not worsen the IR injury or alter serum 
nitrate and nitrite (NOx) levels, indicating that iNOS-derived NO does not influence 
liver IR injury with 45 minutes of ischaemia. However, iNOS-/- mice exhibit worse 
liver injury at 3 hours reperfusion due to a mechanism that is independent of iNOS-
derived NO, which the authors hypothesised could be for example due to altered 
expression of a different gene(s) that is influenced by the iNOS deletion in iNOS-/- 
(258).   
 
In contrast to the confusing situation with short ischaemic periods, iNOS-derived 
NO has consistently been shown to contribute to liver IR injury with prolonged (> 
60 minutes) cold (247,259,260) and warm (249,259,261) liver ischaemic insults. 
The mechanisms underlying the deleterious effects of iNOS-derived NO with 
prolonged ischaemic insults are beyond the scope of this review, suffice to say that 
excessive iNOS-derived NO generation in kupffer cells and neutrophils (247), 
 79 
promote pro-inflammatory cytokine and chemokine release, and leukocyte activation 
and trafficking into the liver (260). In addition, exorbitant NO production reacts with 
superoxide resulting in the formation of peroxynitrite (261,262), a molecule that is 
extremely toxic to cells (262).   
 
Some experimental evidence points to the protective effects of iNOS-derived NO 
during the late phase of liver IR injury, starting at 6 hours and continuing to 48 
hours post reperfusion. In one study of rat OLT (263), donor livers were transduced 
with an adenovirus encoding iNOS four days prior to harvest. The livers were then 
explanted from donors, cold preserved for 18 to 24 hours and transplanted into 
recipients. The adenovirally-transduced livers showed significant expression of 
iNOS and elevated serum NOx levels compared to control livers that had been 
transduced with a control gene. In addition livers that were transduced with iNOS 
showed significant reductions in IR injury and administration of a relative iNOS 
inhibitor to these livers abrogated the protection afforded by iNOS transduction 
(263). As good a study as this was, clearly the precise role of iNOS in protecting 
against or exacerbating liver IR injury, has not been fully elucidated and requires 
more research to establish the exact conditions under which iNOS-derived NO will 
prove beneficial or harmful.   
 
The actions of eNOS-derived NO and iNOS-derived NO in direct and remote 
ischaemic preconditioning are discussed in section 6.1.  
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2.3 L-arginine 
Arginine is an amino acid that is physiologically active in the L-form. It is 
metabolised either by NOS as outlined in the previous section, or by arginase. The 
latter catalyses the reaction:  
  
L-arginine + H2O                  L-ornithine + urea 
 
L-arginine protects the liver from IR injury. However, a review of published 
experimental studies indicate that the mechanisms of this protection are not 
necessarily through L-arginine’s metabolism to NO by NOS enzymes in every 
experimental model, but rather depends on the type of ischaemic insult the liver is 
subjected to. Table 2.1 lists the studies which measured hepatic, plasma, or serum 
NOx levels as a marker of NO production following reperfusion in hepatic IR 
models. In all these studies, with the exception of two (264,265), L-arginine was 
administered to the animals and resulted in significant amelioration of liver IR 
injury. The two studies that did not administer L-arginine, instead administered the 
selective arginase inhibitor nor-NOHA which resulted in a significant increase in 
endogenous L-arginine levels associated with protection against liver IR injury 
(264,265). Table 2.1 indicates that L-arginine protects against liver IR through an 
NO-dependent pathway during short warm ischaemic injury and through an NO-
independent mechanism during prolonged cold ischaemic insults. The in vivo 
experimental evidence summarised in table 2.1 does not shed light if it is the 
ischaemic length, type of ischaemia (cold vs warm), or a combination of both, which 
determines if an NO-dependent or -independent pathway is responsible for L-
arginine’s fate when protecting against hepatic IR injury. However, an in vitro study 
 81 
(266,267) that subjected rat livers to 60 minutes of cold ischaemia followed by 
warm reperfusion with oxygenated Krebs-Henseleit solution in an organ bath, 
showed the livers are protected with L-arginine administration from the effects of 
cold ischaemia in association with a rise in NOx levels, albeit statistical significance 
was only achieved during the first 10 minutes of reperfusion, indicating that short 
ischaemic lengths result in L-arginine protecting against liver IR through an NO-
dependent mechanism regardless of the type of ischaemia (266,267). Nonetheless 
these results need to be corroborated by in vivo short-length cold ischaemic models. 
The question remains how could L-arginine protect against prolonged ischaemic 
insults through an NO-independent pathway? Two explanations are possible. The 
first of these is supported by experimental results showing NOx levels are non-
significantly elevated following prolonged cold ischaemic injury to livers either 
supplemented with L-arginine (268-270) or the arginase-selective inhibitor nor-
NOHA (265) and resulting in significant elevation of plasma L-arginine levels. With 
this explanation L-arginine indeed is metabolised by NOS to form NO which then 
acts to protect the liver, but there is simply insufficient L-arginine to result in 
significant elevation of NOx Levels (265,271) due to the release of arginase from 
livers subjected to prolonged ischaemia (265,268,270,272) that divert L-arginine 
metabolism from NOS to metabolism by arginase. In support of this, prolonged cold 
ischaemia in the setting of OLT results in increased plasma levels of ornithine due to 
metabolism by arginase (265,268,270,272), without an increase in citrulline levels 
from metabolism by NOS (268,270). Moreover, it has also been shown that L-
arginine administration in OLT results in elevated plasma levels of both ornithine 
and citrulline indicating that both pathways, including NOS, catabolise L-arginine 
(268). Therefore it is likely that L-arginine protects against prolonged ischaemic 
 82 
insults through an NO-dependent pathway, but at the same time there is release of 
arginase from these livers subjected to prolonged ischaemia that results in the partial 
diversion of L-arginine away from NOS metabolism to be consumed by arginase. 
The second explanation is that apart from NO and ornithine, L-arginine can be 
catabolised to various other products (273), some of which may yet prove to offer a 
degree of protection against IR injury. However, these products are likely to be of 
minor importance especially with short ischaemic insults, and are therefore not 
discussed in this review.                      
 
Table 2.1 The effects of L-arginine administration on NOx levels in vivo in liver IR 
injury. In all these studies L-arginine administration significantly ameliorated liver 
IR injury.    
Experimental evidence showing L-arginine 
significantly increases NOx levels 
Experimental evidence showing           
L-arginine does not increase NOx 
levels  
Ref.  Species Type of 
ischaemia 
Length of 
ischaemia 
Ref. Species Type of 
ischaemia 
Length of 
ischaemia 
(274) Rats / 
pigs 
Warm 60 min. (268) Pigs Cold 20 hours 
(275) Rats Warm 45 min. (269) Rats Cold 18 hours 
(276) Pigs Warm 120 min. (270) Rats Cold 18 hours 
(277) Rats Warm 30 min. *(265) Rats Cold 18 hours 
(278,279) Rats Warm 45 min.     
(240) Rats Warm 45 min.     
(280,281) Rats Warm 60 min.     
*(264) Mice Warm 60 min.     
#(266,267) Rats Cold 60 min.     
*L-arginine was not administered in these studies but the arginase inhibitor nor-
NOHA was, leading to a rise in endogenous L-arginine levels.  
#This study was performed in vitro in an organ bath. Warm reperfusion was 
performed using oxygenated Krebs-Henseleit solution at 37 ℃. 
  
The protective mechanisms of L-arginine in liver IR injury are a reflection of the 
widespread protective effects of NO in this condition. Specifically, L-arginine 
protects hepatocytes and liver endothelial cells from the deleterious effects of IR 
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injury (275,282). The mechanisms of L-arginine’s protection in liver IR are detailed 
in figure 2.1. These may conceptually be divided into L-arginine’s effects on hepatic 
circulation (283-289), energy stores (276,279,287,290-292), oxidative status 
(276,281,287,290,293), leukocyte activation (283-287,291,294,295), mitochondria 
(280,282,294), and other effects on the liver (279,284,286,287,291,294) (figure 2.1).   
 
 
 
Figure 2.1. Mechanisms of protection of L-arginine in liver IR injury, references are 
in brackets. ATP, adenosine triphosphate; NO, nitric oxide; pO2, partial pressure of 
oxygen. 
 
 
 
Effects on 
circulation:  
• Maintains 
sinusoidal and 
post sinusoidal 
venule diameter 
(283-286) 
• ↑  microcircul-
atory blood flow 
(283, 284, 286-
288) 
• ↑ portal vein 
blood flow (285) 
• ↓ platelet 
aggregation 
(289) 
Effects on 
oxidative 
status:  
• ↑ hepatic and 
plasma thiol 
group 
antioxidants 
e.g. glutathione 
(293) 
• ↓ lipid 
peroxidation 
(293, 276, 281, 
287, 290) 
Effects on 
energy stores:  
• ↑ hepatic ATP 
levels (279, 
291, 292) 
• ↑ hepatic 
glycogen 
storage (276, 
287, 290) 
Effects on 
leukocyte 
activation:  
• ↓ leukocyte 
infiltration of 
liver (285, 287, 
291, 294, 295) 
•↓ leukocyte 
adherence in 
sinusoidal and 
post sinusoidal 
venules (283, 
284, 286) 
•↓ hepatocyte 
P-selectin 
expression 
(291) 
Effects on 
mitochondria:  
• ↑ mitochondri-
al respiratory 
and anioxidant 
enzymes (280) 
• ↓ mitochondri-
al ultrastructur-
al damage 
(280, 294) 
•↓ caspase-3 
activation (282, 
294) 
Other effects 
on liver:  
• ↑ hepatic 
tissue pO2 
(283, 284, 286) 
• ↑ hepatic 
cyclic GMP 
(279) 
• ↑ liver bile 
production 
(291, 294)  
 
NO 
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2.4 sGC-cGMP-PKG  
The soluble guanylyl cyclase (sGC)-cyclic 3’, 5’ guanosine monophosphate 
(cGMP)-protein kinase G (PKG) pathway is one of the commonest utilized by NO 
in mammalian biology. A detailed discussion of the function of sGC and cGMP in 
liver IR is given in section 8.1.  
 
cGMP-dependent protein kinase or PKG is a serine and threonine specific protein 
kinase that is activated by cGMP. PKG plays an important role in the downstream 
pathway of cell protection elicited by NO. It has been shown that isolated 
hepatocytes pre-incubated with a NO donor are resistant to hypoxia-induced cellular 
death through a PKG-dependent pathway, as the protection of the NO donor was 
inhibited by the PKG-selective blocker KT5823 (296). Moreover the protection 
offered by PKG resulted in the phosphorylation, and therefore activation, of p38 
MAPK leading to a significant reduction in intracellular [Na+] ([Na+]i) in hypoxic 
hepatocytes (296). Preconditioning-induced phosphorylation of p38 MAPK in 
hepatocytes results in activation of vacuolar H+-ATPase (V-ATPase) (297). V-
ATPases are proton pumps spanning the membranes of various intracellular 
compartments as well as the plasma membranes of hepatocytes. They are 
responsible for acidification of organelles such as lysosomes and endosomes; and 
play an important role in maintaining intracellular pH homeostatsis (298). Hepatic 
ischaemia results in intracellular acidosis through anaerobic respiration. To restore 
intracellular pH towards normal, the liver cells activate the Na+ / H+ exchanger 
(NHE) and the Na+ / HCO3- cotransporter (NHCT). The NHE extrudes H+ into the 
extracellular space in exchange for Na+ inflow into the cell. The NHCT transports 
Na+ and HCO3- intracellularly (299). Both these mechanisms of correcting the 
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ischaemically-induced intracellular acidotic pH result in intracellular Na+ 
accumulation (299). It is the increase in [Na+]i secondary to intracellular acidosis 
that contributes to hepatocytes death. Preconditioning- and NO-induced 
phosphorylation of p38 MAPK activates V-ATPases leading to extrusion of H+ from 
the cytosol of hepatocytes into the extracellular environment (297), thereby resulting 
in inhibition of the NHE and NHCT with a consequent reduction in [Na+]i and 
protection from hypoxic cellular death. The NO-PKG pathway does not only lead to 
the activation of V-ATPases but may also, through the activation of PI3K in 
hepatocytes, result in the exocytosis of lysosomes and consequent insertion of 
lysosomal V-ATPases into the plasma membrane (300). Therefore through 
activation of two separate molecules (p38 MAPK and PI3K), the NO-PKG cascade 
results in not only the activation of but also in the increase in number of plasma 
membrane V-ATPases. Activated PKG has one other consequence and that pertains 
to the prevention of onset of the mitochondrial permeability transition (MPT) in 
hepatocytes (301); an effect that averts hepatocytes death. It is postulated this effect 
on the MPT could be due to phosphorylation of serine / threonine residues of 
mitochondrial proteins that participate in MPT formation (301) but this has not been 
corroborated by experimental evidence.  
 
A summary of the mechanisms through which the NO-PKG pathway exerts its 
protective actions in liver IR injury is provided in figure 2.2.     
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Figure 2.2. A summary of the main mechanisms involved in NO-mediated protection against liver IR injury. A schematic representation of a 
liver cell with NO-mediated protective pathways shown. cGMP, cyclic 3’, 5’ guanosine monophosphate; eNOS, endothelial nitric oxide 
synthase; GTP, guanosine triphosphate; H+, hydrogen ions; HCO3-, bicarbonate; iNOS, inducible nitric oxide synthase; MPT, mitochondrial 
permeability transition; Na+, sodium ions; NHCT, Na+/HCO3- cotransporter; NHE, Na+/H+ exchanger; NO, nitric oxide; PI3K, phosphoinositide 
3-kinase; PKG, protein kinase G (cGMP-dependent protein kinase); sGC, soluble guanylyl cyclase; V-ATPase, vacuolar H+-ATPase.
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2.5 Conclusions and future directions    
NO is a ubiquitous free radical. Liver IR increases NO synthesis. The ramifications 
of this may be one of protection against or one of contribution towards liver IR 
injury. Whilst eNOS-derived NO is hepato-protective in liver IR injury, the role of 
iNOS-derived NO is much less clear and needs further research to shed light on the 
specific circumstances that determines the benefits, or otherwise, of NO generated 
from iNOS. Furthermore, there is very limited published literature on the effects of 
direct and remote ischaemic preconditioning on eNOS and iNOS expression and 
function. L-arginine supplementation attenuates hepatic IR injury through increased 
NO synthesis. At the same time, IR injury results in the release of arginase with the 
repercussion of diversion of L-arginine away from NO synthesis and towards urea 
and ornithine synthesis. The full significance of arginase release during IR is 
incompletely understood; indeed the implications of preconditioning (direct or 
remote) on arginase release are unknown and require further research. Most of the 
work investigating the actions of PKG in IR was performed in vitro using 
hepatocyte cultures. In vivo work is desperately needed to confirm the applicability 
of these results to liver IR injury. Only by understanding the detailed protective 
actions of NO, including the factors that influence its synthesis, will it be possible to 
design therapeutic strategies against liver IR injury that exploit the full potential of 
this molecule.   
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Materials and Methods 
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3.1 Introduction  
In this thesis an experimental animal model was used to investigate the role of nitric 
oxide (NO) in mediating the protective effects of hindlimb remote ischaemic 
preconditioning (RIPC) on liver ischaemia reperfusion (IR) injury. A mouse 
hindlimb RIPC protocol was developed and validated. Wild type (C57BL/6) and 
eNOS-/- mice were used. Throughout the thesis, quantification of liver injury was 
assessed by plasma liver enzymes and H & E stained liver histopathological 
sections. Transmission electron microscopy was used to provide an insight into the 
cellular structures and organelles that are affected by NO in RIPC. Hepatic 
microcirculatory blood flow measurements were used to understand the effects of 
RIPC and NO on blood flow in the hepatic microcirculation in the context of IR 
injury. eNOS and iNOS protein expression were assessed by Western blots. Plasma 
nitrite and nitrate act as circulating reservoirs of NO and were assessed by a 
colorimetric assay. NO can act through various pathways to exert its effects, 
including the guanylyl cyclase – cGMP route. Therefore, hepatic cGMP levels were 
quantified using an enzyme immunoassay kit.  
   
3.2 Chemicals and reagents 
C-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-
oxide.potassium salt; Alexis Biochemicals) is a direct intravascular NO scavenger. It 
was dissolved in Dulbecco’s – phosphate buffered saline (D-PBS) and was 
administered intravenously at a dose of 1 mg/kg in a volume of 50 µl, based on a 
previous study by Duranski et al (302). C-PTIO reacts with NO stoichiometrically 
(303) and was used to inhibit the effects of NO produced during RIPC. ODQ (1H-
[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one; Alexis Biochemicals) is a highly selective 
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inhibitor of soluble guanylyl cyclase (sGC). It binds to the haem site on sGC in an 
irreversible NO-competitive manner (304,305). It was dissolved in DMSO and was 
administered topically to the liver prior to hindlimb preconditioning and liver IR 
(302) in a volume of 100 µl containing 600 µg of ODQ (256). Sodium nitrite 
(NaNO2, Sigma-Aldrich) was dissolved in D-PBS and was administered into the 
peritoneal cavity in a volume of 50 µl containing 48 nmol (3.31 µg) sodium nitrite 
(167,302). In hypoxic and acidotic environments, typically encountered in ischaemic 
tissues, sodium nitrite is reduced to NO (306), and therefore we administered it to 
eNOS-/- mice undergoing liver IR to replace the deficient NO production. 
 
3.3 Animals 
Male inbred C57BL/6 wild type mice (Charles River laboratories, UK); and mice 
lacking the constitutively expressed enzyme, endothelial nitric oxide synthase 
(eNOS-/-, bred in-house) (307), were utilized in the present study. All mice used 
were aged 8-12 weeks, were kept in a temperature-controlled environment, had a 12 
hour light-dark cycle, and were freely allowed standard mouse chow pellets and 
drinking water.       
 
3.4 Mouse model of hindlimb remote ischaemic preconditioning of 
the liver 
The study was conducted under a license (PPL 70/6626; PIL 70/20759) granted by 
the Home Office in accordance with the Animals (Scientific Procedures) Act 1986. 
In addition the experimental protocols were also approved by the institutional 
animal ethics and welfare committee. Randomly selected mice were anaesthetised in 
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an induction chamber using 2% isoflurane. Maintenance of anaesthesia was 
achieved by the use of 1.5-2.0 % isoflurane via a concentric oronasal mask 
connected to an anaesthetic circuit. Core body temperature was maintained at 37.0 ± 
0.5 ℃ using a heating pad and a rectal temperature probe. 
 
3.4.1 Hepatic IR protocol  
Laparotomy was performed through a midline incision. The falciform ligament and 
the ligament connecting the caudate to the left lobe were divided. A bolus of 400 µl 
of 2.5 U/ml warmed heparinised saline was administered into the peritoneal cavity 
to maintain rehydration and prevent blood clotting. A microvascular clamp was then 
applied to the portal triad supplying the left and median lobes, rendering 
approximately 70% of the liver ischaemic. This well established partial hepatic 
ischaemia model prevents mesenteric venous congestion, intestinal mucosal damage 
caused by venous ischaemia, and subsequent bacterial translocation across the 
intestinal wall by permitting portal decompression through the caudate and right 
lobes of the liver (308-310). Successful occlusion of the portal triad in question was 
confirmed by a change in colour and a reduction in the microvascular blood flow as 
measured by Laser Doppler Flowmetry (LDF). The abdominal wall was sutured shut 
during hepatic ischaemia which lasted 40 minutes. Upon reperfusion of the 
ischaemic lobes, 400 µl of warmed normal saline was administered into the 
peritoneal cavity to prevent dehydration during the subsequent two hours of 
reperfusion in which the abdominal cavity was kept open to permit hepatic 
microcirculatory blood flow (MBF) measurements using LDF.  
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At the end of the reperfusion period blood was collected by cardiac puncture and 
immediately centrifuged at 3500 rpm (1150 g) for 10 minutes. The plasma 
supernatant was stored at -70 ℃ until assayed for liver transaminases and NOx.   
 
The liver lobes subjected to IR were harvested at the end of each procedure. The 
median and part of the left lobe were snap frozen in liquid nitrogen and subsequently 
stored in the same for eNOS, iNOS, and cGMP concentrations. The majority of the 
reminder of the left lobe was stored in 10% formal saline for histopathology and 
immunohistochemistry processing. Samples for transmission electron microscopy 
were also obtained from the left liver lobe at the end of the experiment and were 
stored in 1.5% glutaraldehyde and 2% paraformaldehyde.            
 
Preconditioned hindlimbs were de-skinned and de-skeletonised at the end of the 
experiment. The skeletal muscle remaining was processed in two ways. The 
majority of each sample was snap frozen in liquid nitrogen and subsequently stored 
in the same for eNOS and iNOS protein quantification, the remainder was placed in 
10% formal saline for immunohistochemistry processing.   
 
3.4.2 Technique of hindlimb preconditioning 
Two techniques of RIPC were used. In the preliminary experiments non-invasive 
preconditioning was achieved by alternate inflation and deflation of a pneumatic 
tourniquet placed around the proximal right hindlimb. Based on the neuromuscular 
damage (see results section in chapter 4) observed on recovery of these mice, a 
second method of preconditioning was developed that utilized an open technique. A 
longitudinal skin incision was made over the right antero-medial thigh that extended 
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from the inferior end of the midline laparotomy down to the right knee. The femoral 
vascular bundle (femoral artery and vein) was isolated from the surrounding muscles 
and was clamped using an operating microscope just proximal to its confluence with 
the femoral nerve (figure 3.1). In both techniques of RIPC a protocol of four minutes 
of limb ischaemia followed by four minutes reperfusion for a total of six cycles was 
used. This was based on a study that utilized a similar protocol of hindlimb 
preconditioning prior to myocardial IR, applied via non-invasive finger pressure to 
the femoral vessels (311). Cessation of blood flow to the hindlimb was confirmed by 
the change in foot colour and by the reduction in foot MBF measured by LDF. 
Furthermore, in the tourniquet technique, the LDF was used to determine the 
inflation pressures at which blood flow to the hindlimb ceased in order to prevent  
over inflation of the tourniquet and subsequent soft tissue damage of the hindlimb.  
 
 
 
Figure 3.1. (A) Mouse photograph showing the dissected right femoral vessels and 
nerve with a microvascular clamp on the former. (B) Close up magnification of 
outlined area in (A) with the microvascular clamp applied to the femoral artery and 
vein before the vessels are joined by the femoral nerve thereby protecting the latter 
from any damage.    
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In these preliminary studies, mice that were preconditioned with a tourniquet (n = 
2), and mice from the open clamp technique of RIPC (n = 4) were allowed to 
recover from anaesthesia during the two hour liver reperfusion period in order to 
assess general mobility and hindlimb function following RIPC. From these it 
became clear that the tourniquet technique resulted in limb paralysis probably 
secondary to hindlimb neuromuscular damage as evidenced by gross neuromuscular 
bruising in the preconditioned hindlimb soft tissues. Therefore the tourniquet 
technique was abandoned and all remaining experiments were performed using the 
open method of preconditioning.            
 
3.4.3 Experimental groups 
The experimental groups in the wild type and eNOS-/- mice are summarised in 
figures 3.2 and 3.3 respectively. Each group had a minimum of six animals. The 
total anaesthetic time was equal in all the groups. All animals underwent 
laparotomy, mobilization of the liver, and mobilization of the right femoral vascular 
bundle. In addition some of the groups were each subjected to a specific procedure 
as follows:  
Wild type groups: 
Sham: Only underwent the laparotomy, mobilization of the liver, and mobilization 
of the right femoral vascular bundle described above.  
RIPC: The right hindlimb was preconditioned with 6 cycles of 4 minutes ischaemia 
followed by 4 minutes reperfusion, using a microvascular clamp to occlude the 
femoral vessels under an operating microscope. 
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IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: Animals were subjected to the RIPC followed by the IR procedures.   
C-PTIO + RIPC + IR: The NO scavenger C-PTIO was administered intravenously at 
a dose of 1 mg/kg in 50 µl of D-PBS, followed by the RIPC + IR procedure. 
ODQ + RIPC + IR: The sGC inhibitor ODQ was administered topically to the liver, 
in a volume of 100 µl of DMSO containing 600 µg of ODQ, followed by the RIPC + 
IR procedure.    
eNOS-/- groups: 
Sham: Only underwent laparotomy, mobilization of the liver, and mobilization of 
the right femoral vascular bundle.  
RIPC: The right hindlimb was preconditioned with 6 cycles of 4 minutes ischaemia 
followed by 4 minutes reperfusion, using a microvascular clamp to occlude the 
femoral vessels under an operating microscope. 
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: Animals were subjected to the RIPC followed by the IR procedures.   
Nitrite + IR: Underwent the IR procedure with administration of sodium nitrite, at a 
dose of 48 nmol in 50 µl of D-PBS, topically into the peritoneal cavity 20 minutes 
into liver ischaemia. To elicit the optimal time of sodium nitrite administration, 
plasma transaminases levels and liver MBF were measured in two additional eNOS-
/-
 groups (n = 2 each) that received the sodium nitrite either immediately preceding 
liver ischaemia or just before liver reperfusion at the end of liver ischaemia. 
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Figure 3.2. Wild type animal groups. Group 1 (sham) underwent laparotomy, 
mobilization of the liver, and mobilization of the right femoral vascular bundle. 
RIPC (group 2) had the right hindlimb preconditioned with 6 cycles of 4 min 
ischaemia (using direct femoral vessels clamping) followed by 4 min reperfusion. IR 
(group 3) had 40 min of ischaemia to the median and left liver lobes followed by 2 
hrs reperfusion. RIPC + IR (group 4) underwent the RIPC followed by the IR 
procedures. C-PTIO + RIPC + IR and ODQ + RIPC + IR (groups 5 and 6) were 
administered C-PTIO and ODQ respectively, followed by the RIPC + IR procedure. 
Note the total anaesthetic time was equal in all the groups. HI, hindlimb ischaemia; 
HR, hindlimb reperfusion. 
 
 
 
 
 
liver & hindlimb perfusion 
3 hrs 28 min 
liver & hindlimb perfusion 
48 min 
liver ischaemia 
40 min 
liver & hindlimb perfusion 
120 min 
 
HI1 
4 
min 
liver & hindlimb perfusion  
160 min 
 
liver ischaemia 
40 min 
liver & hindlimb perfusion 
120 min 
 
liver & hindlimb perfusion 
120 min 
 
liver ischaemia 
40 min 
C-PTIO 
1. Sham 
2. RIPC 
3. IR 
4. RIPC + IR 
5. C-PTIO 
liver & hindlimb perfusion 
120 min 
 
liver ischaemia 
40 min 
ODQ 
6. ODQ 
HR1 
4 
min 
HR2 
4 
min 
HI2 
4 
min 
HI4 
4 
min 
HI3 
4 
min 
HR4 
4 
min 
HR3 
4 
min 
HR6 
4 
min 
HI6 
4 
min 
HR5 
4 
min 
HI5 
4 
min 
HI1 
4 
min 
HI6 
4 
min 
HR6 
4 
min 
HR5 
4 
min 
HI5 
4 
min 
HR4 
4 
min 
HI4 
4 
min 
HR2 
4 
min 
HI2 
4 
min 
HR1 
4 
min 
HR1 
4 
min 
HR1 
4 
min 
HI2 
4 
min 
HI2 
4 
min 
HR2 
4 
min 
HR2 
4 
min 
HI1 
4 
min 
HI1 
4 
min 
HI3 
4 
min 
HI3 
4 
min 
HI3 
4 
min 
HR3 
4 
min 
HR3 
4 
min 
HR3 
4 
min 
HI4 
4 
min 
HI4 
4 
min 
HR4 
4 
min 
HR4 
4 
min 
HI5 
4 
min 
HI5 
4 
min 
HR5 
4 
min 
HR5 
4 
min 
HI6 
4 
min 
HI6 
4 
min 
HR6 
4 
min 
HR6 
4 
min 
 97 
 
Figure 3.3. eNOS-/- animal groups. Group 7 (sham) underwent laparotomy, 
mobilization of the liver, and mobilization of the right femoral vascular bundle. 
RIPC (group 8) had the right hindlimb preconditioned with 6 cycles of 4 min 
ischaemia (using direct femoral vessels clamping) followed by 4 min reperfusion. IR 
(group 9) had 40 min of ischaemia to the median and left liver lobes followed by 2 
hrs reperfusion. RIPC + IR (group 10) underwent the RIPC followed by the IR 
procedures. Nitrite + IR (group 11) underwent the IR procedure with administration 
of sodium nitrite 20 min into liver ischaemia. Note the total anaesthetic time was 
equal in all the groups. HI, hindlimb ischaemia; HR, hindlimb reperfusion. 
 
 
3.5 Measurement of liver enzymes 
Plasma concentrations of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were measured by a standard spectrophotometric method 
using an automated clinical analyzer (Modular Analytics P, Roche Diagnostic Ltd, 
West Sussex UK). These enzymes are sensitive markers of liver injury which are 
released from injured hepatocytes into the circulation.    
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3.6 Histopathology 
A liver biopsy was taken from the left lobe at the end of the experiment for each of 
the animals and was immediately fixed in 10% formal saline. The fixed tissues were 
then embedded in paraffin, cut into 3 µm sections and stained with haematoxylin 
and eosin (H&E). Sections were examined under a light microscope using 50x or 
100x magnification for assessment of the degree of liver injury by a liver pathologist 
blinded to the grouping of the animals. Each H&E sample was scored using two 
different methods. In the first of these an overall histopathological injury grade was 
assigned to each sample based on the extent of the injury seen on examining each 
section. This overall grading system was a modification of the ordinal grading scale 
reported by Camargo et al (81) and was as follows:   
 
grade 0 – minimal or no evidence of injury;  
grade 1 – mild injury characterised by cytoplasmic vacuolization and focal 
nuclear pyknosis;  
grade 2 – moderate injury exhibiting cytoplasmic vacuolization, confluent areas 
of hepatocyte ballooning but no frank necrosis, sinusoidal dilatation and 
congestion, and blurring of intercellular borders;      
grade 3 – moderate to severe injury with areas of coagulative necrosis, 
cytoplasmic hypereosinophilia, extensive sinusoidal dilatation and congestion; 
grade 4 – severe injury consisting of severe confluent coagulative necrosis, and 
disintegration of and haemorrhage into hepatic cords leading to loss of tissue 
architecture.  
A photomicrograph example of each of these grades is given in figure 3.4.   
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Figure 3.4. Representative photomicrographs of liver sections demonstrating the 
overall histopathological injury grades: (A) Grade 0; (B) Grade 1; (C) Grade 2; (D) 
Grade 3; (E) Grade 4. See main text for a description of each of these grades.  
 
The second method of analysing the samples consisted of a semi-quantitative 
evaluation of individual histological features of liver IR injury in each sample (Table 
3.1). The individual features are those reported previously (294,302,312,313) but 
with additions and modifications to the scoring criteria of each feature as shown in 
table 3.1. Each of these features was scored in affected areas identified by the 
histopathologist in each of the sections.  
A B 
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E 
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Table 3.1. Scoring system for individual histopathological features of liver IR injury. 
Histopathological 
features of liver injury 
Score  
(S) 
Interpretation of scores 
Neutrophil 
infiltration 
0 
1 
2 
3 
4 
5 
None 
Rarely seen 
Scattered in some lobules 
Scattered in most lobules 
On the verge of confluence or with some 
confluence 
Dense clusters 
Cell necrosis 0 
1 
2 
3 
4 
5 
6 
7 
8 
None   
1-2 apoptotic bodies  
> 3 apoptotic bodies 
Focal necrosis with 1-2 foci seen 
Focal necrosis with 3 or more foci seen 
One confluent area of necrosis 
Multiple bridging confluent areas of cellular death 
Areas of necrosis exceed areas of viable 
parenchyma  
No or very focal viable parenchyma identified 
Eosinophilic 
changes of 
hepatocytes 
0 
1 
2 
3 
4 
None 
Rarely seen 
Scattered in some lobules 
Scattered in most lobules 
Widespread 
Discohesive 
hepatocytes 
1 
2 
3 
Mild  
Moderate 
Severe 
Liver cell 
ballooning  
0 
1 
2 
3 
4 
None 
 Focal, spotted after extensive search 
Some lobules affected  
Most lobules affected 
Widespread 
Cytoplasmic 
vacuolization  
0 
1 
2 
3 
4 
None 
Rarely seen 
Scattered in some lobules 
Scattered in most lobules 
Widespread 
Nuclear pyknosis 0 
1 
2 
3 
4 
None 
Rarely seen 
Scattered in some lobules 
Scattered in most lobules 
Widespread 
Blurring or loss of 
intercellular borders 
0 
1 
2 
3 
4 
None 
Rarely seen 
Scattered in some lobules 
Scattered in most lobules 
Widespread 
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Red blood cell 
extravasation / 
haemorrhage 
0 
1 
2 
3 
4 
 
None 
Rarely seen 
Frequent perivenular 
Frequent perivenular midzonal 
Frequent panlobular 
Sinusoidal dilatation 0 
1 
2 
3 
4 
None 
Rarely seen 
Frequent perivenular 
Frequent perivenular midzonal 
Frequent panlobular 
 
 
3.7 Transmission electron microscopy 
Transmission electron microscopy (TEM) was performed to identify the cellular 
structures and organelles that are protected by hindlimb preconditioning prior to 
liver IR (RIPC + IR group) compared to IR alone, thereby providing an insight into 
the cellular organelles that are receptive to the effects of the remote preconditioning 
process. Furthermore, TEM assessment in eNOS-/- animals, and animals 
administered C-PTIO, ODQ, or sodium nitrite undergoing RIPC allows an 
assessment of cellular ultrastructures that are utilized by nitric oxide in mediating 
the protective effects of RIPC on liver IR injury.   
 
Liver biopsies of approximately 1 mm3 dimensions were cut from the left lobe and 
fixed in a solution containing 1.5% glutaraldehyde and 2% paraformaldehyde in 
PBS overnight. An automated tissue processor (Leica EM TP) was utilized to 
process the samples in the following sequence: repeated washings with PBS; post-
fixation in 1% osmium tetroxide; dehydration through 30, 50, 70, 90, and 100 % 
alcohol; and embedding in Lemix epoxy resin. Semi-thin (1 µm) sections were cut 
and stained with 1% Toluidine Blue – 1% Borax and examined under light 
microscopy to determine the areas to be cut and processed for TEM. Ultrathin (70 
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nm) sections were stained with 2% aqueous uranyl acetate followed by Reynold’s 
lead citrate, and viewed using a Philips 201 TEM. Representative areas were 
photographed and the images were interpreted by a TEM scientist who was blinded 
to the groups. Multiple parameters of ultrastructural injury were evaluated based on 
modifications to those previously reported in liver IR injury studies (314-316). 
Within hepatocytes these were: mitochondrial damage evident by outer membrane 
disruption and cristae shortening and disruption; endoplasmic reticulum dilatation 
and vesiculation; formation of cytosolic vacuoles; formation of phagolysosomes; 
and abundance of lipid droplets and glycogen granules. In addition, injury of the bile 
canaliculi was determined by dilatation and loss of the microvilli; and damage to the 
sinusoids was determined by disruption of the sinusoidal endothelial cells’ 
cytoplasm, presence of sinusoidal luminal debris, extravasation of red blood cells, 
and obliteration of the space of Disse microvilli.      
 
3.8 Assessment of microcirculatory blood flow 
3.8.1 Principle of laser Doppler flowmetry 
Laser Doppler flowmetry (LDF) is an optical technique for assessing tissue 
microcirculation that provides continuous measurements of blood flow in the 
capillaries, arterioles, and venules. Measurements utilising LDF necessitate probe 
placement on the tissue surface. Therefore there is no disruption of tissue 
architecture or interruption to blood flow (317). 
 
The basic principle that underlies LDF is the Doppler shift which describes the 
frequency change that a wave undergoes when emitted from a moving object 
relative to a static detector (318). LDF emits a monochromatic laser light that is 
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carried by the transmitting optical fibre to the tissue. Some of the light photons will 
be scattered by moving red blood cells and therefore undergo Doppler shift. Photons 
that encounter static tissue will not have any frequency change of the light 
wavelength (no Doppler shift). Both Doppler shifted and non-Doppler shifted back-
scattered light from the tissue is conducted through the receiving optical fibre 
(separate from the transmitting optical fibre) to a photo detector that produces an 
electrical signal containing all of the Doppler frequency shift information (318,319). 
Further processing of the signal is performed by the photo detector, and the final 
output signal is displayed as blood flow perfusion units or blood cell ‘Flux’ units. 
The blood flow displayed represents the product of the number of moving red cells 
and their mean velocity (319).         
 
The relationship between total tissue blood flow, such as in the liver or hindlimb, 
and the signal measured by LDF on the surface of the tissue has been shown to be 
linear and reproducible (320). Furthermore, LDF is sensitive to rapid blood flow 
changes within tissues (320). However it is important to note that LDF is only 
accurate in assessing relative changes in tissue perfusion but should not be used to 
quantify tissue MBF in absolute units as there is no conversion factor to achieve this 
(321,322). Hepatic and hindlimb MBF assessments in the mouse using LDF are well 
described (323,324). Hindlimb MBF is assessed by LDF measurements made in the 
foot (323,325).         
 
3.8.2 Measuring liver and hindlimb microcirculatory blood flow  
A dual channel laser Doppler flowmeter (DRT4, Moor Instruments Ltd., UK) was 
used to measure blood flow in the microvasculature of the liver and hindlimb. For 
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each experiment one probe was placed on the left liver lobe, whilst the second was 
placed on the sole of the right foot. In both cases the probe was positioned so that it 
was just in contact with the tissue surface. The hepatic probe was mounted in a 
tubular probe holder in order to prevent the probe from pressing on the hepatic 
surface and causing microvascular occlusion. For a similar reason, the hindlimb 
probe was fixed to the operating table using adhesive tape, with the tip positioned on 
the sole of the right foot (figure 3.5). LDF data was collected as the means of four 
readings recorded over a one minute period. Figure 3.6 shows the time points of 
LDF recordings during the study protocol. The hindlimb LDF measurements were 
made but not recorded, as these were performed only to ensure adequate blood flow 
interruption to the hindlimb during ischaemia, with recovery of blood flow during 
hindlimb reperfusion.  
 
 
Figure 3.5. Photograph of a mouse illustrating LDF probes positioned on the left 
hepatic lobe and sole of the right foot. 
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Figure 3.6. Time points of Laser Doppler Flowmetry (LDF) measurements.      
indicates time points of foot and liver LDF measurements;    indicates time points of 
liver only LDF recordings. The mean of four LDF readings over a one minute period 
was recorded at each time point indicated. Note during cycles 1 to 6 of HI and HR 
the hindlimb LDF measurements were made but not recorded, as these were 
performed only to ensure adequate blood flow interruption to the hindlimb during 
HI, with recovery of blood flow during HR. BL, baseline; HI, hindlimb ischaemia; 
HR, hindlimb reperfusion; BLI, beginning of liver ischaemia; ELI, end of liver 
ischaemia; BR, beginning of liver reperfusion; R30 to R120 - liver reperfusion at 30, 
60, 90, and 120 min post ischaemia.  
 
3.9 eNOS and iNOS Western blot analysis 
3.9.1 Protein extraction and quantification 
Individual samples of liver and skeletal muscle tissues (100 mg) were homogenised 
in liquid nitrogen. Cell lysis was achieved by the addition of RIPA buffer (Sigma) 
containing a protease inhibitor (Roche), and repeat vortexing. The samples were 
then centrifuged at 12,700 rpm (15150 g) for 15 min at 4 ℃. Protein concentrations 
in the supernatants were measured by the modified Lowry protein assay kit (Pierce 
Biotechnology, USA).  
 
3.9.2 SDS gel electrophoresis and Western blotting   
Protein denaturation was achieved by the addition of  Laemmli sample buffer (2X, 
Sigma, UK) to each protein sample (made up with RIPA buffer to a concentration of 
8 µg / µl) in a volumetric ratio of 1:1, followed by heating to 95 ℃. Nu-
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polyacrylamide gel electrophoresis (NuPAGE 4-12% Bis-Tris Gel, Invitrogen, 
USA) in NuPAGE running buffer was used to separate the proteins, which were then 
electro-blotted onto polyvinylidene difluoride (PVDF) membrane (Bio-Rad, USA) 
soaked in NuPAGE transfer buffer. The membranes were blocked with 5 % semi-
skimmed milk powder (Marvel) dissolved in PBS, followed by incubation over night 
with either polyclonal rabbit anti-eNOS or anti-iNOS (Santa Cruz Biotechnology, 
USA) in a 1:200 dilution. The membranes were then washed with PBS, incubated 
with secondary goat anti-rabbit IgG antibody conjugated with HRP in a 1:1000 
dilution for 45 min, washed with PBS, illuminated with Super Signal West Dura 
Extended Duration Substrate (Pierce, USA), and exposed to x-ray films (Fuji 
medical x-ray films) for variable duration to visualise the proteins bound to 
antibody. The x-rays were scanned and the density of the eNOS protein bands were 
analysed with Bio-Rad densitometry software (Molecular Analyst, Windows 
software for Bio-Rad’s image analysis system version 1.5, USA).      
 
3.10 eNOS immunohistochemistry 
The left liver lobe and the thigh of the right hindlimb were biopsied at the end of the 
experiment in each of the animals and were immediately fixed in 10% formal saline. 
The fixed tissues were then embedded in paraffin, cut into 3 µm sections, dewaxed 
in xylene, and taken through alcohol. Endogenous peroxidase was blocked with 
hydrogen peroxide in methanol followed by washing with water. The sections were 
then pressure cooked for three and a half minutes in citrate buffer (pH 6.0), washed 
with water, soaked in Tris Buffered Saline with Tween (TBS-T), and treated with a 
protein solution (Casein- Leica Microsystems) to block background staining. 
Incubation with rabbit polyclonal eNOS primary antibody (Santa Cruz 
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Biotechnology, CA, USA) was done overnight at 4 ℃ in a 1:100 dilution. The 
sections were then washed with buffer, incubated with secondary antibody 
conjugated with HRP for 30 min, washed with buffer, developed with 3,3’-
Diaminobenzidine, washed with water, counterstained with Mayer’s Haematoxylin, 
and mounted for microscopic examination. Placental tissue was used as positive 
control. For negative controls, liver sections were processed without primary 
antibody.  
 
3.11 Nitrite and nitrate measurements 
The plasma nitrite and nitrate (NOx) levels were measured in wild type mice using a 
commercially available colorimetric assay kit (Cayman Chemical, catalogue No. 
780001). The plasma was first deproteinated using 30 kDa centrifugal filters and 
diluted 1 in 8 using assay buffer. Total nitrite and nitrate concentrations were 
determined by the reduction of nitrate to nitrite using nitrate reductase (Cayman 
Chemical, catalogue No. 780010) in the presence of enzyme cofactor (Cayman 
Chemical, catalogue No. 780012). Greiss reagent was then added to the solution 
containing nitrite and the resultant colour development was quantified by reading 
the absorbance at 550 nm. The total NOx (µM) were calculated using the nitrate 
standard curve. 
  
3.12 Measurement of hepatic cGMP  
cGMP (cyclic 3’, 5’ guanosine monophosphate) accumulation in liver tissue was 
determined in wild type mice. To extract cGMP from liver tissue 250 µL of 0.1M 
HCL was added to each liver tissue followed by homogenisation at 50 Hz for 2 
minutes using a TissueLyser (Qiagen). The samples were then centrifuged at 13000 
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rpm for 5 minutes at 4 C and the supernatant was filtered through 30 kDa centrifugal 
filters. The filtrates were dried under vacuum for 4 hrs. Quantification of cGMP in 
the samples was performed using a commercial enzyme immunoassay (EIA) kit 
(Cayman Chemical, catalogue No. 581021). Briefly, the dry pellets were 
resuspended in EIA buffer. Samples (50 µL) or standard solutions of cGMP (50 µL 
of 30 pmol/ml to 0.23 pmol/ml) were incubated together with cGMP EIA antiserum 
(50 µL) and acetylcholinesterase linked to cGMP tracer (50 µL) in a plate pre-coated 
with mouse monoclonal anti-rabbit IgG at room temperature for 18 hours. After the 
plates were washed, colour development was achieved by the addition of Ellman’s 
Reagent (200 µL) and incubation for 60 minutes. Absorbance was measured at 410 
nm. cGMP concentrations were calculated using the standard curve generated.           
 
3.13 Statistical analysis 
Values are expressed as mean ± standard error of the mean (SEM). One way 
analysis of variance (ANOVA) with Post Hoc Bonferroni correction for multiple 
comparisons was used. Independent-samples t-test was used to compare means 
when there were only two groups. Paired-samples t-test was used to compare the 
means within a single group at different points in time. P < 0.05 was considered 
statistically significant in all analyses.   
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Chapter 4 
 
Development of a new mouse model to study the effect of 
hindlimb ischaemic preconditioning on liver IR injury  
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4.1 Introduction 
Hepatic IR injury is seen either in clinical settings causing direct liver ischaemia 
such as liver surgery and transplantation, or in the setting of systemic hypoxemia 
(e.g. respiratory failure) or shock states followed by resuscitation (e.g. haemorrhage, 
sepsis). The consequences of liver IR injury depend not only on the length of the 
ischaemic insult, but also on the background condition of the liver (7). For example 
cirrhotic and steatotic livers are more susceptible to IR compared to normal livers 
(8,9). One of the therapeutic strategies to lessen liver IR injury is remote ischaemic 
preconditioning (RIPC). This concept involves brief ischaemia to one organ 
protecting a remote organ against prolonged ischaemic insults. RIPC was first 
described by Przyklenk et al (326) in 1993 who showed that brief occlusion of the 
circumflex artery in the heart protected against a subsequent prolonged ischaemic 
insult of the myocardial territory supplied by the left anterior descending artery. 
RIPC is a systemic phenomenon, meaning preconditioning of one body region will 
protect all other organs to varying degrees. This observation has led to the search for 
both humoral and neuronal mediators of RIPC, reviewed by Tapuria et al in 2008 
(327). The hepato-protective effects of direct liver preconditioning (IPC) are seen 
over two time windows (328). The early phase of preconditioning commences 
immediately following a brief ischaemic stimulus and lasts under four hours. The 
late phase begins 12-24 hours after preconditioning and lasts 72-96 hours. Similarly, 
RIPC has also been shown to exert its beneficial effects over the same timeframe 
(327).    
 
The main advantage of RIPC over direct IPC is the applicability of the former to the 
upper or lower limb in a non-invasive manner through the use of external pressure 
 111 
on the limb, to achieve vessel occlusion and blood flow cessation. Simple devices 
such as tourniquets and blood pressure cuffs are ideal. The clinical attractiveness and 
safety of this non-invasive approach to preconditioning is obvious. Human studies, 
including randomised clinical trials, have shown the heart and vascular endothelium 
to be protected by limb RIPC (329,330). However, to date there are no published 
human studies on the benefits of limb RIPC in ameliorating liver IR injury.  
 
The protective effects of limb RIPC against liver IR injury in the rabbit (227), and 
the rat (229) have previously been demonstrated. Recently a mouse model of limb 
RIPC followed by liver IR was described (226). The authors of this study used an 
elastic band to induce hindlimb ischaemia in female mice and they reported a 
reduction in liver IR injury. However, they did not objectively measure blood flow 
in the limb. In addition, elastic bands lose elasticity with repeated usage and will 
produce variable pressures when applied to the limb. Furthermore, the female 
hormone oestrogen and its derivatives are known to protect against IR injury of the 
liver (331). Therefore the variation in oestrogen levels during the oestrous cycle in 
females leads to variable susceptibility to IR injury congruent with the stage of the 
oestrous cycle (332). In light of this the majority of experimental IR injury models 
use male animals only.  
 
Mice are the only species with commercially available transgenic strains. The use of 
transgenics in scientific research represents one of the most accurate methods of 
delineating the functions of specific gene products or proteins, and thereby of the 
underlying molecular pathways underpinning the benefits of RIPC. If the molecular 
mechanisms of RIPC are understood then it may be possible to develop targeted 
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pharmacological interventions to mitigate the harmful effects of IR injury. Mouse 
limb RIPC models have been described that offer protection against myocardial, 
pulmonary, and intestinal IR injury (234,333). Experimental hindlimb 
preconditioning may be performed either with the application of an external device 
to occlude femoral blood flow, such as with the use of a tourniquet or a rubber band; 
or maybe done through an open incision and direct clamping of the femoral artery, 
or femoral artery and vein. The open method has the advantage of not exerting any 
direct pressure on the neuro-musculature of the groin, which could lead to pressure 
necrosis of these structures and a consequent inflammatory reaction with 
disturbances in limb and systemic haemodynamics.      
 
In the present study, we developed a mouse model of hindlimb RIPC that protects 
against liver IR injury and that could be utilized to shed light on the mechanisms 
underlying the protection of RIPC.  
 
4.2 Materials and methods 
The detailed methodology was described in chapter 3. A summary of the most 
pertinent points is given below. 
 
4.2.1 Mouse model of hindlimb remote ischaemic preconditioning of 
the liver 
Inbred male C57BL/6 wild type mice (Charles River laboratories, UK) were utilized 
in the present studies. The animals were anaesthetised using 2% isoflurane. Core 
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body temperature was maintained at 37.0 ± 0.5 ℃ using a heating pad and 
monitored by a rectal temperature probe.  
 
Laparotomy was performed through a midline incision. The falciform ligament and 
the ligament connecting the caudate to the left lobe were divided. A microvascular 
clamp was then applied to the portal triad supplying the left and median lobes. 
Successful occlusion of the portal triad was confirmed by a change in colour and a 
reduction in microcirculatory blood flow (MBF) as measured by laser Doppler 
flowmetry (LDF). The animals were subjected to 40 minutes of hepatic ischaemia 
followed by two hours of reperfusion. At the end of the reperfusion period the 
animals were terminated by exsanguination through cardiac puncture and blood 
collection. The blood was immediately centrifuged and the plasma supernatant was 
stored at -70 ℃ until assayed for liver transaminases. The left and median liver 
lobes were harvested at the end of each procedure for histopathology and transition 
electron microscopy.  
 
The preliminary experiments involved recovering the animals from anaesthesia 
during the two hour liver reperfusion period in order to assess general mobility and 
hindlimb function following RIPC. The RIPC protocol consisted of four minutes 
ischaemia followed by four minutes reperfusion for a total of six cycles. Cessation 
of blood flow to the hindlimb was confirmed by the change in foot colour and by the 
reduction in foot MBF as measured by LDF. From these preliminary experiments it 
became clear that the tourniquet technique resulted in limb paralysis probably 
secondary to hindlimb neuromuscular damage as evidenced by gross neuromuscular 
bruising in the preconditioned hindlimb soft tissues. Therefore the tourniquet 
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technique was abandoned and all remaining experiments were performed using the 
open method of preconditioning.            
 
4.2.2 Non-recovery experimental groups 
Four groups with a minimum of six animals in each were used (Figure 3.2). The 
total anaesthetic time was equal in all the groups. All animals underwent 
laparotomy, mobilization of the liver, and mobilization of the right femoral vascular 
bundle. In addition some of the groups were each subjected to a specific procedure 
as follows: 
  
Sham: Only underwent the laparotomy, mobilization of the liver, and mobilization 
of the right femoral vascular bundle described above.  
RIPC: The right hindlimb was preconditioned with 6 cycles of 4 minutes ischaemia 
followed by 4 minutes reperfusion, using a microvascular clamp to occlude the 
femoral vessels under an operating microscope. 
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: Animals were subjected to the RIPC followed by the IR procedures.   
 
The plasma ALT and AST levels, and the histological and ultrastructural markers of 
liver damage were all assessed at the end of two hours of reperfusion following liver 
ischaemia (or equivalent time points in the sham and RIPC groups). 
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4.2.3 Measurement of liver enzymes  
The concentrations of ALT and AST were measured in the plasma using an 
automated clinical analyzer (section 3.5). These enzymes are sensitive markers of 
liver injury which are released from injured hepatocytes into the circulation.    
          
4.2.4 Histopathology 
A liver biopsy was taken from the left ischaemic lobe of each animal at the end of 
the experiment and was immediately fixed in 10% formal saline. The fixed tissues 
were embedded in paraffin, and stained with H&E. Sections were assessed by a liver 
pathologist blinded to the animal groups. Each H&E sample was scored using two 
different methods as described in section 3.6.  
 
4.2.5 Transmission electron microscopy  
Liver biopsies were obtained from the left lobe at termination of the animals and 
were fixed in a glutaraldehyde / paraformaldehyde mixture overnight. An automated 
tissue processor (Leica EM TP) embedded the samples in Lemix epoxy resin. 
Stained semi-thin sections were examined under light microscopy to determine the 
areas exhibiting damage. Ultrathin sections of these were then cut, stained, and 
viewed with a transmission electron microscope. Representative areas were 
photographed and the images were interpreted by a transition electron microscopy 
(TEM) scientist who was blinded to the groups. Assessment of the images was 
performed according to the parameters outlined in section 3.7. 
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4.2.6 Liver and hindlimb microcirculatory blood flow 
A dual channel laser Doppler flowmeter (DRT4, Moor Instruments Ltd., UK) was 
used to measure blood flow in the microvasculature of the liver and hindlimb 
(section 3.8). One probe was placed on the left liver lobe, whilst the second was 
placed on the sole of the right foot. In both cases the probe was positioned so that it 
was just in contact with the tissue surface. Hepatic LDF data was collected as the 
means of four readings recorded over a one minute period. Figure 3.6 shows the 
time points of the LDF recordings during the study protocol. The hindlimb LDF 
measurements were made but not recorded, as these were performed only to ensure 
adequate blood flow interruption to the hindlimb during ischaemia, with recovery of 
blood flow during hindlimb reperfusion.  
 
4.2.7 Animal survival and postoperative complications 
In order to evaluate the delayed benefits and side effects of hindlimb 
preconditioning, the clinical postoperative course of mice in the sham, IR, and RIPC 
+ IR group (n = 6 per group) was followed for 28 days. Each group underwent its 
respective surgical procedure followed by a recovery period of up to 28 days. At the 
end of this period the animals were humanely terminated.    
 
4.2.8 Statistical analysis 
 
Values are expressed as mean ± SEM. One way analysis of variance (ANOVA) with 
Post Hoc Bonferroni correction for multiple comparisons was used. Paired-samples 
t-test was used to compare the means within a single group at different points in 
time. P < 0.05 was considered statistically significant in all analyses.    
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4.3 Results 
4.3.1 Preliminary recovery experiments: Hindlimb RIPC limits hepatic 
IR injury but the tourniquet technique causes hindlimb paralysis 
The initial experiments were designed to test: 1. the effectiveness of hindlimb RIPC 
in mitigating liver IR injury; and 2. the possible side effects of the tourniquet versus 
the open clamp techniques of hindlimb RIPC. To this end the mice were recovered 
from anaesthesia during the two hours of liver reperfusion.   
The plasma ALT and AST levels were lower in the animals that had either the 
tourniquet (n = 2) or open clamp (n = 4) methods of hindlimb preconditioning prior 
to liver IR (RIPC + IR group) compared to the group that had liver IR alone. Whilst 
the difference in ALT levels between the IR and the two RIPC + IR (tourniquet and 
open clamp) groups did not reach statistical significance (P > 0.05), those of AST 
were significantly lower in the preconditioned groups (P = 0.034 vs RIPC + IR 
(tourniquet); P = 0.004 vs RIPC + IR (open clamp)).  There were no significant 
differences in both the ALT or AST levels between the two techniques of 
preconditioning.  
 
On recovery of the animals from general anaesthesia, the group that had the 
tourniquet technique of hindlimb RIPC was noted to be paralysed in the 
preconditioned limb upon ambulation. Moreover, physical bruising of skeletal 
muscles and femoral nerves were noted following animal termination and dissection 
of preconditioned hindlimbs. The group that was preconditioned using direct 
application of a microvascular clamp to the femoral vessels (open clamp technique) 
did not show paralysis, or neuromuscular bruising of the preconditioned hindlimb. 
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Similarly, the liver IR alone group with a sham exposure and mobilisation of vessels 
showed no limb neuromuscular damage.  
 
Based on the results of the preliminary experiments showing equipotent benefit with 
both the invasive and non-invasive techniques of hindlimb preconditioning, but 
revealing neuromuscular paralysis only with the latter, all subsequent experiments (n 
≥ 6 in each group) were performed using the open clamp method of preconditioning. 
The biochemical, histological, and ultrastructural markers of liver damage were 
assessed at the end of the two hours of reperfusion following liver ischaemia in all 
these experiments, or the equivalent time points in the sham and RIPC groups 
(figure 3.2).  
 
4.3.2 Hindlimb RIPC reduces plasma transaminases levels   
The two groups (sham and RIPC) not subjected to liver IR had minimal increases in 
both plasma ALT and AST levels at the end of the experimental protocol. In 
comparison the IR group had significantly higher levels of both enzymes (figure 
4.1), indicating significant liver damage. When hindlimb RIPC preceded liver IR 
(RIPC + IR group) there was a significant reduction in plasma levels of both 
enzymes in comparison to the IR group (P < 0.05).  
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Figure 4.1. Plasma liver enzyme levels. (A) Alanine aminotransferase (ALT). *P < 
0.05 vs IR; #P < 0.05 vs RIPC+IR. (B) Aspartate aminotransferase (AST). *P < 0.05 
vs IR; #P < 0.05 vs RIPC+IR.  
 
 
4.3.3 Hindlimb RIPC attenuates IR-induced liver histopathological 
injury 
An overall histopathological grade was assigned to each sample (figure 4.2). The 
sham and RIPC groups showed minimal signs of liver IR injury with a mean overall 
grade of 0 in each. Liver IR resulted in a significant increase in the mean overall 
injury grade (IR group mean overall grade = 1.83) compared to the sham and RIPC 
groups (P < 0.05). Preconditioning prior to liver IR (RIPC + IR group) decreased the 
mean overall injury score to 1.33 (P < 0.05 vs sham or RIPC; P > 0.5 vs IR).  
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Figure 4.2. Vertical scatter plot of histopathological grades. Each dot represents the 
overall grade assigned to each individual liver biopsy sample (n = 6 per group). 
Horizontal bars represent the means. *P < 0.05 vs sham or RIPC. 
 
To confirm the findings of the overall grade of injury and to further explore the 
histopathological features which are most improved by hindlimb preconditioning in 
liver IR injury, each sample was assessed and scored for each feature of injury as 
outlined in the methods. The sham and RIPC groups had equal mean scores in 6 out 
of the 10 individual features assessed. The remaining 4 features had a higher mean 
score in the RIPC compared to the sham, although in none of these was statistical 
significance achieved (figure 4.3). 
 
Liver IR resulted in a higher mean score in all 10 individual features compared to 
both the sham and RIPC alone groups (figure 4.3). However, statistical significance 
(P < 0.05) was only achieved in 4 of these features (discohesive hepatocytes, liver 
cell ballooning, blurred intercellular borders, RBC extravasation).  
 
 
* * 
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In contrast the RIPC + IR group resulted in a higher mean score in 8 of the 10 
individual features compared to both the sham and RIPC alone groups, with 
statistical significance achieved in only two of these features compared to sham 
(discohesive hepatocytes, liver cell ballooning) and in none compared to RIPC 
(figure 4.3). Compared to IR, the RIPC + IR group resulted in a lower mean score in 
8 out of the 10 individual features. The remaining 2 features (neutrophil infiltration 
and nuclear pyknosis) had a higher mean score in the RIPC + IR compared to the IR 
group (figure 4.3). None of the differences between the RIPC + IR and the IR alone 
group reached statistical significance.  
 
4.3.4 Ultrastructural damage is ameliorated by hindlimb RIPC 
Table 4.1 details the ultrastructural damage seen in each of the animal groups. The 
sham group showed normal ultrastructural appearances. The RIPC group showed 
pleomorphic undamaged mitochondria, endoplasmic reticulum (ER) dilatation, 
phagolysosomal formation, lipid droplet formation, and cytosolic glycogen granules. 
The IR group exhibited extensive mitochondrial damage, ER dilatation, cytosolic 
vacuole formation, phagolysosomal formation, lipid droplet formation, glycogen 
depletion, bile canaliculi dilatation with damaged microvilli, and sinusoidal 
endothelial cell (SEC) disruption with extravasation of red blood cells (RBC) into 
the liver parenchyma. In contrast the main ultrastructural features exhibited by the 
RIPC + IR group consisted of pleomorphic undamaged mitochondria, ER dilatation, 
phagolysosomal formation, lipid droplet formation, glycogen depletion, and 
disruption of SEC but without RBC extravasation. Figure 4.4 shows representative 
transmission electron micrographs from each animal group.        
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Figure 4.3. Histopathological scores of individual features of liver IR injury. Each 
bar chart is the mean histopathological score of six animals in that group. The error 
bars are the standard error of the means. *P < 0.05 vs sham; #P < 0.05 vs RIPC.   
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Animal 
group 
Mitochondrial 
damage 
ER dilatation Vacuolation Phagolysos-
omes 
Lipid 
droplets 
Glycogen 
granules 
Bile 
canaliculi 
Sinusoidal 
damage 
Sham Rare Rare Rare Rare Rare Frequent Rarely dilated, 
microvilli 
present 
Normal SEC 
microvilli in 
SD 
RIPC Rarely damaged 
but pleomorphic 
Frequent with 
vesiculation 
Rare Frequent 
 
Frequent Frequent Rarely dilated, 
microvilli 
present 
Rare SEC 
damage with 
sinusoidal 
debris. Micro-
villi in SD 
IR Frequently 
damaged and 
pleomorphic 
Homogenous 
dilatation and 
vesiculation 
Abundant, 
variable size 
and contain 
amorphous 
material 
Frequent Frequent Rare Frequently 
dilated, 
microvilli 
disrupted 
Severe disrup- 
tion to SEC, 
sinusoidal 
debris, 
frequent RBC  
extravasation, 
damaged SD  
microvilli 
RIPC + IR Rarely damaged 
but pleomorphic 
Frequent with 
vesiculation 
Rare Frequent Frequent Rare Rarely dilated, 
microvilli 
present 
Frequent 
disruption to 
SEC, sinusoid-
dal debris, rare 
RBC extravas-
ation. Microvi-
lli in SD 
 
Table 4.1. Summary of TEM appearances in each animal group. RBC, red blood cell; ER, endoplasmic reticulum; SD, space of Disse; SEC, 
sinusoidal endothelial cell. 
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Figure 4.4. Hepatic transmission electron micrographs. The liver samples were taken at the end of the respective procedure in each group. (A) 
& (B) Sham group showing normal endoplasmic reticulum (er), bile canaliculi with microvilli (bc), mitochondria (m), glycogen (gl), sinusoidal 
endothelial cells (sec), and microvilli in space of Disse (ms). (C) & (D) RIPC group showing pleomorphic mitochondria (m), normal (er) and 
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dilated (der) endoplasmic reticulum, bile canaliculi with microvilli (bc), glycogen (gl), lipid droplets (ld), phagolysosomes (pl), sinusoidal 
endothelial cells (sec), microvilli in space of Disse (ms), and red blood cells in the sinusoidal lumen (rbc). (E) & (F) IR group demonstrating 
irreversibly damaged mitochondria (dm) with some merging into vacuoles (vc), dilatation and vesiculation of endoplasmic reticulum (der), lipid 
droplets (ld), lysosomes (ly) and phagolysosomes (pl), and severely damaged sinusoidal endothelial cells (dsec) associated with extravasation of 
red blood cells (erbc) and obliteration of the space of Disse (sd). (G) & (H) RIPC + IR group demonstrating pleomorphic mitochondria (m), 
normal (er) and dilated (der) endoplasmic reticulum, lipid droplets (ld), lysosomes (ly) and phagolysosomes (pl), damaged sinusoidal 
endothelial cells (dsec), and microvilli in space of Disse (ms).  
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4.3.5 Hepatic microcirculatory blood flow is preserved by hindlimb 
RIPC   
The MBF expressed as a percentage of baseline (defined as 100%) is illustrated in 
figure 4.5.  
 
The sham (group 1) and RIPC (group 2) groups did not show any significant 
changes in hepatic MBF, as compared to their respective baseline measurements or 
to each other. The IR (group 3) and RIPC + IR (group 4) groups exhibited constant 
MBF with no significant deviation either from their respective baselines, or mean 
values of other groups, up to the time point of hepatic ischaemia induction (BLI in 
figure 4.5). 
   
With the onset of partial hepatic ischaemia, the blood flow in the affected lobe 
decreased to 39.1% and 41.0% of pre-ischaemic baseline levels in the IR and RIPC 
+ IR groups respectively. At the end of 40 minutes of ischaemia, immediately 
preceding liver reperfusion, the flow remained low averaging 36.3% and 46.6% 
respectively in the two groups. The MBF levels during hepatic ischaemia were 
significantly lower in both the IR and RIPC + IR groups compared to their baselines 
and to the sham and RIPC groups (figure 4.5). There was no significant difference 
between the IR and RIPC + IR groups during hepatic ischaemia. 
  
Upon reperfusion of the liver, recovery of the microcirculation was greater in the 
group with RIPC preceding liver IR as compared to the IR only group. At the 
beginning of liver reperfusion in the IR group the flow increased but was still low at 
58.0% of baseline (P = 0.006 vs baseline, P < 0.0001 vs sham, P = 0.001 vs RIPC, P 
 127 
= 0.046 vs RIPC + IR), whilst that of the RIPC + IR group showed much greater 
recovery of MBF to 84.3% (P = 0.08 vs baseline, P > 0.05 vs sham or RIPC). 
During the ensuing two hours of liver reperfusion, the MBF continued to improve in 
the RIPC + IR group, so that the mean flow at 30, 60, 90, and 120 minutes of 
reperfusion recovered towards 90% of baseline levels, and was not significantly 
different from either the baseline or from the sham or RIPC groups. In the RIPC + 
IR group the mean flow at 120 minutes was as high as 93.5% of baseline. In contrast 
over the same period the flow in the IR group remained significantly depressed, 
recording a mean of 53.4% of baseline at the end of two hours reperfusion. At all 
time points of reperfusion the flow was significantly lower in the IR group 
compared to the baseline and to the sham, RIPC, and RIPC + IR groups (P < 0.01 vs 
baseline, Sham, RIPC, or RIPC + IR, at 30, 60, 90, and 120 minutes reperfusion).     
 
Considered together these findings show that antecedent hindlimb preconditioning 
preserves the blood flow through the hepatic microvasculature in livers subjected to 
IR injury. 
 
4.3.6 Animal survival and postoperative complications  
There were no postoperative complications or mortality during the 28 day recovery 
period. Furthermore, none of the mice suffered any problems with mobility during 
this interval.  
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Figure 4.5. Hepatic microcirculatory blood flow, measured by LDF, is illustrated as 
mean percentage compared to pre-ischaemic baseline. The coloured * at each time 
point indicates P < 0.05 vs baseline value (100%) for each group. Significant (P < 
0.05) inter-group differences are shown vertically above the time points on the x-
axis. BL, baseline; HI, hindlimb ischaemia; HR, hindlimb reperfusion; BLI, 
beginning of liver ischaemia; ELI, end of liver ischaemia; BR, beginning of liver 
reperfusion; R30 to R120, liver reperfusion at 30, 60, 90, and 120 min post 
ischaemia.      
 
4.4 Discussion 
The clinical need for effective strategies to reduce IR injury emanating from liver 
surgery and transplantation is great. One of these strategies is hindlimb RIPC which 
has been shown to decrease hepatic IR injury in the rabbit (227) and rat (229). In 
this study we have described and validated a mouse model in which hindlimb RIPC 
significantly reduced liver IR injury. Mice are the only species that currently offer 
transgenic animals with targeted gene mutations, and therefore represent one of the 
most useful tools available to study the molecular pathways underpinning the 
protection exhibited by hindlimb RIPC upon liver IR injury.  
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The liver ischaemia protocol we used is well described in the literature (334), and 
encompasses clamping the left and median liver lobes thereby rendering 70% of the 
liver ischaemic. This produces a significant liver injury but also permits portal 
venous decompression through the right and caudate lobes, preventing intestinal 
venous congestion and ischaemia. In order to establish a hindlimb preconditioning 
protocol we initially used an inflatable tourniquet to occlude the blood flow to the 
hindlimb in a non-invasive manner. Whilst this technique did achieve hindlimb 
ischaemia, as measured by the MBF in the foot using LDF, it resulted in 
neuromuscular bruising and paralysis at tourniquet pressures needed to cause 
cessation of blood flow to the hindlimb. This was an important finding as the 
bruising indicated damage and ischaemia to the limb neuromuscular structures 
which in itself could cause remote IR injury of the liver (335,336). In our previous 
studies using an external tourniquet to induce hindlimb RIPC in the rabbit and rat 
(227,229), no hindlimb damage was sustained. The neuromuscular structures in the 
limbs of mice are more delicate and fragile compared to those of rabbits and rats; 
hence the mouse is much more susceptible to pressure necrosis brought about by 
external circumferential pressure devices applied to the limbs. Based on these 
findings we established an invasive model of hindlimb preconditioning that involved 
direct clamping of the femoral vascular bundle, whilst avoiding any soft tissue 
injury. All animals, including the sham and IR groups, underwent mobilisation of 
the femoral vessels thereby ensuring all the groups are exposed to comparable levels 
of surgical stress induced by the hindlimb incision and vascular bundle dissection. 
To verify limb ischaemia and ensure comparability between the groups we used 
LDF on the sole of the foot to measure MBF.    
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Recently Wang et al (226) described the use of an elastic band to produce hindlimb 
ischaemia in female mice. The authors did not determine whether hindlimb soft 
tissue injury was present. Furthermore the use of elastic bands can produce variable 
pressures (and therefore variable degrees of vessel occlusion) on application to the 
limb due to two factors. First repeated usage may result in loss of some of the elastic 
recoil of elastic bands (become slack); secondly the pressure exerted by the elastic 
band is dependent on the circumference of the thigh and hence the exact level of the 
band on the leg, with larger thighs being subjected to greater pressures. Objective 
confirmation of blood flow cessation to the limb is therefore essential in 
preconditioning models. In addition the female hormone oestrogen and its 
derivatives are known to protect against IR injury of the liver (331), therefore usage 
of female mice is to be avoided in IR research as the variation in oestrogen levels 
during the oestrous cycle may lead to variable susceptibility to IR injury (332). To 
ensure the reliability and validity of any animal model of limb RIPC it is important 
to address these confounding variables, otherwise systemic errors may be introduced 
into the results. In the invasive hindlimb preconditioning model we describe, the 
effects of confounding variables were minimised through the measurement and 
control of body temperature, utilisation of an inbred strain of mice, usage of only 
male animals of similar age and weight, random selection of mice into each 
experimental group, subjection of all animals to the same sham procedure in 
addition to any group-specific procedure, confirmation of liver and hindlimb 
ischaemia by LDF measurements, and assessment of histopathological and 
ultrastructural damage to the liver by experts blinded to group allocation. The model 
demonstrated a consistent reduction in plasma transaminases, histopathological and 
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ultrastructural liver injury, and an improvement in hepatic MBF as a result of remote 
preconditioning.  
 
Other mouse models of limb RIPC have been used to ameliorate IR injury in other 
organs. In two of these studies bilateral limb rubber bands or tourniquets were used 
(234,333) for preconditioning, but assessment of the adequacy of limb blood flow 
interruption during ischaemia was not reported. In the third study external finger 
pressure was applied to the femoral vessels and limb ischaemia was verified by 
means of pulse oximetry (311). Although digital pressure is less likely to result in 
neuromuscular damage the degree of inflow occlusion is unlikely to be consistent.         
 
The invasive hindlimb RIPC mouse model described herein is primarily to be 
utilized as a well-controlled, robust experimental model to study the mechanisms 
underlying RIPC. The preconditioning protocol is vital to the modulation of liver IR 
and is species specific (337). The optimal number of cycles and the length of each 
cycle have not been determined for different animal species. We found a protocol of 
six cycles of four minutes ischaemia followed by four minutes reperfusion results in 
significant reductions of liver IR injury in our model.  
 
With this model of open clamping technique of limb preconditioning, both the ALT 
and AST plasma levels were significantly lower in the RIPC + IR compared to the 
IR alone group. In agreement with this, the overall histopathological grade (figure 
4.2) and eight out of the ten individual features of histopathological injury (figure 
4.3) showed less injury in the RIPC + IR compared to IR alone. Interestingly, in this 
model with a two hour reperfusion period all ten individual features had a higher 
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mean score in the IR compared to the sham group but statistical significance was 
only achieved in four of these features. In order to explain the lack of statistical 
significance for the RIPC + IR compared to IR alone, and in six of the ten individual 
features for the IR compared to sham, it is important to understand that the sequence 
of events in liver IR injury is conceptually divided into two phases (338). The early 
or acute phase covers the first two hours following reperfusion and is dominated by 
kupffer cell activation and release of various mediators such as reactive oxygen 
species and cytokines. The late phase commences at about six hours of reperfusion 
and is characterised by neutrophil accumulation in the liver and progression of 
hepatocyte and sinusoidal endothelial cell damage. These events form a continuum 
of injury progression, and importantly different cellular morphological changes may 
have different kinetics of expression and temporally lag behind the molecular events 
following microcirculation injury (339,340). In our mouse model liver biopsies were 
taken at the end of two hours of reperfusion, which represents the early phase of 
injury when histopathological features of IR injury are in their early stages before 
they have exhibited their full manifestations, hence explaining the lack of statistical 
significance in the eight histopathological features of liver IR injury (and the overall 
grade) that showed less damage with RIPC + IR compared to IR. In addition the fact 
that liver biopsies in our model were obtained at the end of two hours of reperfusion 
would also explain why statistical significance was only observed in four out of the 
ten features that had a higher mean score in the IR compared to sham. Previous 
studies support our results by showing that for a given period of liver ischaemia, the 
degree of histopathological manifestations of liver injury is dependent on the length 
of liver reperfusion. Hines et al (258) showed a 45 minute partial liver ischaemia 
results in a gradual increase in histopathological injury scores as length of the 
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reperfusion period increases with statistical significance only achieved between the 
sham and IR groups at six hours of reperfusion. Other studies support this concept of 
increasing severity of histopathological manifestations of liver IR injury with 
increasing liver reperfusion length, up to a 24 hour reperfusion period, for a given 
length of liver ischaemia (341,342). In contrast the histopathological benefits 
afforded by direct liver IPC do not seem to be dependent on the length of the 
reperfusion period, as there is significant attenuation of histopathological injury with 
IPC that is seen from 30 minutes post reperfusion in some studies, and that is 
extended to various time points of up to 48 hours of reperfusion in others 
(82,312,343-345).           
 
Assessment of ultrastructural changes by TEM showed hindlimb RIPC acts on 
multiple subcellular structures to protect against liver IR. Specifically RIPC 
protected against mitochondrial damage, vacuole formation, bile canaliculi damage, 
and limited the extent of damage to the sinusoids. Mitochondrial damage is a central 
event in liver IR injury and has been shown, at least at an ultrastructural level, to be 
ameliorated by direct liver ischaemic preconditioning (312), and now we have 
demonstrated a reduction in mitochondrial ultrastructural damage by remote 
preconditioning. Hepatocyte vacuole formation has been shown to be induced by 
tissue anoxia in a time-dependent manner, with prominence of larger coalescing 
vacuoles as the anoxic period increases (315,346). Moreover, vacuoles are mainly 
thought to contain sinusoidal plasma and to a lesser extent cellular organelles debris. 
Vacuoles probably arise secondary to disruption of the plasma membrane in 
combination with the high intrahepatic venous blood pressure that forces the 
sinusoidal plasma into hepatocytes to form vacuoles (346). Our results in this study 
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show an abundance of vacuole formation in the IR group that are reduced by 
antecedent RIPC, indicating RIPC protects against the  formation of vacuoles. 
Previous work has shown direct liver ischaemic preconditioning reduces IR-induced 
ultrastructural SEC injury (347). We have extended these results by showing RIPC 
of the hindlimb has similar beneficial effects in reducing the damaging effects of 
liver IR on the sinusoids and SEC. The RIPC alone group showed mild signs of 
hepatic ultrastructural injury which were probably caused by the systematic effects 
of the remote IR stimulus (335,336). Two main differences were noted between the 
RIPC alone and RIPC + IR group. The first of these pertained to an abundance of 
glycogen in the RIPC alone group and an almost complete lack of this in the RIPC + 
IR group. This is because during liver ischaemia, anaerobic metabolism of hepatic 
glycogen predominates, resulting in significantly less energy being produced per 
molecule of glycogen compared to the aerobic metabolism of the RIPC alone group, 
and therefore more of the hepatic glycogen stores are consumed by anaerobic 
metabolism during ischaemia in order to maintain the energy levels required for 
cellular function (25,26). The second difference concerned the more severe damage 
to the sinusoids and the SEC seen in the RIPC + IR compared to the RIPC alone 
group. Whilst the RIPC + IR group exhibited some signs of ultrastructural damage, 
the injury sustained by the IR alone group was noticeably much worse across all the 
parameters that were assessed, indicating RIPC prior to IR significantly attenuated 
ultrastructural evidence of damage.  
 
In the present study MBF was assessed using LDF. Within the liver LDF measures 
blood flow in the sinusoids, arterioles, and portal and hepatic venules. Liver 
ischaemia caused significant reductions in MBF and upon reperfusion there was 
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minimal improvement in the IR group for the two hour reperfusion period. In 
contrast the RIPC + IR group showed significant improvement in LDF readings that 
started at reperfusion, and continued to recover towards baseline flow rates for the 
subsequent two hour reperfusion period. Our group has previously shown that direct 
liver IPC prior to liver IR results in improvements in MBF during reperfusion (279), 
and we are the first group now to show significant improvement in liver MBF with 
RIPC prior to liver IR. Multiple factors are thought to contribute to the reductions in 
MBF following hepatic IR injury (30). Additionally, our current TEM results 
indicate significant destruction of the sinusoids and the SEC with sinusoidal luminal 
debris. The end result is a significant reduction of MBF on reperfusion including 
some areas with complete absence of blood flow known as “no-reflow” (30). The 
observed benefits of RIPC upon the microcirculation indicate the factors responsible 
start working during liver ischaemia as there is significant improvement in RIPC + 
IR compared to the IR group commencing at the start of reperfusion. In agreement 
with the current results, we previously showed, using intravital microscopy in a rat 
model, hindlimb RIPC prior to liver IR significantly increases the ratio of perfused 
hepatic sinusoids  (229).  
 
The 28 day mouse recovery experiments were performed to evaluate the long term 
outcome of hepatic IR injury and hindlimb RIPC. The results showed no 
complications or mortality during this period indicating that the partial hepatic 
ischaemia model used is non-lethal, and that the hindlimb RIPC model we utilized 
does not have any complications associated with it.  
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The signal(s) mediating the effects of hindlimb RIPC may in theory be conveyed to 
the liver either through the blood or through a neural network (327). The evidence 
for a humoral signal is stronger and possible candidates include HMGB-1, 
adenosine, NO acting through nitrite, cytokines, and free radicals (226,327). Further 
research is needed to ascertain the exact identity of humoral mediators of hindlimb 
RIPC. 
 
In conclusion we described and validated a new mouse model of hindlimb RIPC that 
significantly reduces liver IR injury. This experimental model is consistent, shows 
no side effects of preconditioning, minimises confounding variables, and should 
prove useful in investigating the mechanisms of RIPC in the mouse.   
 
In this chapter it was shown hindlimb RIPC protects against liver IR injury in the 
mouse. In the next chapter we will investigate the role of nitric oxide, through the 
use of the nitric oxide scavenger C-PTIO, in mediating the protective effects of 
RIPC upon liver IR injury.   
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Chapter 5 
 
The nitric oxide scavenger Carboxy-PTIO blocks the 
protective effects of remote ischaemic preconditioning 
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5.1 Introduction 
NO is an important molecule in IR injury. Previous work has suggested a 
dichotomous role for NO in IR injury with some studies showing NO worsens IR 
injury (348,349); and others pointing to a protective role for NO, reviewed in 
Phillips et al (29). These opposing effects of the role of NO in IR injury maybe due 
to the enzymatic source and concentration of the synthesised NO, factors that are in 
turn influenced by the experimental conditions including, such variables as the 
length of the ischaemic insult, the organ being studied, the cellular redox status of 
the organ, time of reperfusion, and in vivo versus in vitro experimental set up. The 
concentration of released NO is important because it may determine the benefits, or 
otherwise, of NO in IR injury; with high concentrations of NO promoting the 
formation of reactive nitrogen species such as peroxynitrite (ONOO-) that enhance 
IR injury; and lower concentrations of NO being protective (262,350,351).    
 
Direct organ ischaemic preconditioning (IPC) protects against subsequent IR injury 
at least partially through an NO-dependent mechanism. This has been shown in 
several organ systems, including the liver (352). Supporting evidence for the role of 
NO in mediating the protection offered by direct IPC comes from experiments 
showing inhibition of nitric oxide synthase (NOS) isoforms by the non-selective 
NOS inhibitor N-Nitro-L-arginine methyl ester (L-NAME) results in abrogation of 
the protective effects of IPC (240,353). Additionally, IPC results in increased NOS 
expression (240,354) with a subsequent increase in the NO oxidation products, 
nitrite and nitrate, that connotes a rise in NO levels (240,355). In contrast to the 
known beneficial effects of NO in direct liver IPC, its role in RIPC of the liver is 
currently unknown.  
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NO is a highly reactive free radical molecule, with a short half life that is in the 
order of 5-10 seconds. Therefore direct measurement of in vivo NO production in IR 
research is impractical and quantification of the reaction products of NO such as 
nitrites, nitrates, and S-nitrosothiols is performed and the results are extrapolated to 
reflect the levels of NO. An alternative approach, in order to mitigate the 
inaccuracies associated with the assumption that all the NO reaction products bear a 
linear relationship to the concentration of NO in IR research, which it does not, is to 
directly eliminate the released NO through the use of the direct NO scavenger 
carboxy-PTIO (C-PTIO) (303).             
 
There are no previous studies evaluating the effects of C-PTIO on the protection 
afforded by RIPC on liver IR injury. Therefore the aim of the present study was to 
determine the effects of scavenging the NO produced during hindlimb RIPC, 
through the use of C-PTIO, on liver IR injury. It was found that NO plays an 
important role in mediating the protective effects of RIPC on liver IR injury.  
 
5.2 Materials and methods 
The detailed methodology was described in chapter 3. A summary of the most 
pertinent points is given below. 
 
5.2.1 Animal surgical procedure 
Male inbred C57BL/6 wild type mice (Charles River laboratories, UK) were utilized 
in the present study. The animals were anaesthetised using 2% isoflurane. Core body 
temperature was maintained at 37.0 ± 0.5 ℃ using a heating pad and a rectal 
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temperature probe. Hepatic IR was performed as detailed in section 3.4.1. At the end 
of the reperfusion period the animals were terminated by exsanguination through 
needle cardiac puncture and blood collection. The blood was immediately 
centrifuged and the plasma supernatant was stored at -70 ℃ until assayed for liver 
transaminases. The left and median liver lobes were harvested at the end of each 
procedure for histopathology and transition electron microscopy. Hindlimb 
preconditioning consisted of microvascular clamping of the femoral vessels for four 
minutes followed by four minutes reperfusion for a total of six cycles as described in 
section 3.4.2.  
 
5.2.2 Experimental groups 
Four groups with a minimum of six animals in each were used (Figure 3.2). The 
total anaesthetic time was equal in all the groups. All animals underwent 
laparotomy, mobilization of the liver, and mobilization of the right femoral vascular 
bundle. In addition some of the groups were each subjected to a specific procedure 
as follows:  
 
Sham: Only underwent the laparotomy, mobilization of the liver, and mobilization 
of the right femoral vascular bundle described above.  
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: The right hindlimb was preconditioned with 6 cycles of 4 minutes 
ischaemia followed by 4 minutes reperfusion, using a microvascular clamp to 
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occlude the femoral vessels under an operating microscope. This was followed by 
the IR group procedure described above.    
C-PTIO + RIPC + IR: The NO scavenger C-PTIO was administered intravenously at 
a dose of 1 mg/kg in 50 µl of D-PBS, followed by the RIPC + IR procedure.   
 
5.2.3 Measurement of liver enzymes 
The concentrations of ALT and AST were measured in the plasma using an 
automated clinical analyzer as described in section 3.5.  
          
5.2.4 Histopathology 
A liver biopsy was taken from the left ischaemic lobe of each animal at the end of 
the experiment and was immediately fixed in 10% formal saline. The fixed tissues 
were embedded in paraffin, and stained with H&E. Sections were assessed by a liver 
pathologist blinded to the animal groups. Each H&E sample was scored using two 
different methods as described in section 3.6.  
 
5.2.5 Transmission electron microscopy 
Liver biopsies were obtained from the left lobe at termination of the animals and 
were fixed in a glutaraldehyde / paraformaldehyde mixture overnight, processed as 
described in section 3.7, and viewed with a transmission electron microscope. 
Representative areas were photographed and the images were interpreted by a 
transition electron microscopy (TEM) scientist who was blinded to the groups. 
Assessment of the images was performed according to the parameters outlined in 
section 3.7. 
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5.2.6 Liver and hindlimb microcirculatory blood flow 
Laser Doppler flowmetry (LDF) was used to measure blood flow in the 
microvasculature of the liver as described in section 3.8. The probe was placed on 
the left liver lobe so that it was just in contact with the tissue surface. LDF data was 
collected as the mean of four readings recorded over a one minute period. In 
addition, a second LDF probe was positioned on the sole of the right foot to ensure 
blood flow interruption and reperfusion during femoral vessels clamping and 
unclamping respectively. Figure 3.6 shows the time points of the LDF recordings 
during the study protocol.  
 
5.2.7 Statistical analysis 
 
Values are expressed as mean ± SEM. One way analysis of variance (ANOVA) with 
Post Hoc Bonferroni correction for multiple comparisons was used. P < 0.05 was 
considered statistically significant in all analyses. 
   
5.3 Results 
The plasma transaminases levels, histopathological scores, ultrastructural changes, 
and MBF results of the C-PTIO + RIPC + IR group obtained in this chapter were 
compared to results of the sham, IR, and RIPC + IR groups described in chapter 4. 
 
5.3.1 C-PTIO increases plasma transaminases levels in hindlimb 
preconditioned mice undergoing liver IR  
Liver IR caused a significant rise in the plasma levels of ALT and AST compared to 
the sham group (P < 0.05). Antecedent hindlimb preconditioning (RIPC + IR group) 
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significantly reduced the plasma transaminases levels compared to IR alone (P < 
0.05). Intravenous administration of C-PTIO prior to hindlimb RIPC and liver IR 
(C-PTIO + RIPC + IR group) resulted in a significant increase (P < 0.05) in the 
plasma levels of ALT and AST compared to the RIPC + IR group (figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Plasma liver enzyme levels. (A) Alanine aminotransferase (ALT). *P < 
0.05 vs IR, RIPC+IR, or C-PTIO   (C-PTIO+RIPC+IR group). (B) Aspartate 
aminotransferase (AST). *P < 0.05 vs IR, RIPC+IR, or C-PTIO (C-PTIO+RIPC+IR 
group).  
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5.3.2 C-PTIO non-significantly abrogates the beneficial effects of 
RIPC on liver histopathological injury  
The mean overall histopathological grade for each animal group is given in figure 
5.2. The sham group showed minimal signs of liver IR injury with a mean overall 
grade of 0. Liver IR resulted in a significant increase in the mean overall injury 
grade (IR group mean overall grade = 1.83) compared to the sham group (P < 0.05). 
Preconditioning prior to liver IR (RIPC + IR group) decreased the mean overall 
injury score to 1.33, which is not significantly different from the sham or IR groups 
(P > 0.05). Administration of C-PTIO prior to RIPC + IR (C-PTIO + RIPC + IR 
group) resulted in an increase of the mean overall injury grade to 1.5 (P < 0.05 vs 
sham; P > 0.05 vs IR or RIPC + IR).             
 
 
Figure 5.2. Vertical scatter plot of histopathological grades. Each dot represents the 
overall grade assigned to each individual liver biopsy sample (n = 6 per group). 
Horizontal bars represent the means. 
P < 0.05 
P < 0.05 
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Five individual histopathological features of liver IR injury (discohesive 
hepatocytes, liver cell ballooning, cytoplasmic vacuolation, blurred intercellular 
borders, RBC extravasation) showed a significant increase in the mean score in each 
of the IR and C-PTIO + RIPC + IR groups compared to sham (P < 0.05). 
Additionally, the mean score of the C-PTIO + RIPC + IR group in cytoplasmic 
vacuolation was significantly higher (P < 0.05) than the mean score in the RIPC + 
IR group (figure 5.3). Despite there being no statistically significant differences 
between the mean scores of the RIPC + IR compared to the C-PTIO + RIPC + IR 
group in the majority of the individual features assessed; there was a trend showing 
an increase of the mean scores in the C-PTIO + RIPC + IR compared to the RIPC + 
IR group in 7 of the individual features assessed (figure 5.3).    
 
5.3.3 C-PTIO nullifies the protective effects of hindlimb RIPC on 
specific features of ultrastructural damage in liver IR 
Figure 5.4 illustrates representative changes exhibited by each of the animal groups. 
The sham group showed normal ultrastructural appearances. The IR group exhibited 
extensive mitochondrial damage, ER dilatation, cytosolic vacuole formation, 
phagolysosomal formation, lipid droplet formation, glycogen depletion, bile 
canaliculi dilatation with microvilli damage, and sinusoidal endothelial cell (SEC) 
disruption with extravasation of red blood cells (RBC) into the liver parenchyma. In 
contrast the ultrastructural damage sustained by the RIPC + IR group consisted of 
ER dilatation, phagolysosomal formation, lipid droplet formation, glycogen 
depletion, and disruption of SEC but without RBC extravasation.  
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The administration of C-PTIO prior to RIPC + IR resulted in extensive 
mitochondrial damage, vacuole formation, lipid droplet formation, bile canaliculi 
dilatation with microvilli destruction, and homogenous SEC disruption with RBC 
extravasation. In addition this group exhibited frequent condensed crescent shaped 
lengths of ER indicative of ER membrane damage secondary to lipid peroxidation.   
 
Figure 5.3. Histopathological scores of individual features of liver IR  injury. Each 
bar chart is the mean histopathological score of six animals in that group. The error 
bars are the standard error of the means.  *P < 0.05 vs sham; #P < 0.05 vs C-PTIO + 
RIPC + IR.   
* 
* 
* 
# 
* 
* 
* 
 * 
 * 
* 
* 
* 
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Figure 5.4. Hepatic transmission electron micrographs. The liver samples were taken at the end of the procedure in each group. (A) & (B) 
Sham group showing normal endoplasmic reticulum (er), bile canaliculi with microvilli (bc), mitochondria (m), glycogen (gl), and sinusoidal 
endothelial cells (sec) with microvilli in space of Disse (sdm). (C) & (D) IR group demonstrating irreversibly damaged mitochondria (dm) with 
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some merging into vacuoles (vc), dilatation and vesiculation of endoplasmic reticulum (der), lysosomes (ly) and phagolysosomes (pl), lipid 
droplets (ld), and severely damaged sinusoidal endothelial cells (dsec) associated with extravasated red blood cells (erbc) and plasma (ep). (E) 
& (F) RIPC + IR group demonstrating undamaged pleomorhic mitochondria (m), lipid droplets (ld), lysosomes (ly) and phagolysosomes (pl), 
normal (er) and dilated (der) endoplasmic reticulum, bile canaliculi with microvilli (bc), glycogen (gl), and damaged sinusoidal endothelial cells 
(sec) but without RBC extravasation. (G) & (H) C-PTIO + RIPC + IR group showing damaged mitochondria (dm), vacuolation (vc), lipid 
droplets (ld), severely damaged sinusoidal endothelial cells (dsec) associated with red blood cell extravasation (erbc), and condensed crescent 
shaped lengths of endoplasmic reticulum indicative of lipid peroxidation of the endoplasmic reticulum membrane (ler).  
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5.3.4 The protective effects of hindlimb RIPC on hepatic 
microcirculatory blood flow in liver IR are abolished by C-PTIO 
Figure 5.5 illustrates hepatic MBF for the duration of the experiment. The sham 
group demonstrated constant hepatic MBF, whilst the IR and RIPC + IR exhibited a 
significant reduction of MBF during liver ischaemia. Upon reperfusion the IR group 
showed no significant improvement in MBF, whilst the RIPC + IR group 
demonstrated significant recovery of MBF towards baseline values compared to the 
IR group (P < 0.05).  
 
C-PTIO administration prior to RIPC + IR (C-PTIO + RIPC + IR group) resulted in 
reductions of MBF throughout the duration of the experiment. During the first 
hindlimb ischaemia (HI1) the mean MBF was 93.8% of baseline (P = 0.038 vs 
sham; P = 0.045 vs IR; P > 0.05 vs RIPC + IR). Similarly, during the first hindlimb 
reperfusion (HR1) the mean MBF was 93.8% of baseline (P = 0.025 vs sham; P = 
0.007 vs IR; P > 0.05 vs RIPC + IR). In comparison there were no significant 
differences in mean MBF values between the C-PTIO + RIPC + IR and the other 
groups during the sixth HI and HR. Commencement of liver ischaemia resulted in a 
significant reduction in MBF compared to the sham but not the IR or RIPC + IR 
groups. Following reperfusion, MBF in the C-PTIO + RIPC + IR group failed to 
recover, showing significant differences compared to the sham and RIPC + IR 
groups throughout reperfusion (P < 0.05). At the end of the 2 hour reperfusion 
period the mean MBF value was 48.2% of baseline in the C-PTIO + RIPC + IR 
group compared to 93.5% of baseline in the RIPC + IR group (P < 0.0001). There 
were no significant differences in the mean MBF values between the C-PTIO + 
RIPC + IR and the IR groups throughout the reperfusion period (figure 5.5).     
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Figure 5.5. Hepatic microcirculatory blood flow, measured by LDF, is illustrated as 
mean percentage compared to pre-ischaemic baseline. Significant (P < 0.05) inter-
group differences are shown vertically below each time point on the x-axis. BL, 
baseline; HI, hindlimb ischaemia; HR, hindlimb reperfusion; BLI, beginning of liver 
ischaemia; ELI, end of liver ischaemia; BR, beginning of liver reperfusion; R30 to 
R120, liver reperfusion at 30, 60, 90, and 120 min post ischaemia.      
 
5.4 Discussion  
C-PTIO is a nitronyl nitroxide that neutralises the actions of NO in biological 
systems in a reaction that results in the production of NO2 and the amino nitroxide 
C-PTI (303,356). The substrate C-PTIO directly extinguishes the NO generated by 
NOS without affecting NOS activity (356). C-PTIO has been used extensively in 
vivo to investigate the biological effects of NO, including in liver IR research 
(302,357) where administration of C-PTIO has been shown to abolish the protective 
effects of nitrite-derived NO (302,357).  
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The role of NO in mediating the protective effects of RIPC on liver IR injury is 
currently unknown. The only study to allude to this measured the plasma nitrite and 
nitrate (NOx) levels in peripheral arterial and hepatic venous blood following 
hindlimb RIPC and hepatic IR in a rabbit model (227). The plasma NOx levels were 
non-significantly lowered following hepatic IR compared to the sham group in both 
peripheral arterial and hepatic venous blood. Hindlimb RIPC prior to hepatic IR 
resulted in an increase in NOx levels compared to the IR alone group which only 
reached statistical significance in hepatic venous blood samples but not in arterial 
samples (227). These results indicated RIPC prior to liver IR prevented a reduction 
in NOx plasma levels compared to IR alone. With regards to the role of NO in 
mediating the protective effects of RIPC in other organs, various experimental 
designs have been utilized to elicit this in different combinations of RIPC sites and 
organs subjected to index ischaemic insults. This approach mainly revolved around 
the use of NOS inhibitors to block NO synthesis, or the use of NOS knockout 
animals. Shahid et al (233) showed femoral artery preconditioning prior to 
myocardial ischaemia significantly reduces myocardial infarct size and improves 
cardiac function compared to non-preconditioned animals. Administration of the 
NOS inhibitor L-NAME abrogated the protection furnished by preconditioning 
(233). Similarly, infusion of L-NAME prior to hindlimb RIPC abolished its 
protective effects against subsequent abdominal adipocutaneous flap ischaemia 
(232). Other NOS inhibitors such as N omega-nitro-L-arginine (L-NNA) and S-
methylthiosulfourea have also been shown to block the protective effects of femoral 
artery RIPC, but in these studies the index ischaemic insult was global brain 
ischaemia (358,359). The use of NOS knockout animals has been limited to a study 
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in which iNOS-/- mice lost the protection afforded by hindlimb RIPC in reducing 
myocardial IR injury compared to wild type animals (234).    
 
The results of the current study showed that NO is a pre-requisite for full 
manifestations of the benefits of RIPC upon liver IR injury, as neutralisation of NO 
with C-PTIO abolished the protection of RIPC. The plasma liver enzymes showed a 
significant elevation in the C-PTIO + RIPC + IR compared to the RIPC + IR group. 
The overall histopathological grade and 7 individual histopathological features of 
liver IR injury, showed increased mean scores when NO was abolished using C-
PTIO, although only in one individual feature, cytoplasmic vacuolation, was the 
difference statistically significant. The reason for this has been discussed in chapter 
4 and mainly pertains to the short (2 hour) reperfusion period in this experimental 
model, which means histopathological manifestations of IR injury at levels 
detectable by light microscopy are in their early stages. However, when higher 
power studies using TEM were performed to assess liver ultrastructural IR injury, 
clearer negative effects of C-PTIO on RIPC protection were seen.    
 
The ultrastructural changes in the C-PTIO + RIPC + IR group showed increased 
mitochondrial damage, ER membrane lipid peroxidation, and increased SEC 
damage compared to the RIPC + IR group. NO has many protective functions within 
cells. In liver IR injury NO has been shown to decrease hepatic injury by preserving 
the mitochondria and antioxidant enzyme activity (280,360,361), hence providing an 
explanation for the increase in mitochondrial damage and ER membrane lipid 
peroxidation observed in our study. Moreover, NO is one of the main endothelial 
cell homeostatic factors, fulfilling a range of functions to maintain the endothelium 
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physiological status quo, including anti-inflammatory actions (362). Therefore 
removal of NO in our study led to SEC damage to an extent not seen in the RIPC + 
IR group.  
 
The explanation for the significant reductions in hepatic MBF during liver 
reperfusion, seen in the C-PTIO + RIPC + IR compared to the RIPC + IR group, is 
likely to be multifactorial. SEC damage was worse in the group receiving C-PTIO 
and this would have contributed to the reduction in blood flow within the sinusoids. 
In addition NO significantly increases hepatic MBF during direct liver IPC (279) 
and our results here indicate RIPC has a similar effect. Moreover, NO is a 
vasodilator (362) and is known to induce an increase in MBF in chronically 
ischaemic limbs which is significantly reduced by administration of C-PTIO (363). 
Therefore removal of NO through the use of C-PTIO in livers subjected to 
ischaemia in our experiments was likely to be a main contributor to the reductions in 
hepatic MBF seen during reperfusion. It is important to note that the use of C-PTIO 
has been shown either not to affect mean arterial blood pressure (364), or only to 
cause a slight transient increase in blood pressure (365); and therefore the failure of 
MBF recovery during liver reperfusion in the C-PTIO + RIPC + IR group in our 
experiments is likely to be independent of any changes in systemic blood pressure, 
although this was not directly measured in our study. C-PTIO was administered 
prior to the first cycle of hindlimb RIPC and interestingly resulted in a small but 
significant hepatic MBF reduction prior to any liver ischaemia induction, only 
during the first hindlimb RIPC cycle, compared to the sham and IR groups. This is 
likely a transient effect of C-PTIO administration as hepatic MBF values were not 
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significantly different from other groups during the second to the sixth hindlimb 
RIPC cycles.  
 
An additional control animal group that could have been included in this study 
would have been C-PTIO + IR. However this group has been included in a previous 
study (302) and as expected showed a significant worsening of liver injury 
compared to the IR alone group. Hence this group was not repeated in the present 
study.     
 
In conclusion, scavenging NO through the administration of C-PTIO prior to limb 
preconditioning and liver IR leads to abrogation of several of the protective effects 
of RIPC on liver IR injury. These results indicate that NO mediates the effects of 
RIPC by reducing ultrastructural damage to the mitochondria, ER membranes, and 
SEC. In addition NO is needed to preserve the protective effects of RIPC on hepatic 
MBF.  
 
In this chapter it was shown NO is required for the protective effects of RIPC in 
liver IR injury. In the next chapter we will investigate the contribution of the nitric 
oxide synthase isoforms in the protection afforded by hindlimb RIPC.  
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Chapter 6 
 
The role of nitric oxide synthase in remote 
ischaemic preconditioning of the liver 
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6.1 Introduction 
Nitric oxide (NO) is synthesised by one of three nitric oxide synthase (NOS) 
isoforms. The expression of the neuronal NOS (nNOS) is mostly limited to neural 
tissue and will not be discussed further. Endothelial NOS (eNOS) is constitutively 
expressed in many cell types, including liver endothelial cells and hepatocytes (240-
243). Inducible NOS (iNOS) is not expressed under normal circumstances, but is up-
regulated in inflammatory conditions including ischaemia reperfusion (IR) injury of 
the liver, in hepatocytes, endothelial cells, biliary cells, kupffer cells, neutrophils, 
and T-lymphocytes (245-249).  
 
There is a limited amount of literature on eNOS and iNOS in direct ischaemic 
preconditioning (IPC) of the liver. One study (240) assessed eNOS expression in 
IPC and showed increased expression in rats undergoing hepatic IPC + IR compared 
to those subjected to IR alone. Furthermore, the increase in eNOS expression was 
associated with significantly higher plasma nitrite and nitrate (NOx) levels in the 
preconditioned (IPC + IR) compared to the IR alone group. Three studies assessed 
iNOS expression in IPC. One of these, a human study that evaluated gene 
expression in living donor liver transplants, showed increased iNOS expression 
following IPC performed prior to liver procurement compared to non-
preconditioned group (354). Similarly, iNOS expression was also increased in rats 
livers receiving IPC + IR compared to those subjected to IR alone (366). 
Additionally, this study demonstrated an increase in plasma NOx levels in 
association with the increased iNOS expression in the IPC group (366). In contrast 
the work by Koti et al (240) showed iNOS expression was absent in all experimental 
groups, including the IPC + IR and the IR alone groups.  
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The role of eNOS in remote ischaemic preconditioning (RIPC) of any organ has not 
been studied. However that of iNOS has, and three studies seem to indicate iNOS is 
required for the protection of RIPC. Li et al (234) demonstrated hindlimb RIPC 
protects against delayed myocardial ischaemia, at 24 hours post RIPC, that is 
associated with increased myocardial iNOS expression. However, iNOS-/- animals 
lose the protection provided by RIPC (234). Likewise, intestinal preconditioning 
protects against myocardial ischaemia 24 hours post preconditioning, which is 
accompanied by increased iNOS activity (367). Moreover, the relative iNOS 
inhibitors, aminoguanidine and S-methylisothiourea, inhibited the protective effects 
of intestinal RIPC (367). Spontaneous or induced brain ischaemia has also been 
shown to protect against subsequent myocardial ischaemia in wild type but not 
iNOS-/- animals 24 hours after brain ischaemia (368). However, iNOS expression 
was not increased in wild types at 24 hours post brain ischaemia, which was 
interpreted by the authors to indicate NO acts as a trigger rather than a mediator of 
RIPC (368).  
 
The aim of the current study was to assess for the first time the contribution of 
eNOS in the protection furnished by RIPC on liver IR injury. Furthermore, we 
wished to examine the effects of RIPC on iNOS expression.     
      
6.2 Materials and methods 
The detailed methodology was described in chapter 3. A summary of the most 
pertinent points is given below. 
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6.2.1 Animal surgical procedure 
Male inbred C57BL/6 wild type mice (Charles River laboratories, UK); and mice 
lacking the constitutively expressed enzyme, endothelial nitric oxide synthase 
(eNOS-/-, bred in-house) were utilized in the present study. The animals were 
anaesthetised using 2% isoflurane. Core body temperature was maintained at 37.0 ± 
0.5 ℃ using a heating pad and a rectal temperature probe. Hepatic IR was performed 
as detailed in section 3.4.1. At the end of the reperfusion period the animals were 
terminated by exsanguination through needle cardiac puncture and blood collection. 
The blood was immediately centrifuged and the plasma supernatant was stored at -
70 ℃ until assayed for liver transaminases. The left and median liver lobes were 
harvested at the end of each procedure for histopathology and transition electron 
microscopy.  
 
Hindlimb preconditioning consisted of microvascular clamping of the femoral 
vessels for four minutes followed by four minutes reperfusion for a total of six 
cycles as described in section 3.4.2.  
 
6.2.2 Experimental groups 
Four groups of eNOS-/- mice (figure 3.3) with a minimum of six animals in each 
were used to investigate the effects of RIPC on liver IR injury through the 
assessment of liver enzymes, histopathological scores, TEM damage, and MBF. In 
addition four groups of wild type mice (figure 3.2) were used to investigate the 
effects of RIPC on liver and hindlimb expression of eNOS and iNOS; as well as the 
cellular distribution of eNOS expression. The total anaesthetic time was equal in all 
the groups. All animals underwent laparotomy, mobilization of the liver, and 
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mobilization of the right femoral vascular bundle. In addition some of the groups 
were each subjected to a specific procedure as follows:  
 
eNOS-/- groups: 
Sham: Only underwent the laparotomy, mobilization of the liver, and mobilization 
of the right femoral vascular bundle described previously.  
RIPC: The right hindlimb was preconditioned with 6 cycles of 4 minutes ischaemia 
followed by 4 minutes reperfusion, using a microvascular clamp to occlude the 
femoral vessels under an operating microscope. 
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: Animals were subjected to the RIPC followed by the IR procedures.   
 
Wild type groups: 
Sham: Only underwent the laparotomy, mobilization of the liver, and mobilization 
of the right femoral vascular bundle described above.  
RIPC: The right hindlimb was preconditioned with 6 cycles of 4 minutes ischaemia 
followed by 4 minutes reperfusion, using a microvascular clamp to occlude the 
femoral vessels under an operating microscope. 
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: Animals were subjected to the RIPC followed by the IR procedures.   
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6.2.3 Measurement of liver enzymes 
The concentrations of ALT and AST in the plasma of eNOS-/- animals were 
measured using an automated clinical analyzer as described in section 3.5.  
 
6.2.4 Histopathology 
The histopathological damage sustained by the eNOS-/- groups was assessed. A liver 
biopsy was taken from the left lobe of each animal at the end of the experiment and 
fixed in 10% formal saline. The fixed tissues were embedded in paraffin and stained 
with H&E. Sections were assessed by a liver pathologist blinded to the animal 
groups. Each H&E sample was scored using two different methods as described in 
section 3.6.  
 
6.2.5 Transmission electron microscopy 
Liver biopsies were obtained from the left lobes of eNOS-/- mice at termination, and 
were fixed in a glutaraldehyde / paraformaldehyde mixture overnight, processed as 
described in section 3.7, and viewed with a transmission electron microscope. 
Representative areas were photographed and the images were interpreted by a TEM 
scientist who was blinded to the groups. Assessment of the images was performed 
according to the parameters outlined in section 3.7. 
 
6.2.6 Liver and hindlimb microcirculatory blood flow 
eNOS-/- MBF measurements were performed in this chapter. Laser Doppler 
flowmetry (LDF) was used to measure blood flow in the microvasculature of the 
liver as described in section 3.8. One probe was placed on the left liver lobe so that 
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it was just in contact with the tissue surface. LDF data was collected as the mean of 
four readings recorded over a one minute period. In addition, a second LDF probe 
was positioned on the sole of the right foot to ensure blood flow interruption and 
reperfusion during femoral vessels clamping and unclamping respectively. Figure 
3.6 shows the time points of the LDF recordings during the study protocol.  
 
6.2.7 eNOS and iNOS Western blot analysis 
Individual samples of liver and skeletal muscle tissues (100 mg) from wild type 
mice were homogenised in liquid nitrogen. Cell lysis was achieved by RIPA buffer 
and repeat vortexing. Following centrifusion, protein concentrations in the 
supernatants were measured by the modified Lowry protein assay kit. Protein 
denaturation was achieved by Laemmli sample buffer and heating to 95 ℃. Nu-
polyacrylamide gel electrophoresis was used to separate the proteins, which were 
then electro-blotted onto polyvinylidene difluoride membrane. The membranes were 
incubated with either polyclonal rabbit anti-eNOS or anti-iNOS in a 1:200 dilution, 
followed by incubation with secondary goat anti-rabbit IgG antibody and 
illumination with Super Signal West Dura Extended Duration Substrate. The 
membranes were exposed to x-ray films for variable durations to visualise the 
proteins. The density of the eNOS protein bands were analysed with densitometry 
software.      
 
6.2.8 eNOS immunohistochemistry 
In order to ascertain the cellular distribution of eNOS in wild type animals, the left 
liver lobe and the thigh of the right hindlimb were biopsied at the end of the 
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experiment in each of the animals and were immediately fixed in 10% formal saline. 
The tissues were processed as described in section 3.10.  
 
6.2.9 Statistical analysis 
Values are expressed as mean ± SEM. One way analysis of variance (ANOVA) with 
Post Hoc Bonferroni correction for multiple comparisons was used. P < 0.05 was 
considered statistically significant in all analyses. 
 
6.3 Results 
6.3.1 Antecedent hindlimb RIPC reduces plasma transaminases levels 
in wild type but not eNOS-/- mice 
In this study the sham and RIPC groups in eNOS-/- animals showed only small 
elevations of plasma ALT and AST. The IR group showed a significant rise of these 
enzymes compared to sham and RIPC (P < 0.05). Hindlimb preconditioning 
preceding liver IR (RIPC + IR group) in eNOS-/- animals did not reduce neither the 
plasma ALT nor the plasma AST compared to the IR alone group (P > 0.05) (figure 
6.1).  
 
These findings are in contrast to the previous findings in section 4.3.2 (figure 4.1) 
which demonstrated that in wild type animals hindlimb preconditioning preceding 
liver IR (RIPC + IR group) significantly reduced the plasma transaminases levels 
compared to IR alone (P < 0.05).   
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Figure 6.1. Plasma liver enzyme levels in eNOS-/- mice. (A) Alanine 
aminotransferase (ALT). *P < 0.05 vs IR; #P < 0.05 vs RIPC + IR. (B) Aspartate 
aminotransferase (AST). *P < 0.05 vs IR; #P < 0.05 vs RIPC + IR.  
 
6.3.2 Histopathological injury is attenuated by hindlimb RIPC 
preceding liver IR in wild type but not eNOS-/- animals   
The mean overall histopathological injury grades in wild type animal groups were 
given in section 4.3.3 (figure 4.2). For comparison these results of wild type groups 
are shown again next to the results of eNOS-/- animals in figure 6.2. The mean 
overall histopathological grades in eNOS-/- animals were: 0.33 in the sham, 0.5 in 
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the RIPC, 1.0 in the IR, and 1.0 in the RIPC + IR groups. None of the differences 
between these mean overall histopathological grades in the eNOS-/- mice reached 
statistical significance (P > 0.05) (figure 6.2). Wild type sham and RIPC groups 
demonstrated minimal signs of liver IR injury with a mean overall grade of 0 in 
each. However, the wild type IR group resulted in a significant increase in the mean 
overall injury grade (IR group mean = 1.83) compared to the sham and RIPC groups 
(P < 0.05). Preconditioning in wild types prior to liver IR (RIPC + IR group) 
decreased the mean overall injury grade to 1.33 (P < 0.05 vs sham or RIPC; P > 0.05 
vs IR).           
 
 
 
Figure 6.2. Vertical scatter plot of histopathological grades in wild type and eNOS-/- 
mice. Each point represents the overall grade assigned to each individual liver 
biopsy sample (n = 6 per group) in wild type and eNOS-/- mice. Horizontal bars 
represent the means. In the wild type group *P < 0.05 vs sham or RIPC. 
 
* * 
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The mean scores of individual histopathological features of liver IR injury in wild 
type mice were also given in section 4.3.3 (figure 4.3). For ease of comparison the 
results for each individual feature of liver IR injury in the wild type groups are 
shown next to the results of eNOS-/- animals in figure 6.3. There were no statistically 
significant differences, in any of the individual features of liver IR injury, between 
any of the eNOS-/- animal groups (figure 6.3). In comparison in wild type groups, 4 
individual features (discohesive hepatocytes, liver cell ballooning, blurred 
intercellular borders, RBC extravasation) had a significantly higher mean score in 
the IR compared to the sham and RIPC groups (P < 0.05). In addition discohesive 
hepatocytes and liver cell ballooning were also significantly higher in the RIPC + IR 
compared to the RIPC group (P < 0.05). There were no other statistically significant 
differences amongst wild type groups.  
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Figure 6.3. Histopathological scores of individual features of liver IR  injury in wild 
type and eNOS-/- mice. Each bar chart is the mean histopathological score of six 
animals in that group. The error bars are the standard error of the means. In the wild 
type group *P < 0.05 vs sham; #P < 0.05 vs RIPC.   
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6.3.3 Hepatic ultrastructural damage is ameliorated by hindlimb RIPC 
preceding liver IR in wild type but not eNOS-/- mice 
Representative ultrastructural appearances in each of the eNOS-/- groups are shown 
in figure 6.4. The sham group showed some ultrastructural disturbances consisting 
of sporadic endoplasmic reticulum (ER) dilatation, phagolysosomal and lipid droplet 
formation. The RIPC group showed frequent ER dilatation and phagolysosomal 
formation. The IR group exhibited extensive mitochondrial damage, ER dilatation, 
cytosolic vacuole formation, phagolysosomal formation, lipid droplet formation, 
glycogen depletion, bile canaliculi dilatation with microvilli disruption, and 
sinusoidal endothelial cell (SEC) disruption with extravasation of red blood cells 
(RBC) and plasma into the liver parenchyma. Importantly the RIPC + IR group 
sustained similar damage to the IR group, indicating the protective effects of 
hindlimb preconditioning on ultrastructural features of liver IR injury act through an 
eNOS-dependent mechanism.   
 
In comparison the typical appearances seen in the wild type mouse groups were 
discussed in section 4.3.4 (figure 4.4). The sham group showed normal 
ultrastructural appearances. The RIPC group showed ER dilatation, phagolysosomal 
formation, and lipid droplet formation. The IR group exhibited extensive 
mitochondrial damage, ER dilatation, cytosolic vacuole formation, phagolysosomal 
formation, lipid droplet formation, glycogen depletion, bile canaliculi dilatation with 
microvilli damage, and SEC disruption with extravasation of RBC into the liver 
parenchyma. In contrast the ultrastructural damage sustained by the RIPC + IR 
group consisted of ER dilatation, phagolysosomal formation, lipid droplet formation, 
glycogen depletion, and disruption of SEC but without RBC extravasation.  
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Figure 6.4. Hepatic transmission electron micrographs of eNOS-/- mice. The liver samples were taken at the end of the procedure in each group. 
(A) & (B) Sham group showing normal looking mitochondria (m), normal (er) and dilated (der) endoplasmic reticulum, phagolysosomes (pl), 
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bile canaliculi with microvilli (bc), sinusoidal endothelial cells (sec), and microvilli in the space of Disse (ms). (C) & (D) RIPC group 
demonstrating normal mitochondria (m), normal (er) and dilated (der) endoplasmic reticulum, and lysosomes (ly) with phagolysosomal (pl) 
formation. (E) & (F) IR group demonstrating damaged mitochondria (dm), dilated endoplasmic reticulum (der), vacuole formation (vc), 
lysosomes (ly), lipid droplet formation (ld), and damaged sinusoidal endothelial cells (dsec) with extravasated red blood cell (erbc), 
polymorphonucelocyte (epmn), and plasma (ep) into the hepatocytes. (G) & (H) RIPC + IR group showing damaged mitochondria (dm), dilated 
endoplasmic reticulum (der), vacuolation (vc), phagolysosome formation (pl), lipid droplet formation (ld), dilated bile canaliculi (dbc), and 
damaged sinusoidal endothelial cells (dsec) associated with extravasated red blood cell (erbc). 
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6.3.4 Hepatic microcirculatory blood flow is preserved by hindlimb 
RIPC in wild type but not eNOS-/- animals  
In eNOS-/- mice, the sham and RIPC groups displayed constant hepatic MBF 
throughout the experimental protocol. MBF was significantly lower during liver 
ischaemia in the IR and RIPC + IR compared to the sham and RIPC groups (P < 
0.05). Throughout liver reperfusion, the MBF remained significantly lower in the IR 
compared to the sham and RIPC groups, so that at the end of the 2 hour reperfusion 
period the mean MBF was 52.2% of baseline in the IR group (figure 6.5). The 
highest mean MBF during liver reperfusion in the IR group was recorded at 90 
minutes and was 52.6% of baseline. The RIPC + IR group displayed transient 
improvement in MBF during the first 30 minutes of reperfusion with a mean value 
of 69.0% (P = 0.034 vs IR) and 76.5% (P = 0.014 vs IR) at the beginning and at 30 
minutes of liver reperfusion respectively. During the remaining reperfusion period 
MBF in the RIPC + IR group dropped, with mean recorded values of 61.6%, 64.3%, 
and 62.6% at 60, 90, and 120 minutes reperfusion. The mean MBF values in the 
RIPC + IR group at 60, 90, and 120 minutes of reperfusion were significantly lower 
than those of the sham and RIPC groups (P < 0.05), but not significantly different 
from those of the IR group  (P > 0.05) (figure 6.5).  
 
These results are in stark contrast to those we discovered in wild type animals 
described in section 4.3.5 (figure 4.5). Following liver reperfusion wild type IR 
group did not significantly recover MBF values compared to the sham, IR, and 
RIPC + IR groups. At the end of the two hour reperfusion period the flow remained 
significantly low, recording a mean of 53.4% of baseline in the IR group. In 
contrast, MBF in the wild type RIPC + IR group continued to recover towards 
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baseline values during reperfusion, so that the mean flow at 120 minutes was 93.5% 
of baseline. At all time points of liver reperfusion the flow was significantly lower in 
the wild type IR group compared to the wild type sham, RIPC, and RIPC + IR 
groups (P < 0.01 vs sham, RIPC, or RIPC + IR, at 30, 60, 90, and 120 minutes 
reperfusion); and at the same time points there were no significant differences 
between mean MBF in the RIPC + IR compared to the sham and RIPC groups (P > 
0.05).      
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Figure 6.5. Hepatic microcirculatory blood flow in eNOS-/- mice, measured by LDF, 
is illustrated as mean percentage ± SEM of pre-ischaemic baseline (n = 6 for each 
group). Significant (P < 0.05) inter-group differences are shown vertically below 
each time point on the x-axis. BL, baseline; HI, hindlimb ischaemia; HR, hindlimb 
reperfusion; BLI, beginning of liver ischaemia; ELI, end of liver ischaemia; BR, 
beginning of liver reperfusion; R30 to R120, liver reperfusion at 30, 60, 90, and 120 
min post ischaemia.    
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6.3.5 Hindlimb RIPC alters iNOS but not eNOS expression in liver 
and hindlimb skeletal muscle of wild type mice 
At the end of the two hours of reperfusion eNOS expression, as assessed by Western 
blotting in liver and hindlimb skeletal muscle samples, was evident in all the animal 
groups (figure 6.6). As eNOS is constitutively expressed, semi-quantitative grading 
of the blots was performed using densitometric analysis of each protein band to 
ascertain differential expression between the groups. However none of the groups, 
either in liver or hindlimb skeletal muscle samples, revealed any significant 
difference in eNOS expression (data not shown). In contrast, at the end of two hours 
of reperfusion iNOS protein expression was only seen in the RIPC and RIPC+IR 
groups, in both the liver and hindlimb skeletal muscle samples (figure 6.7). The 
sham and IR groups did not show iNOS expression in either tissue type. Semi-
quantitative densitometric analysis was not performed on the iNOS blots as iNOS is 
an inducible enzyme and the purpose of iNOS Western blots was to ascertain the 
effects of hindlimb RIPC on absolute iNOS expression.               
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Figure 6.6. eNOS Western blots in wild type mice. Representative eNOS protein 
expression as measured by Western blotting. Each band represents an individual 
animal in the corresponding group. (A) Liver samples. (B) Hindlimb skeletal muscle 
samples.    
 
 
Figure 6.7. iNOS Western blots in wild type mice. Representative iNOS protein 
expression as measured by Western blotting. Each band represents an individual 
animal in the corresponding group. (A) Liver samples. (B) Hindlimb skeletal muscle 
samples.    
 
B Sham RIPC IR RIPC + IR 
A RIPC + IR IR RIPC Sham 
A RIPC + IR IR RIPC Sham 
B Sham RIPC IR RIPC + IR 
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6.3.6 Cellular eNOS distribution in liver and hindlimb skeletal muscle 
of wild type mice 
Figure 6.8 and figure 6.9 illustrate representative photomicrographs of eNOS-
stained immunohistochemical sections of the liver and hindlimb skeletal muscle 
respectively. The trophoblasts in the placental positive control sections stained 
universally, whilst the negative controls had no staining. Within the liver eNOS 
immunostaining was localized to hepatocytes and the vascular endothelium (figure 
6.8). In the hindlimb skeletal muscle eNOS staining was seen in the myocytes and 
vascular endothelium (figure 6.9).    
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Figure 6.8. eNOS immunohistochemical staining of liver sections (X20 
magnification) in wild type mice. The brown colour uptake is the eNOS stain. Both 
hepatocytes (closed arrow heads) and endothelial cells (arrows) demonstrated eNOS 
expression in all the experimental groups: (A) Sham; (B) RIPC; (C) IR; (D) RIPC + 
IR. (E) Placental positive control showing brown eNOS staining (open arrow heads) 
of the trophoblastic cell layer. (F) Liver negative controls showing lack of any 
brown staining.       
 
 
 
 
A B 
C D 
E F 
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Figure 6.9. eNOS immunohistochemical staining of hindlimb skeletal muscle 
sections (X20 magnification) in wild type mice. The brown colour uptake is the 
eNOS stain. Both skeletal myocytes (arrow heads) and endothelial cells (arrows) 
demonstrated eNOS expression in all experimental groups: (A) Sham; (B) RIPC; 
(C) IR; (D) RIPC + IR.       
 
6.4 Discussion 
The findings of this study show that eNOS is a critical enzyme in mediating the 
protective effects of RIPC on liver IR injury. Moreover it was demonstrated that 
eNOS is responsible for the preservation of liver MBF in hindlimb preconditioned 
animals. Additionally hindlimb RIPC, but not liver IR, up-regulates the expression 
of iNOS in the liver and hindlimb skeletal muscle.  
 
We previously established and validated a new mouse model in which hindlimb 
RIPC significantly ameliorated liver IR injury (chapter 4). In the current study the 
D C 
B A 
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same mouse model was used to begin exploring the molecular mechanisms 
underlying the protection offered by hindlimb RIPC against liver IR injury.  
 
The eNOS and iNOS enzymes are responsible for manufacturing NO in vivo in 
extraneural tissues. Their role, if any, in the protection afforded by RIPC is 
unknown. eNOS-/- mice were used and the protection that had previously been 
exhibited by wild type mice (chapter 4) subjected to liver IR with antecedent 
hindlimb RIPC dissipated. The loss of protection of hindlimb preconditioning in 
eNOS-/- animals was evidenced by an increase in the plasma transaminases levels, 
histopathological injury scores, and ultrastructural markers of injury in the RIPC + 
IR compared to the IR alone group. This was in contrast to the decrease observed in 
these parameters of hepatic injury in the RIPC + IR compared to IR alone group in 
wild type mice. Amongst these parameters of liver IR injury the overall 
histopathological grades and the histopathological scores of individual features of 
liver IR injury showed a lack of statistical significance between the different eNOS-/- 
groups, and a lack of significance between the RIPC + IR compared to the IR alone 
group in wild type animals. This was due to the fact that liver biopsies for 
histopathological scoring were performed at 2 hours of reperfusion, which is too 
early for the full histopathological manifestations of liver IR injury.  
 
Our group previously showed that eNOS-derived NO is an important mediator of the 
protective effects of direct liver ischaemic preconditioning (240). The current study 
adds to this by demonstrating, for the first time in any remote preconditioning model 
of any organ, that eNOS is an essential prerequisite for the protective effects of 
RIPC upon hepatic IR injury at 2 hours of liver reperfusion. Moreover hepatic and 
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hindlimb skeletal muscle eNOS protein expression, as semi-quantified by 
densitometric analysis of eNOS protein bands of Western blots, was similar amongst 
the various wild type animal groups. This would imply that at 2 hours of reperfusion 
it is likely that eNOS activation rather than increased expression causes the observed 
protection of RIPC, although eNOS activity was not specifically measured in this 
study. eNOS activation is controlled by several overlapping mechanisms that 
dynamically regulate eNOS function. These mechanisms include eNOS acylation, 
Ca2+ / calmodulin binding, phosphorylation, and denitrosylation (239,369); all 
process that can be completed in a much shorter time period than eNOS up-
regulation. An increase in enzyme expression entails amino acid synthesis, DNA 
transcription, post-transcriptional modification and translation of mRNA, and post-
translational modifications of the enzyme; processes that take hours to complete 
rather than the minutes required for the activation of the enzyme.  
 
The expression of eNOS within the liver was observed in hepatocytes and the 
vascular endothelium; results that are congruent with those reported previously 
(240,241). In hindlimb skeletal muscle sections eNOS expression was apparent in 
the myocytes and vascular endothelium; cellular structures that have also been 
reported to express eNOS (370,371). It is likely that both hepatic and preconditioned 
hindlimb skeletal muscle eNOS contribute to the protection of RIPC. However, 
arguably it is also possible that only hindlimb eNOS is activated and increases its 
production of NO, that through one of its metabolic end products traverses the 
circulation to reach the liver where it exerts its protective effects. Alternatively, it 
maybe that a none NO-related, RIPC-induced factor, is released into the circulation 
to reach the liver and activate hepatic eNOS which then affords protection against 
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liver IR injury. Further research is needed to clarify this issue. An interesting result 
we uncovered was that iNOS expression, in the liver and hindlimb skeletal muscle, 
was only seen in the two groups subjected to hindlimb preconditioning, the RIPC 
alone group and the RIPC + IR groups. iNOS is induced in inflammatory conditions 
(372) and it would have been expected that iNOS might be up-regulated, at least 
within the liver, in the IR group. However, no iNOS expression was observed in any 
of the liver samples in the IR alone group subjected to Western blots. This may 
indicate a protective role for iNOS since its expression was only associated with 
hindlimb preconditioned mice. Only one previous study assessed iNOS expression 
following RIPC (234). In this study bilateral hindlimb preconditioning was followed 
by global myocardial ischaemia 24 hours post the RIPC stimulus resulting in 
significant reduction in the myocardial infarct size. The hindlimb RIPC was 
associated with increased myocardial iNOS mRNA expression starting at 3 hours 
post the RIPC stimulus and peaking at 24 hours (234). Furthermore, nuclear 
translocation of NF-κB was observed in heart and preconditioned skeletal muscle 
following hindlimb RIPC (234). NF-κB is a transcription factor that is well known 
for up-regulating iNOS expression, and therefore this study demonstrated that 
hindlimb RIPC results in iNOS expression in the myocardium, and possibly 
increases iNOS expression, through NF-κB activation in skeletal muscle; although 
direct iNOS expression was not measured in skeletal muscle (234). There are no 
previous studies that measure iNOS expression in RIPC of the liver.  
 
In this study it was demonstrated that one of the mechanisms through which eNOS 
mediates the protective effects of RIPC on liver IR injury comprise preservation of 
hepatic MBF. We previously proved, in wild type animals, hindlimb RIPC prior to 
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liver IR preserves hepatic MBF during the early reperfusion period, compared to 
animals subjected to IR alone (chapter 4). In contrast, the current study failed to 
demonstrate preservation of hepatic MBF in the RIPC + IR group in eNOS-/- mice 
compared to liver IR alone group. This would indicate an essential role for eNOS in 
preservation of the hepatic microvasculature, which is in accord with the well known 
functions of eNOS-derived NO as a vascular homeostatic factor, acting to protect the 
endothelium against various insults (362). The non-significant improvement of 
hepatic MBF in the RIPC + IR compared to the IR alone group in eNOS-/- animals 
during the two reperfusion period is in contrast to the results in chapter 5 showing 
no improvement in the MBF of the C-PTIO + RIPC + IR group compared to the IR 
group. The explanation for this probably lies in the fact that C-PTIO ‘mops-up’ all 
of the synthesized NO, whilst eNOS-/- animals can maintain some NO production 
through up-regulation of iNOS.     
 
In conclusion we demonstrated that eNOS is an essential prerequisite for the 
protective effects of hindlimb RIPC on liver IR injury. At 2 hours of reperfusion this 
is probably due to increased activation of eNOS rather than increased expression of 
this enzyme. We also demonstrated an increase in the expression of iNOS in 
preconditioned groups, which may be contributing to the protection of RIPC but this 
needs further research to prove.  
 
In this chapter we demonstrated an essential function for eNOS in the protection 
afforded by RIPC. In the next chapter we will investigate the role of nitrite / nitrate 
as the signal released from the preconditioned hindlimb into the circulation to elicit 
protection against hepatic IR injury.              
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Chapter 7 
 
Nitrite and nitrate as circulating carriers of 
nitric oxide induced by hindlimb RIPC 
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7.1 Introduction 
Nitric oxide (NO) is a highly reactive free radical molecule and consequently has a 
short half life that is in the order of 5-10 seconds. NO, which is synthesised by one 
or more of the nitric oxide synthase (NOS) isoforms, is rapidly oxidised to nitrite 
(NO2-) and nitrate (NO3-). Oxidation to NO2- is accomplished either via auto-
oxidation using molecular O2, or through a more rapidly occurring reaction that 
utilizes the copper-containing protein ceruloplasmin (373). NO3- is generated by one 
of two reactions that utilize oxyhaemoglobin. In the first of these NO2- reacts with 
oxyhaemoglobin to generate NO3- and methaemoglobin (374). In the second 
reaction oxyhaemoglobin directly reacts with NO to yield NO3- (373).      
 
Both NO2- and NO3- (NOx) are released into the circulation, and act as reservoirs of 
NO under specific circumstances (374,375). NO2- is reduced to NO by enzymatic 
and non-enzymatic pathways. Enzymatic nitrite reductases include xanthine 
oxidoreductase, cytochrome P450, and complexes III and IV of the mitochondrial 
electron transport chain (375). The non-enzymatic nitrite reductases include 
deoxyhaemoglobin and myoglobin (375). The reduction of NO3- to NO requires a 
nitrate reductase enzyme that was thought to be absent in mammalian cells. 
However, increasing evidence supports a role for xanthine oxidoreductase as a 
nitrate reductase (376,377). Additionally, dietary NO3- represents a significant 
contribution to the circulating pool of NO2-, through the conversion of NO3- to NO2- 
by the bacterial reductase enzyme found in the oral and gastrointestinal tract 
commensal population. The contribution of these pathways to the rate of NO 
generation from nitrite in a specific tissue type is dependent on the local pH and 
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oxygen tension, with acidosis and tissue hypoxia greatly enhancing NO production 
from the above pathways (375).  
 
Organs subjected to ischaemia reperfusion are typically hypoxic and acidotic at the 
end of the ischaemic period, and consequently it is thought nitrite reduction to NO is 
greatly increased locally at these sites (373,375). Evidence supportive of NO2- 
protecting against IR injury, through its reduction to NO, is accumulating for most 
major organs. Exogenous administration of sodium nitrite protects against brain 
(378), heart (302), Kidney (379), and lung (380) IR injury. Moreover, inhalation of 
NO results in elevated plasma NOx levels, that have been shown to reduce heart 
(381), lung (380), and lower extremity (382) IR injury.  
  
Experimental liver IR injury is also reduced by sodium nitrite administration 
(167,302). In further support of this, a human randomized controlled trial that 
assessed the benefits of inhaled NO in recipients of orthotopic liver transplants, 
found patients that were administered inhalational NO had significantly raised 
plasma NO2- levels that were associated with significant improvements in liver 
function tests in the postoperative period, significant decrease in hepatocyte 
apoptosis, and a significant decrease in hospital length of stay compared to placebo 
group (383). Evidence for the protective role of endogenously generated NO2- in 
liver IR injury comes from an experiment that utilized wild type and mice with 
cardiac-specific over-expression of eNOS (CS-eNOS-Tg). Plasma and hepatic NOx 
levels were elevated in the CS-eNOS-Tg mice compared to wild types, with a 
consequent significant protection against liver IR injury in CS-eNOS-Tg but not 
wild type mice (384). 
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The role of NOx generated as a consequence of hindlimb RIPC, in the protection 
against liver IR injury is currently unknown. The aim of the present study was to 
evaluate the role of endogenously generated NOx during hindlimb RIPC in wild 
type mice, in protecting against liver IR injury. Based on the initial results we 
elicited, we proceeded to determine the effects of exogenous nitrite administration 
on liver IR injury in eNOS-/- mice.   
 
7.2 Materials and methods 
The detailed methodology was described in chapter 3. A summary of the most 
pertinent points is given below. 
 
7.2.1 Animal surgical procedure 
Male inbred C57BL/6 wild type mice (Charles River laboratories, UK); and mice 
lacking the constitutively expressed enzyme, endothelial nitric oxide synthase 
(eNOS-/-, bred in-house) were utilized in the present study. The animals were 
anaesthetised using 2% isoflurane. Core body temperature was maintained at 37.0 ± 
0.5 ℃ using a heating pad and a rectal temperature probe. Hepatic IR was performed 
as detailed in section 3.4.1. At the end of the reperfusion period the animals were 
terminated by exsanguination through needle cardiac puncture and blood collection. 
The blood was immediately centrifuged and the plasma supernatant was stored at -
70 ℃ until assayed for liver transaminases. The left and median liver lobes were 
harvested at the end of each procedure for histopathology and transition electron 
microscopy (TEM). Hindlimb preconditioning consisted of microvascular clamping 
of the femoral vessels for four minutes followed by four minutes reperfusion for a 
total of six cycles as described in section 3.4.2. 
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7.2.2 Experimental groups 
Wild type animal groups (figure 3.2) were used to measure plasma NOx levels. The 
results of these experiments demonstrated a significant rise in plasma NOx levels in 
hindlimb preconditioned animals. Therefore further experiments were conducted to 
evaluate the effects of exogenous nitrite administration on liver IR injury in eNOS-/- 
animal groups (figure 3.3). Total anaesthetic time was equal in all the groups. All 
animals underwent laparotomy, mobilization of the liver, and mobilization of the 
right femoral vascular bundle. In addition some of the groups were each subjected to 
a specific procedure as follows:  
 
Wild type groups: 
Sham: Underwent the laparotomy, mobilization of the liver, and mobilization of the 
right femoral vascular bundle described above.  
RIPC: The right hindlimb was preconditioned with 6 cycles of 4 minutes ischaemia 
followed by 4 minutes reperfusion, using a microvascular clamp to occlude the 
femoral vessels under an operating microscope. 
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: Animals were subjected to the RIPC followed by the IR procedures.   
 
These wild type groups were used to measure the plasma NOx levels in the current 
chapter. The extent of liver injury in these groups was previously assessed in chapter 
4 using plasma transaminases levels, evaluation of histopathological and 
ultrastructural features of IR injury, and hepatic MBF measurements.   
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eNOS-/- groups: 
Sham: Underwent the laparotomy, mobilization of the liver, and mobilization of the 
right femoral vascular bundle described previously.  
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
Nitrite + IR: Underwent the IR procedure with administration of sodium nitrite, at a 
dose of 48 nmol in 50 µl of D-PBS (167,302), topically into the peritoneal cavity 20 
minutes into liver ischaemia. To elicit the optimal time of sodium nitrite 
administration, plasma transaminases levels and liver MBF were measured in two 
additional eNOS-/- groups (n = 2 each) that received the sodium nitrite either 
immediately preceding liver ischaemia or just before liver reperfusion at the end of 
liver ischaemia.  
 
These eNOS-/-groups were used in the present chapter to assess the plasma liver 
enzymes, histopathological and ultrastructural features of IR injury, and MBF 
measurements.  
 
7.2.3 Nitrite and nitrate measurements 
The plasma nitrite and nitrate (NOx) levels were measured in wild type mice using a 
commercially available colorimetric assay kit (Cayman Chemical, catalogue No. 
780001) as detailed in section 3.11.  
 
 
 
 187 
7.2.4 Measurement of liver enzymes 
The plasma concentrations of ALT and AST were measured in the eNOS-/- groups 
using an automated clinical analyzer as described in section 3.5.  
 
7.2.5 Histopathology 
A liver biopsy was taken from the left lobe of each eNOS-/- animal at the end of the 
experiment and fixed in 10% formal saline. The fixed tissues were embedded in 
paraffin and stained with H&E. Sections were assessed by a liver pathologist 
blinded to the animal groups. Each H&E sample was scored for features of liver IR 
injury using two different methods as described in section 3.6.  
 
7.2.6 Transmission electron microscopy 
Liver biopsies were obtained from the left lobe of each eNOS-/- animal at 
termination, and were fixed in a glutaraldehyde / paraformaldehyde mixture 
overnight, processed as described in section 3.7, and viewed with a transmission 
electron microscope. Representative areas were photographed and the images were 
interpreted by a TEM scientist who was blinded to the groups. Assessment of the 
images was performed according to the parameters outlined in section 3.7. 
 
7.2.7 Liver and hindlimb microcirculatory blood flow  
Laser Doppler flowmetry (LDF) was used to measure blood flow in the liver 
microvasculature of eNOS-/- animals as described in section 3.8. The probe was 
placed on the left liver lobe so that it was just in contact with the tissue surface. LDF 
data was collected as the mean of four readings recorded over a one minute period. 
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In addition, a second LDF probe was positioned on the sole of the right foot to 
ensure blood flow interruption and reperfusion during femoral vessels clamping and 
unclamping respectively. Figure 3.6 shows the time points of the LDF recordings 
during the study protocol.  
 
7.2.8 Statistical analysis 
Values are expressed as mean ± SEM. One way analysis of variance (ANOVA) with 
Post Hoc Bonferroni correction for multiple comparisons was used. P < 0.05 was 
considered statistically significant in all analyses. 
 
7.3 Results 
The plasma transaminases levels, histopathological scores, ultrastructural changes, 
and MBF results of the Nitrite + IR group in eNOS-/- animals obtained in this 
chapter, were compared to the results of the sham and IR groups in eNOS-/- animals 
described in chapter 6. 
 
7.3.1 Hindlimb RIPC significantly increases plasma NOx levels 
Total plasma nitrite and nitrate (NOx) levels were measured in wild type animals. 
Both the RIPC and RIPC + IR groups showed a significant increase in plasma NOx 
levels compared to sham (P < 0.05) (figure 7.1). In addition the RIPC + IR group 
demonstrated a significant rise in the NOx levels compared to the IR group (P < 
0.05).   
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Figure 7.1. Plasma nitrite and nitrate (NOx) levels in wild type mice (n ≥ 6 per 
group). *P < 0.05 vs sham. #P < 0.05 vs IR.  
 
 
7.3.2 Sodium nitrite administration, to eNOS-/- mice subjected to 
hepatic IR, does not reduce plasma transaminases levels 
Liver IR resulted in a significant rise in the plasma ALT and AST compared to the 
sham group (P < 0.05). Sodium nitrite administration 20 minutes into IR did not 
reduce the plasma transaminases levels (figure 7.2). Two further experimental 
groups were performed (n = 2 each) to determine if the time of administration of 
sodium nitrite affects the transaminases levels. Neither the administration of sodium 
nitrite immediately preceding liver ischaemia nor just before liver reperfusion at the 
end of liver ischaemia, had any effect on plasma transaminases levels (data not 
shown).  
 
 
 * 
* # 
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Figure 7.2. Plasma liver enzyme levels in eNOS-/- mice. (A) Alanine 
aminotransferase (ALT). *P < 0.05 vs sham. (B) Aspartate aminotransferase (AST). 
*P < 0.05 vs sham.  
 
7.3.3 Liver histopathological IR injury is not attenuated by sodium 
nitrite administration in eNOS-/- animals 
The sham group demonstrated some signs of liver IR injury with a mean overall 
grade of 0.33 (figure 7.3). The IR group resulted in a non-significant increase in the 
mean overall injury grade to 1.0. The administration of sodium nitrite during IR 
(nitrite + IR group) resulted in a significant worsening of the overall 
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histopathological manifestations of IR injury compared to the sham but not IR 
groups (P < 0.05 vs sham; P > 0.05 vs IR).    
  
Four individual features of liver IR injury (liver cell ballooning, nuclear pyknosis, 
blurred intercellular borders, RBC extravasation) demonstrated significantly 
increased scores in the nitrite + IR compared to the sham group (P < 0.5) (figure 
7.4). None of the other individual features of liver IR injury showed significant 
differences between any of the animal groups comparisons.   
 
 
 
Figure 7.3. Vertical scatter plot of histopathological grades in eNOS-/-. Each dot 
represents the overall grade assigned to each individual liver biopsy sample (n = 6 
per group). Horizontal bars represent the means. *P < 0.05 vs sham.  
 
 
 
* 
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Figure 7.4. Histopathological scores of individual features of liver injury in eNOS-/- 
animals. Each bar chart is the mean histopathological score of six animals in that 
group. The error bars are the standard error of the means.  *P < 0.05 vs Nitrite + IR.   
 
 
 
 
* 
* 
* * 
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7.3.4 IR-induced liver ultrastructural damage is not reduced by 
sodium nitrite administration in eNOS-/- mice  
Representative ultrastructural images from each of the groups are shown in figure 
7.5. The sham group showed some ultrastructural disturbances consisting of 
sporadic ER dilatation, phagolysosomal and lipid droplet formation. The IR group 
exhibited extensive mitochondrial damage, ER dilatation, cytosolic vacuole 
formation, phagolysosomal formation, lipid droplet formation, glycogen depletion, 
bile canaliculi dilatation with microvilli disruption, and SEC disruption with 
extravasation of RBC and plasma into the liver parenchyma. Importantly the 
administration of nitrite during ischaemia (nitrite + IR) did not alter the IR-induced 
ultrastructural damage resulting in appearances that were comparable to those in the 
IR group (figure 7.5).   
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Figure 7.5. Hepatic transmission electron micrographs in eNOS-/- mice. The liver 
samples were taken at the end of the procedure in each group. (A) & (B) Sham 
group showing normal looking mitochondria (m), normal (er) and dilated 
endoplasmic reticulum (der), phagolysosomes (pl), bile canaliculi with microvilli 
(bc), sinusoidal endothelial cells (sec), and microvilli in the space of Disse (ms). (C) 
& (D) IR group demonstrating damaged mitochondria (dm), dilated endoplasmic 
reticulum (der), vacuole formation (vc), lysosomes (ly), lipid droplet formation (ld), 
and damaged sinusoidal endothelial cells (dsec) with extravasated red blood cell 
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(erbc), polymorphonucelocyte (epmn), and plasma (ep) into the hepatocytes. (E) & 
(F) Nitrite + IR group showing damaged mitochondria (dm), dilated endoplasmic 
reticulum (der), vacuolation (vc), lysosomes (ly) and phagolysosomal formation (pl), 
lipid droplet formation (ld), damaged sinusoidal endothelial cells (dsec) associated 
with obliteration of the space of Disse (osd), and myelin figure (mf) indicative of 
membranous damage. 
 
7.3.5 The reductions in hepatic microcirculatory blood flow seen with 
IR injury in eNOS-/- animals are unaffected by exogenous sodium 
nitrite 
Hepatic MBF remained relatively constant throughout the experiment in the sham 
group (figure 7.6).  
 
In the IR group the MBF decreased from a mean of 99.3% of baseline during the 
pre-ischaemic period, to a mean of 31% of baseline during hepatic ischaemia (figure 
7.6). Immediately following liver reperfusion, the mean MBF was 35.7%, and this 
improved to 52.3% of baseline at 30 minutes of reperfusion. The MBF remained 
relatively constant from then on, recording a reading of 52.2% at the end of the 2 
hour reperfusion period.  
 
Administration of nitrite during IR (nitrite + IR group) resulted in a mean MBF of 
67.4% of baseline (figure 7.6) immediately following reperfusion, which is 
significantly higher than the MBF observed in the IR group at this time point (P < 
0.05). Throughout the remainder of the reperfusion period the mean MBF ranged 
between 60.1% - 67.9% of baseline (P > 0.05 vs IR). Between 30 minutes to the end 
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of the reperfusion period at 2 hours, the difference between the sham and the other 2 
groups (IR and nitrite + IR) was statistically significant (P < 0.05).     
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Figure 7.6. Hepatic microcirculatory blood flow in eNOS-/- animals, measured by 
LDF, is illustrated as mean percentage of pre-ischaemic baseline. Significant (P < 
0.05) inter-group differences are shown vertically above the time points on the x-
axis. BL, baseline; HI, hindlimb ischaemia; HR, hindlimb reperfusion; BLI, 
beginning of liver ischaemia; ELI, end of liver ischaemia; BR, beginning of liver 
reperfusion; R30 to R120, liver reperfusion at 30, 60, 90, and 120 min post 
ischaemia.    
 
 
7.4 Discussion 
The results of the experiments in this chapter showed that hindlimb RIPC (RIPC and 
RIPC + IR groups) in wild type mice results in a significant elevation of plasma 
NOx levels. In contrast exogenous nitrite administration to eNOS-/- mice did not 
attenuate liver IR injury.  
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The wild type animal experiments in this study demonstrated that RIPC alone 
significantly increases plasma NOx levels compared to sham animals. This indicates 
limb RIPC results in increased NO production that is rapidly oxidised to NO2- and 
NO3-. Further support for the theory that limb RIPC increases NO production comes 
from the demonstration in these experiments that RIPC + IR significantly increased 
plasma NOx levels compared to IR alone. In addition the RIPC + IR group had NOx 
levels that were significantly higher compared to those of sham. These results in 
combination with the results in chapter 4, showing that in wild type mice limb RIPC 
significantly reduces liver IR injury and increases hepatic MBF, would support the 
hypothesis that RIPC-induced NO synthesis is responsible for protection against 
liver IR injury. Only one previous publication described the measurement of plasma 
NOx levels following RIPC of the liver (227). In this study peripheral arterial and 
hepatic venous plasma NOx levels were quantified following hindlimb RIPC and 
hepatic IR in a rabbit model (227). The plasma NOx levels were non-significantly 
lowered following hepatic IR compared to the sham group in both peripheral arterial 
and hepatic venous blood. Hindlimb RIPC prior to hepatic IR resulted in an increase 
in NOx levels compared to the IR alone group which only reached statistical 
significance in hepatic venous blood samples but not in arterial samples (227), 
suggesting that liver IR leads to reduction in NO synthesis whilst antecedent limb 
RIPC acts to prevent this reduction in NO levels. In the present study we did not 
observe a reduction in plasma NOx levels in the IR compared to the sham group, but 
we did see a significant elevation of plasma NOx levels in the RIPC compared to the 
sham group and in the RIPC + IR compared to the IR group. Our results imply limb 
RIPC protects against liver IR injury through the elevation of NOx, and therefore 
NO levels.   
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Direct ischaemic preconditioning is known to increase NO synthesis (385) which in 
turn is rapidly oxidised to NO2- and NO3-. Oxidation to NO2- is accomplished via 
auto-oxidation using molecular O2 and through a more rapidly occurring reaction 
that uses the protein ceruloplasmin (373). Oxidation of NO to NO3- uses 
oxyhaemoglobin as the oxidising agent (373). Circulating NO2- and NO3- enter the 
liver upon reperfusion to encounter an acidotic and a hypoxic environment that 
accelerate the reduction of these molecules to NO (375,386). Whilst NO, resulting 
from the reduction of NO2- and NO3- in the post-ischaemic liver environment, is the 
commonest pathway through which these molecules act to protect against IR injury 
(374,386); other NO-independent pathways may mediate the beneficial effects of 
NO2- and NO3-, however the role of these pathways in protection against liver IR 
injury is currently unclear (374,386).         
 
Based on the findings of elevated plasma NOx levels in limb preconditioned wild 
type animals; exogenous sodium nitrite was administered to eNOS-/- animals to 
establish if exogenous nitrite possesses the beneficial effects we demonstrated with 
elevated endogenous NOx levels secondary to limb RIPC. However, we were unable 
to reproduce the protective effects of endogenous NOx through the administration of 
exogenous nitrite. Histopathologically the overall injury grade and 4 individual 
features of liver IR injury demonstrated a significant increase in the nitrite + IR 
group scores compared to the sham group scores. This is in contrast to the IR group 
scores which did not show significant differences from sham scores. These results 
could suggest that exogenous nitrite administration, at least on histopathological 
assessment, may increase liver damage in the context of IR. However, this would 
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need further research to establish, as neither the overall nor the individual features 
scores showed significant differences between the IR and IR + nitrite groups.  
More than a single explanation is possible for the lack of protection of exogenously 
administered nitrite to eNOS-/- mice. The dose of the administered nitrite was based 
on previous dosing studies (167,302) that showed 48 nmol of sodium nitrite elicits 
maximal protection in both, wild type and eNOS-/- animals. Moreover, the route and 
timing of nitrite administration was also as previously reported (167,302). Despite 
all of this we were unable to elicit protection against liver IR injury with exogenous 
nitrite administration. This may have been due to differing experimental variables 
such as the type of anaesthesia used or exact lengths of the ischaemia and 
reperfusion periods. Future dosing studies would be needed to clarify the role of 
exogenous nitrite in protection against liver IR injury. These experiments would 
evaluate the effects of altering the dose, timing and route of nitrite administration, 
on liver IR injury in the mouse model described in this thesis. An alternative 
explanation for the lack of efficacy of exogenous nitrite administration in eNOS-/- 
animals pertains to the fact that eNOS acts as a nitrite reductase under hypoxic 
conditions (387) leading to the reduction of nitrite to NO which in turn elicits 
protection. In an in vivo renal IR injury model, it has been shown that topical 
administration of nitrite to wild type but not eNOS-/- exhibit protection against 
kidney damage (388). Furthermore this has been corroborated by in vitro work in 
which wild type and eNOS-/- kidney homogenates, under hypoxic and acidotic 
conditions, had nitrite-derived NO quantified. The results showed that wild type 
homogenates produce significantly more NO compared to eNOS-/- homogenates 
(388). These results suggest that eNOS is an essential nitrite reductase under 
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hypoxic and acidotic conditions. The mechanisms underlying the nitrite reductase 
activity of eNOS are reviewed elsewhere (374). 
 
In conclusion based on the results observed, endogenous circulating NOx levels are 
elevated following hindlimb RIPC and are associated with protection against liver 
IR injury. However, administration of exogenous nitrite to eNOS-/- mice at the dose, 
timing, and route described did not afford hepatic protection against liver IR injury.  
 
In this chapter it was shown that hindlimb RIPC increases circulating levels of NO2- 
and NO3-. In the next chapter the role of the hepatic soluble guanylyl cyclase-cyclic 
GMP pathway in mediating the protective effects of hindlimb RIPC on liver IR 
injury will be evaluated.     
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Chapter 8 
 
Importance of the hepatic sGC-cGMP pathway in the 
protective effects of RIPC against liver IR injury 
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8.1 Introduction 
Nitric oxide (NO) may act through various pathways within the liver to exert its 
protective effects; including through the soluble guanylyl cyclase (sGC)-cyclic 3’, 5’ 
guanosine monophosphate (cGMP) pathway in the setting of liver IR injury (29).  
 
The purification, quantification, and measurement of the activity of sGC is very 
difficult (389). Therefore, the inhibition or stimulation of sGC, using specific 
blockers or activators respectively, is used to elicit its functions in experimental 
models (389). sGC has been shown to mediate the protective effects of NO in liver 
IR injury, and administration of the sGC blocker ODQ abrogates these beneficial 
effects of NO, indicating NO acts through sGC in protecting the liver against IR 
injury (256,296,302,360). This has been shown in vivo (256,302) and in cultured 
hepatocytes models (296,360). Moreover, the specific sGC activator YC-1 reduces 
IR injury when administered to mice being subjected to liver IR (256).  
 
Several experimental studies show NO protects against liver IR injury by elevating 
cGMP levels. Mice over-expressing the eNOS gene have significantly elevated 
hepatic cGMP levels compared to wild types which is associated with protection 
against liver IR injury (256). Other in vivo work showed rat pretreatment with the 
cGMP analogue 8-bromoguanosine 3',5' monophosphate (8-Br-cGMP) diminished 
subsequent hepatic IR injury (390). Furthermore, pretreatment with the non-
selective NOS inhibitor N-omega-nitro-L-arginine (NA) worsens liver IR injury, 
however when the administration of NA is preceded by 8-Br-cGMP then the NA-
induced adverse effects on IR are prevented (391) indicating that NOS-derived NO 
acts through cGMP to exert its protective effects. In vitro studies using cultured 
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hepatocytes further support the in vivo work, by demonstrating NO donors 
ameliorate hypoxia re-oxygenation injury through the elevation of cGMP levels 
(360). Moreover, re-oxygenation of hypoxic hepatocytes pretreated with 8-Br-cGMP 
ameliorated the IR-induced cell necrosis (296,360). The administration of the 
phosphodiesterase inhibitor sildenafil, which raises cGMP levels, to mice subjected 
to liver IR has also been shown to significantly ameliorate the IR injury (256).     
 
The role of the sGC-cGMP pathway in mediating the protective effects of direct 
liver ischaemic preconditioning (IPC) has been evaluated. IPC reduces liver IR 
injury through increased production of hepatic cGMP (279). In contrast the role of 
the hepatic sGC-cGMP pathway in mediating the protective effects of RIPC on liver 
IR injury has not been studied. The aim of the current study was therefore to assess 
involvement of the hepatic sGC-cGMP pathway in mediating the protective 
functions of hindlimb RIPC on liver IR injury.  
 
8.2 Materials and methods 
The detailed methodology was described in chapter 3. A summary of the most 
pertinent points is given below. 
 
8.2.1 Animal surgical procedure 
Male inbred C57BL/6 wild type mice (Charles River laboratories, UK) were utilized 
in the present study. The animals were anaesthetised using 2% isoflurane. Core body 
temperature was maintained at 37.0 ± 0.5 ℃ using a heating pad and a rectal 
temperature probe. Hepatic IR was performed as detailed in section 3.4.1. At the end 
of the reperfusion period the animals were terminated by exsanguination through 
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needle cardiac puncture and blood collection. The blood was immediately 
centrifuged and the plasma supernatant was stored at -70 ℃ until assayed for liver 
transaminases. The left and median liver lobes were harvested at the end of each 
procedure for histopathology and transition electron microscopy. Hindlimb 
preconditioning consisted of microvascular clamping of the femoral vessels for four 
minutes followed by four minutes reperfusion for a total of six cycles as described in 
section 3.4.2.  
 
8.2.2 Experimental groups 
Four wild type groups with a minimum of six animals in each were used (Figure 
3.2). The total anaesthetic time was equal in all the groups. All animals underwent 
laparotomy, mobilization of the liver, and mobilization of the right femoral vascular 
bundle. In addition some of the groups were each subjected to a specific procedure 
as follows:  
 
Sham: Only underwent the laparotomy, mobilization of the liver, and mobilization 
of the right femoral vascular bundle described above.  
IR: The median and left hepatic lobes were rendered ischaemic for 40 minutes 
followed by 2 hours reperfusion, using a microvascular clamp to occlude the portal 
triad branch to these lobes.   
RIPC + IR: The right hindlimb was preconditioned with 6 cycles of 4 minutes 
ischaemia followed by 4 minutes reperfusion, using a microvascular clamp to 
occlude the femoral vessels under an operating microscope. This was followed by 
the IR group procedure described above.    
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ODQ + RIPC + IR: The sGC inhibitor ODQ was administered topically to the liver, 
in a volume of 100 µl of DMSO containing 600 µg of ODQ, followed by the RIPC + 
IR procedure.    
 
8.2.3 Measurement of liver enzymes 
The concentrations of ALT and AST were measured in the plasma using an 
automated clinical analyzer as described in section 3.5.  
          
8.2.4 Histopathology 
A liver biopsy was taken from the left lobe of each animal at the end of the 
experiment and fixed in 10% formal saline. The fixed tissues were embedded in 
paraffin and stained with H&E. Sections were assessed by a liver pathologist 
blinded to the animal groups. Each H&E sample was scored using two different 
methods as described in section 3.6.  
 
8.2.5 Transmission electron microscopy 
Liver biopsies were obtained from the left lobe at termination of the animals and 
were fixed in a glutaraldehyde / paraformaldehyde mixture overnight, processed as 
described in section 3.7, and viewed with a transmission electron microscope. 
Representative areas were photographed and the images were interpreted by a 
transition electron microscopy (TEM) scientist who was blinded to the groups. 
Assessment of the images was performed according to the parameters outlined in 
section 3.7. 
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8.2.6 Liver and hindlimb microcirculatory blood flow 
Laser Doppler flowmetry (LDF) was used to measure blood flow in the 
microvasculature of the liver as described in section 3.8. The probe was placed on 
the left liver lobe so that it was just in contact with the tissue surface. LDF data was 
collected as the mean of four readings recorded over a one minute period. In 
addition, a second LDF probe was positioned on the sole of the right foot to ensure 
blood flow interruption and reperfusion during femoral vessels clamping and 
unclamping respectively. Figure 3.6 shows the time points of the LDF recordings 
during the study protocol.  
 
8.2.7 Measurement of hepatic cGMP 
Hepatic cGMP levels were measured using a commercially available enzyme 
immunoassay kit (Cayman Chemical, catalogue No. 581021) as detailed in section 
3.12.  
 
8.2.8 Statistical analysis 
Values are expressed as mean ± SEM. One way analysis of variance (ANOVA) with 
Post Hoc Bonferroni correction for multiple comparisons was used. P < 0.05 was 
considered statistically significant in all analyses. 
 
 8.3 Results 
The plasma transaminases levels, histopathological scores, ultrastructural changes, 
and MBF results of the ODQ + RIPC + IR group obtained in this chapter were 
compared to the results of the sham, IR, and RIPC + IR groups obtained in chapter 
4. 
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8.3.1 ODQ increases plasma transaminases levels in hindlimb 
preconditioned mice 
The results of the plasma transaminases are summarised in figure 8.1. Liver IR 
resulted in a significant increase in the plasma levels of ALT and AST compared to 
the sham group (P < 0.05). Hindlimb preconditioning preceding liver IR (RIPC + IR 
group) significantly reduced the plasma transaminases levels compared to IR alone 
(P < 0.05). Topical administration of ODQ to the liver, prior to hindlimb RIPC and 
liver IR (ODQ + RIPC + IR group), increases ALT and AST compared to the RIPC 
+ IR group but this did not reach statistical significance.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1. Plasma liver enzyme levels. (A) Alanine aminotransferase (ALT). *P < 
0.05 vs sham; #P < 0.05 vs IR. (B) Aspartate aminotransferase (AST). *P < 0.05 vs 
sham; #P < 0.05 vs IR.  
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8.3.2 The protective effects of hindlimb RIPC on hepatic 
histopathological IR injury are diminished by ODQ  
The overall IR injury grade assigned to each sample and the mean overall grade for 
each animal group are both given in figure 8.2. The sham group showed minimal 
signs of liver IR injury with a mean overall grade of 0. Liver IR resulted in a 
significant increase in the mean overall injury grade (IR group mean overall grade = 
1.83) compared to the sham group (P < 0.05). Preconditioning prior to liver IR 
(RIPC + IR group) decreased the mean overall injury score to 1.33, which is not 
significantly different from the sham or IR groups (P > 0.05). Administration of 
ODQ prior to RIPC + IR (ODQ + RIPC + IR group) resulted in an increase of the 
mean overall injury grade to 1.5 (P < 0.05 vs sham; P > 0.05 vs IR or RIPC + IR).             
 
 
Figure 8.2. Vertical scatter plot of histopathological grades. Each dot represents the 
overall grade assigned to each individual liver biopsy sample (n = 6 per group). 
Horizontal bars represent the means. *P < 0.05 vs sham.  
* * 
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Assessment of the 10 individual histopathological features of liver IR injury 
revealed a higher mean score of all 10 features in the IR compared to the sham 
group, although statistical significance (P < 0.05) was only achieved in 5 of the 10 
individual features. (figure 8.3).  
 
Compared to IR, the RIPC + IR group resulted in a lower mean score in 8 out of the 
10 individual features, although in none of these was statistical significance reached. 
The remaining 2 features (neutrophil infiltration and nuclear pyknosis) had a higher 
mean score in the RIPC + IR compared to the IR group (figure 8.3).  
 
Administration of ODQ prior to RIPC + IR (ODQ + RIPC + IR group) resulted in a 
higher mean score in 7 out of the 10 individual features compared to the RIPC + IR 
group, although none of these reached statistical significance (figure 8.3). Two of 
the remaining features (sinusoidal dilatation and eosinophilia) had mean scores that 
were identical in the ODQ + RIPC + IR and the RIPC + IR group. One feature 
(nuclear pyknosis) showed a lower mean score in the ODQ + RIPC + IR compared 
to RIPC + IR.    
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Figure 8.3. Histopathological scores of individual features of liver injury. Each bar 
chart is the mean histopathological score of six animals in that group. The error bars 
are the standard error of the means.  *P < 0.05 vs sham.  
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8.3.3 ODQ inhibits the protective effects of hindlimb RIPC on 
ultrastructural damage in liver IR 
Figure 8.4 illustrates representative changes exhibited by each of the animal groups. 
The sham group showed normal ultrastructural appearances. The IR group exhibited 
extensive mitochondrial damage, ER dilatation, cytosolic vacuole formation, 
phagolysosomal formation, lipid droplet formation, glycogen depletion, bile 
canaliculi dilatation with microvilli damage, and sinusoidal endothelial cell (SEC) 
disruption with extravasation of red blood cells (RBC) into the liver parenchyma. In 
contrast the ultrastructural damage sustained by the RIPC + IR group consisted of 
ER dilatation, phagolysosomal formation, lipid droplet formation, glycogen 
depletion, and disruption of SEC but without RBC extravasation.  
  
The administration of ODQ prior to RIPC + IR (ODQ + RIPC + IR group) resulted 
in appearances that are very similar to the IR group and that consisted of  extensive 
mitochondrial damage, ER dilatation with vesiculation, vacuole formation, lipid 
droplet formation, glycogen depletion, and homogenous SEC disruption with RBC 
extravasation.  
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Figure 8.4. Hepatic transmission electron micrographs. The liver samples were taken at the end of the procedure in each group. (A) & (B) 
Sham group showing normal endoplasmic reticulum (er), bile canaliculi with microvilli (bc), mitochondria (m), glycogen (gl), and sinusoidal 
endothelial cells (sec). (C) & (D) IR group demonstrating irreversibly damaged mitochondria (dm) with some merging into vacuoles (vc), 
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dilatation and vesiculation of endoplasmic reticulum (der), lysosomes (ly) and phagolysosomes (pl), lipid droplets (ld), and severely damaged 
sinusoidal endothelial cells (dsec) associated with red blood cell extravasation (erbc). (E) & (F) RIPC + IR group demonstrating undamaged but 
pleomorhic mitochondria (m), lipid droplets (ld), lysosomes (ly) and phagolysosomes (pl), and damaged sinusoidal endothelial cells (sec) but 
without RBC extravasation. (G) & (H) ODQ + RIPC + IR group showing irreversibly damaged mitochondria (dm) some of which are 
coalescing into vacuoles (vc), dilatiation and vesiculation of endoplasmic reticulum (er), lipid droplets (ld), severely damaged sinusoidal 
endothelial cells (dsec) associated with obliteration of the space of Disse (osd) and extravasation of red blood cells (erbc) and plasma (ep). 
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    8.3.4 ODQ abolishes the protective effects of hindlimb RIPC on 
hepatic microcirculatory blood flow in liver IR 
Figure 8.5 illustrates hepatic MBF for the duration of the experiment. The sham 
group demonstrated constant hepatic MBF, whilst the IR and RIPC + IR exhibited a 
significant reduction of MBF during liver ischaemia compared to sham. Upon 
reperfusion the IR group showed no significant improvement in MBF, whilst the 
RIPC + IR group demonstrates significant recovery of MBF towards baseline values 
compared to the IR group (P < 0.05). 
  
The ODQ + RIPC + IR group did not show significant deviations in MBF from the 
other groups during the pre-ischaemic period. However, during liver ischaemia MBF 
readings dropped significantly compared to the sham but not the IR or RIPC + IR 
groups. Upon reperfusion MBF in the ODQ + RIPC + IR group failed to recover, 
showing significant differences compared to the RIPC + IR group throughout 
reperfusion (P < 0.05). At the end of the 2 hour reperfusion period the mean MBF 
value was 41.5% of baseline in the ODQ + RIPC + IR group compared to 93.5% of 
baseline in the RIPC + IR group (P < 0.0001). There were no significant differences 
in the mean MBF values between the ODQ + RIPC + IR and the IR groups 
throughout the reperfusion period (figure 8.5).     
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Figure 8.5. Hepatic microcirculatory blood flow, measured by LDF, is illustrated as 
mean percentage compared to pre-ischaemic baseline. Significant (P < 0.05) inter-
group differences are shown vertically above the time points on the x-axis. BL, 
baseline; HI, hindlimb ischaemia; HR, hindlimb reperfusion; BLI, beginning of liver 
ischaemia; ELI, end of liver ischaemia; BR, beginning of liver reperfusion; R30 to 
R120, liver reperfusion at 30, 60, 90, and 120 min post ischaemia.     
 
8.3.5 RIPC alone but not RIPC + IR significantly elevates hepatic 
cGMP levels 
The RIPC alone group showed significantly higher levels of hepatic cGMP 
compared to the sham group. There were no significant differences between the 
remaining groups (figure 8.6).  
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Figure 8.6. Hepatic cGMP levels in wild type mice (n = 6 per group). *P < 0.05 vs 
Sham.  
 
8.4 Discussion 
The results of the current study indicated that protective mechanisms of hindlimb 
RIPC include the hepatic sGC-cGMP pathway. This was attested to by a trend 
showing an elevation in the ALT and AST plasma levels, and an increase in the 
overall histopathological injury grade and in seven out of the ten individual features 
of liver IR injury, in the ODQ + RIPC + IR compared to the RIPC + IR group. 
Moreover, hepatic MBF measurements during liver reperfusion were significantly 
reduced in the ODQ + RIPC + IR compared to the RIPC + IR group. Finally, hepatic 
cGMP levels were significantly elevated in the RIPC alone group compared to the 
sham group.  
     
Eukaryotic sGC possesses high affinity for NO as an activating ligand (392). More 
than a single explanation is possible as to why the enzyme and histopathological 
 * 
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markers of liver IR injury were not significantly higher in the ODQ + RIPC + IR 
compared to the RIPC + IR group. Firstly the selective sGC inhibitor ODQ acts 
through an interaction with the iron of haem prosthetic groups and therefore would 
bind not just sGC but also haemoglobin in the circulation and restrict its 
effectiveness when administered intravenously (389). To minimise the interaction 
with haemoglobin ODQ was administered topically to the liver in the present study. 
Topical administration however, would have still allowed interaction of ODQ with 
the haem iron centres of other proteins found in the liver such as cytochrome P450. 
Nonetheless, topical intraperitoneal ODQ has been used in multiple in vivo studies 
in the past to investigate the effects of inhibiting sGC on organ IR injury 
(256,302,393,394). The second explanation for the presence of a trend but not a 
significant difference in the increase in plasma enzymes and histopathological 
markers of liver IR injury may relate to the fact that NO can act through multiple 
different pathways (395-397) to exert its effects. Therefore it is feasible that NO 
acted through an alternate mechanism; such as formation of peroxynitrite, 
nitrosylation of thiol and amine groups, or nitration of amino acids such as tyrosine 
and tryptophan (395-397) that subsequently provided heptoprotection against liver 
IR injury; in addition to the sGC-cGMP pathway. However, this requires further 
research to ascertain. 
  
The results of hepatic cGMP levels suggested this second messenger is at least 
partially responsible for mediating the effects of hindlimb RIPC. This is because the 
RIPC alone group had a significantly elevated levels of cGMP compared to sham; 
whilst at the same time the cGMP levels in the RIPC + IR group did not differ from 
those in the IR alone group. An alternate explanation is that IR completely abrogated 
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the effects of RIPC on hepatic cGMP levels. We are the first group to demonstrate a 
possible role for the hepatic sGC-cGMP pathway in mediating the protective effects 
of RIPC. Previous in  vivo (256,390,391) and in vitro studies (296,360) have 
demonstrated a protective role for the NO-sGC-cGMP pathway in protecting against 
liver IR injury. Moreover, direct liver ischaemic preconditioning preceding liver IR 
(IPC + IR) significantly elevates cGMP levels compared to sham and IR alone 
(279).  
 
In this study it was demonstrated that hepatic MBF during liver reperfusion is 
significantly reduced in the ODQ + RIPC + IR compared to the RIPC + IR group. 
Considering that sGC possesses high affinity for NO (392) and that the only known 
end product of sGC catalysis is cGMP, then these results suggest hindlimb RIPC 
acts through NO and the sGC-cGMP pathway to maintain hepatic MBF during the 2 
hour reperfusion time period following liver ischaemia. In support of these results, a 
previous study showed that intraportal administration of the cGMP analogue 8-Br-
cGMP for 30 minutes immediately prior to and following liver ischaemia in pigs 
results in a significant improvement in hepatic MBF, compared to control animals 
that received intraportal saline, as measured by LDF during 3 hours of liver 
reperfusion following 60 minutes of hepatic ischaemia (398).  
 
In conclusion the sGC-cGMP pathway contributes to mediating the protective 
effects of hindlimb RIPC on liver IR injury. However, other pathways are probably 
involved as the protection exhibited by sGC-cGMP was incomplete. Additionally, 
the hindlimb RIPC-induced sGC-cGMP pathway preserves the hepatic MBF during 
the reperfusion period following liver ischaemia.     
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Chapter 9 
Thesis discussion, conclusions, and future directions 
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9.1 Methodological considerations 
9.1.1 The experimental model 
Understanding the molecular mechanisms that underpin the protective effects of 
RIPC on liver IR injury will facilitate the design of pharmacological interventions 
that mimic the beneficial effects of RIPC. Animal models of liver IR injury offer 
standardised reproducible experimental strategies in which to dissect the molecular 
pathways mediating the beneficial effects of RIPC.  
 
Experimental work using mice offers many advantages over the use of other animal 
species. The most important of these is the commercial availability of numerous 
transgenic strains that no other species offer. In addition mice reproduce quickly, are 
easy to maintain, and the mouse genome has many similarities to the human genome 
(399). For example, the mouse genome contains 2.5Gb whilst that of humans 
contain 2.9Gb; 40% of the human genome can be aligned to the mouse genome at 
the nucleotide level; both human and mouse genome contain 30000 genes each; and 
the proportion of mouse genes with a single identifiable orthologue in the human 
genome is approximately 80%, and the proportion of mouse genes without any 
homologue currently detectable in the human genome (and vice versa) seems to be 
less than 1%  (399). The use of mice in research may also present disadvantages 
including the small size and therefore small circulating and solid tissue volumes; the 
cost which is strain-dependent; and breeding difficulty and high mortality seen in 
some strains.       
 
In this thesis inbred C57BL/6 wild type and eNOS-/- mice were used. C57BL/6 mice 
are the commonest ‘control’ strain used in medical research. eNOS-/- mice have been 
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generated that had disruption to each of the four alleles found in the mouse eNOS 
gene (307,400-402). The eNOS-/- mice used in this research were originally 
produced as an F1 hybrid between SV129 and C57BL/6 (307), with all subsequent 
matings and generations conducted as SV129/BLK6 x SV129/BLK6 homozygotes 
in a closed colony.   
 
The liver ischaemic model used in this thesis is well established and involves 
clamping the portal triad supplying the left and median lobes, rendering 
approximately 70% of the liver ischaemic. This partial hepatic ischaemia prevents 
mesenteric venous congestion and subsequent intestinal mucosal damage leading to 
bacterial translocation across the intestinal wall by permitting portal decompression 
through the caudate and right lobes of the liver (308-310). A disadvantage of partial 
hepatic ischaemia is that it does not accurately mimic clinical total hepatic ischaemia 
following performance of the Pringle manoeuvre during liver resections; or the total 
hepatic ischaemia livers are subjected to during transplantation. Animals poorly 
tolerate ischaemia to the whole liver. For example 30 minutes of total hepatic 
ischaemia in rabbits results in cardiac arrest due to metabolic acidosis (403). An 
alternative would have been a liver transplant model. However, such a model would 
have involved cold ischaemic injury to the liver, the molecular pathways of which 
differ from those mediating normothermic ischaemia. Moreover, liver 
transplantation in the mouse is technically very demanding, and all transplantation 
models involve denervation of the liver and may involve immunologically-mediated 
damage to donor livers once implanted in recipients; factors that could significantly 
influence the results of the endpoints assessed in this thesis.  
 
 222 
An invasive hindlimb RIPC protocol involving open clamping of the femoral vessels 
was used based on the findings of the preliminary experiments that demonstrated 
non-invasive hindlimb RIPC resulted in hindlimb neuro-muscular bruising and 
paralysis. In contrast direct clamping of femoral vessels did not lead to any 
complications. Hence the decision was taken to adopt the open clamping technique. 
The other main advantage of the open method of femoral vessel occlusion is the 
ability to induce hindlimb ischaemia in every animal at exactly the same position on 
the thigh. In comparison it would be difficult to control the precise position of non-
invasive techniques, such as the use of finger pressure or tourniquet to induce 
hindlimb ischaemia. Furthermore some non-invasive methods such as finger 
pressure or elastic bands may induce variable and unreliable pressures during vessel 
occlusion. The clinical applicability of the open clamping method to perform 
hindlimb RIPC in humans prior to liver resection or transplantation is limited as it is 
very unlikely femoral vessel dissection and direct clamping would be done for the 
sole purpose of preconditioning. In contrast, non-invasive techniques of femoral 
vessel occlusion may have better clinical applications in inducing hindlimb 
ischaemia. However, the gist of using an invasive technique in this thesis was to 
establish a well-controlled and validated animal model to be used for studying the 
mechanisms underlying the protective effects of RIPC on liver IR injury.    
 
A total of 142 mice were used for this thesis. This number consisted of 113 animals 
that were used successfully in the experimental protocols. The remaining 29 animals 
used did not contribute to the experimental results as these either died during the 
experimental procedure, or sustained a complication such as perforation of the colon 
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from the rectal temperature probe or vessel damage from intravenous drug 
administration.  
 
9.1.2 Liver enzymes 
The liver is responsible for multiple metabolic and excretory pathways and 
consequently a single method of quantifying liver function is not possible. To fully 
assess the state of health of the liver would entail measurement of all the various 
functions performed by the liver, in addition to assessment of markers of liver 
injury. True liver function tests would entail measurement of the synthetic function 
of the liver such as serum levels of albumin and clotting factors; and measurement 
of the liver’s excretory function such as indocyanine green clearance and rate of urea 
formation. Furthermore, the physiological reserve of the liver allows it to sustain 
severe damage with only minimal metabolic derangement.      
 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are released 
into the circulation from damaged hepatocytes, where both enzymes are found in the 
cytoplasm. The degree of release of these enzymes into the circulation correlates 
with length of the ischaemic insult and subsequent liver injury (404-407). ALT is 
very specific for hepatocyte damage whilst AST is also released from many other 
tissue types such as cardiomyocytes, skeletal myocytes, and erythrocytes. Serum 
levels of both these enzymes reflect the integrity of the plasma membrane as well as 
the proportion of parenchymal cells affected. Therefore these enzymes are a measure 
of liver damage rather than liver function per se. Our results showed that WT 
animals had greater ALT and AST levels compared to eNOS-/- mice. This may 
reflect different sensitivity to IR injury between the two groups, but this would 
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require further research to clarify, especially as this thesis concentrated on the 
benefits or otherwise of RIPC in each species.     
 
9.1.3 Histopathology 
In this thesis two semi-quantitative injury grading scales were used; an overall score 
and scores of individual features of liver IR injury. The specific criteria in each of 
the scales has been described and used multiple times in various publications 
(81,294,302,312,313). A liver histopathologist performed the scoring whilst 
unaware of the animal grouping. This histological assessment of liver sections 
allows objective appraisal of ischaemically damaged tissue. However the main 
disadvantage of using such a technique at 2 hours of reperfusion is that lethally 
damaged cells may appear relatively intact at this early stage, and hence significant 
differences between the animal groups were frequently lacking despite 
demonstrating a trend. Ideally the histological assessment should have been 
performed at 8 to 48 hours of reperfusion.    
 
9.1.4 Transmission electron microscopy 
Transmission electron microscopy (TEM) facilitates assessment of structural 
damage to subcellular structures. Unlike histopathological damage to whole cells, 
which is not usually manifested during the early phase of reperfusion injury; damage 
to subcellular organelles of a cell is seen during the early phase of reperfusion, 
however the extent of such damage is organelle-dependent. For example nuclear 
damage manifests at a much later point in time compared to mitochondrial damage. 
Some ultrastructural appearances are indicative of biochemical processes within a 
cell. For example in chapter 5 the observation that some of the endoplasmic 
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reticulum (ER) within hepatocytes exhibited condensation was indicative of lipid 
peroxidation damage to the membranous structure of ER. 
 
The assessment of the degree of ultrastructural damage on TEM was performed by a 
TEM scientist who was blinded to the animal groups. TEM may be best used for 
qualitative rather than quantitative damage appraisal. This is because it is very 
difficult to process and assess a whole section of a liver lobe for TEM. However 
sampling errors that could be introduced if a single liver biopsy was processed for 
TEM were minimized by performing multiple biopsies from different regions of the 
left liver lobe in each animal.          
    
9.1.5 Laser Doppler flowmetry 
Laser Doppler flowmetry (LDF) was used to: 1. quantify hepatic microcirculatory 
blood flow (MBF); 2. ensure adequate blood flow disruption during hindlimb 
ischaemia with adequate blood reperfusion during the preconditioning protocol. 
There is good evidence that hepatic IR injury results from altered MBF secondary to 
damage of the liver microvasculature (408-410). Moreover hepatic MBF alterations 
following reperfusion in liver transplant recipients directly correlate with the 
maximum postoperative AST levels (411). Changes in hepatic MBF following IR 
have also been shown to be useful in predicting the severity of liver IR injury (412).        
 
Liver IR injury results in multiple consequences for the microcirculation that include 
Kupffer cell and sinusoidal endothelial cell swelling (25,26), an increase in the 
vasoconstrictors endothelin (27) and thromboxane A2 (28), and a decrease in the 
vasodilator nitric oxide (29). These effects combine to cause sinusoidal narrowing. 
 226 
In addition, on reperfusion there is increased adhesion and aggregation of 
neutrophils and platelets in the sinusoids; with the end result being a significant 
reduction in MBF on reperfusion (30). LDF is a reliable optical technique for the 
assessment of hepatic microcirculation and provides continuous measurements of 
blood flow in the sinusoids, arterioles, and venules (317). The wavelength of the 
laser used was 785nm which measured MBF at a sampling rate of 1 Hz in tissue 
volumes of 0.6-2.3 mm3. This penetration range of the LDF laser is considered 
sufficient to study MBF in a liver lobe with a maximum thickness of 4 mm. LDF 
does not measure MBF in the liver as a whole. This would be ideal; however, the 
positioning of the LDF probe on a fixed site of the liver surface permits the 
continuous measurement of MBF throughout the experimental procedure at that 
point which reflects the relative changes in MBF occurring elsewhere in the liver 
lobes subjected to IR. We previously studied intersite variability of LDF 
measurements and found a co-efficient of variation of ∼ 4% (413). This suggested 
that a single point to assess hepatic MBF satisfactorily reflects the MBF in the rest 
of the affected lobe. The mean relative percentage alteration in liver MBF compared 
to baseline (which was taken as 100% in each experiment); and to the other animal 
groups as a percentage of baseline at each time point was quantified. Relative 
changes in MBF are more important than absolute values in these experiments as 
they reflect the consequences of each intervention on the liver microcirculation.  
 
The use of LDF to assess the dynamic changes in the liver microcirculation of the 
mouse presents few challenges. One being motion artefact. Vibration and other 
movements of the LDF probe cause artefact signals on the laser Doppler monitor. In 
addition respiratory movements in the mouse may lead to liver movements. 
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However, these were considerably reduced by sufficient mobilisation of the liver to 
avoid diaphragmatic movements; and by positioning the probe loosely in a solid 
plastic tubing (held firmly in place by a clamp) with the laser emitting end 
protruding through the plastic tube and being loosely in contact with the surface of 
the liver, allowing the probe to move with any slight movement of the liver.          
 
9.1.6 Nitrite and nitrate studies 
Nitric oxide (NO) is a free radical molecule and therefore is highly unstable. The 
transient and volatile nature of NO means it is rapidly oxidised to nitrite and nitrate 
(NOx), the commonest stable end products of in vivo NO reactivity. The 
concentration of NOx is commonly used as a quantitative measure of NO production 
in vivo (414). Moreover both nitrite and nitrate are reduced to NO, a process that is 
accelerated in the hypoxic and acidotic liver environment (375,386) during IR. 
Therefore nitrite and nitrate act as circulating stable reservoirs of NO. A colorimetric 
assay kit was used to measure plasma NOx levels. This kit is well established, of 
proven efficacy, and has been used numerous times in the published literature 
(415,416).   
 
Exogenous sodium nitrite was administered to eNOS-/- mice with the expectation 
that this would ameliorate liver IR injury. The dose and timing of the administered 
nitrite was based on those previously shown to significantly reduce liver IR injury in 
mice (167,302). However, no protection was elicited. This could be due to any one 
of multiple reasons discussed in chapter 7, and would entail the need for further 
dosing studies to determine the accurateness of the results described in previous 
studies.  
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9.1.7 Assessment of the sGC-cGMP pathway 
The specific soluble guanylyl cyclase (sGC) blocker ODQ has been used numerous 
times in the published literature in vivo studies (256,302). ODQ interacts with the 
iron of haem prosthetic groups and therefore would bind to haemoglobin in the 
circulation and restrict its effectiveness when administered intravenously (389). 
However, topical administration to the liver as was done in chapter 8 circumvents 
the problem of the interaction between ODQ and haemoglobin. An enzyme 
immunoassay was used to measure cyclic GMP (cGMP) in liver samples. This 
technique is well established, of proven efficacy, and is well described in the 
published literature (256,279). 
 
9.2. Summary of the thesis’s findings  
The aim of the thesis was to establish a mouse model of hindlimb RIPC that protects 
against liver IR injury, and subsequently to use this model to evaluate the role of the 
NO pathway in this protection.  
 
In chapter 4 a model of hindlimb RIPC that protects against liver IR injury was 
established and validated in wild type mice. This model used open clamping of the 
femoral vessels to induce hindlimb RIPC rather than a tourniquet technique as the 
latter resulted in damage to the neuro-muscular structures in the limb. In contrast the 
open method had no side effects. This mouse model of limb RIPC significantly 
reduced liver IR injury and preserved hepatic MBF during the 2 hour liver 
reperfusion period. 
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In chapter 5 the NO scavenger C-PTIO was administered to wild type mice, and as a 
consequence the protective effects of hindlimb RIPC against liver IR injury 
disappeared. In addition, the C-PTIO + RIPC + IR group exhibited significantly 
lower hepatic MBF measurements, during the 2 hour liver reperfusion, compared to 
the RIPC + IR group. These findings indicated NO mediated the protective effects of 
limb RIPC against liver IR injury.  
 
In chapter 6 eNOS-/- mice were used. The protection that had been exhibited by 
RIPC in wild type mice disappeared in eNOS-/- mice. Furthermore eNOS-/- mice did 
not demonstrate any benefit of limb RIPC on hepatic MBF, which is in contrast to 
the protective effects of limb RIPC on hepatic MBF observed in wild type mice. 
Liver and hindlimb skeletal muscle eNOS Western blots demonstrated equal protein 
expression amongst the various animal groups. eNOS immunohistochemistry 
showed eNOS was expressed in hepatocytes and the vascular endothelium within 
the liver; whilst within the hindlimb eNOS was expressed in skeletal myocytes and 
the vascular endothelium. Liver and hindlimb skeletal muscle iNOS Western blots 
showed protein expression only in the RIPC and RIPC + IR groups. Taken together 
these results indicated that eNOS is essential for the protective effects of limb RIPC 
on liver IR injury, and it is likely at 2 hours of liver reperfusion this protection is due 
to increased activation of eNOS rather than increased expression of this enzyme. 
Additionally there is increased expression of iNOS in preconditioned groups, which 
may be contributing to the protection of RIPC but this needs further research to 
prove.  
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In chapter 7 the initial experiments were performed on wild type mice to measure 
plasma nitrite and nitrate concentrations. The results showed hindlimb RIPC alone 
significantly increased plasma NOx levels compared to the sham group; and RIPC + 
IR significantly elevated plasma NOx compared to the IR and sham groups. Based 
on these results, the effects of exogenous nitrite on liver IR injury in eNOS-/- mice 
were assessed, and were found not to protect the liver against IR injury. The dose, 
route, and time of administration of the exogenous nitrite were based on previous 
published studies that administered nitrite to mice subjected to liver IR as discussed 
in chapter 7. Therefore, further nitrite dosing studies using the mouse model we 
describe in this thesis are needed to clarify what beneficial effects, if any, exogenous 
nitrite may have on liver IR injury.               
 
In chapter 8 the sGC inhibitor ODQ was administered to wild type mice. The results 
showed the ODQ + RIPC + IR group sustained a non-significant increase in liver IR 
injury compared to the RIPC + IR group. However, hepatic MBF was significantly 
decreased during the 2 hour liver reperfusion period in the ODQ + RIPC + IR 
compared to the RIPC + IR group. Quantification of hepatic cGMP levels showed a 
significant increase of this second messenger in the RIPC compared to the sham 
group; but there was no significant difference between the IR and RIPC + IR groups. 
Taken together these results suggested that in the context of hindlimb RIPC, NO is 
likely to exert its protective effects against liver IR injury at least partially through 
the hepatic sGC-cGMP pathway. In addition NO may also be acting through a 
second different pathway to exert its protective effects and further research is 
warranted to identify other pathways that NO may be acting through.     
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9.3 Overall conclusions arising from thesis and future directions 
The major conclusions drawn from this study were: 
1. Hindlimb ischaemic preconditioning significantly attenuates liver IR injury in the 
mouse. In contrast to the tourniquet method, the invasive technique of inducing 
hindlimb ischaemia does not result in neuromuscular bruising and paralysis. 
2. eNOS-derived NO mediates the protective effects of hindlimb RIPC on liver IR 
injury.  
3. Circulating levels of nitrite and nitrate increase as a consequence of hindlimb 
RIPC. These circulating molecules are end products of NO oxidation and are 
associated with hepato-protection against liver IR injury.  
4. The hepatic sGC-cGMP pathway is at least partially responsible for mediating the 
protective effects of hindlimb RIPC on liver IR injury.    
5. Hindlimb RIPC, acting through NO, preserves hepatic MBF during liver 
reperfusion following liver ischaemia.  
 
The above conclusions support the hypothesis of this thesis. The findings are 
applicable to the early reperfusion period as all the experiments, with the exception 
of the survival studies in chapter 4, were performed with a reperfusion period of 2 
hours. The potential clinical applications of the findings arising from this thesis are 
two fold. Firstly, whilst it maybe clinically unethical to use an open technique of 
femoral vessel clamping for the sole purpose of hindlimb preconditioning preceding 
either liver surgery performed with the Pringle manoeuvre or liver transplantation; it 
would be acceptable clinically to use a non-invasive technique, such as a tourniquet, 
to induce hindlimb preconditioning. Secondly, and perhaps more pertinently, the 
new mouse model described in this thesis was designed with the main aim of having 
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a validated and robust animal model to study the mechanisms underlying the 
protective effects of RIPC. This would then facilitate the development of 
pharmacological agents that mimic the beneficial effects of hindlimb RIPC.  
 
Although clinical non-invasive hindlimb RIPC would be simple to implement prior 
to liver surgery or transplantation; a number of legitimate concerns may arise from 
the use of this technique on humans such as safety of RIPC in diseased hindlimbs 
(e.g. peripheral arterial disease, diabetics), and the potential effect of RIPC on 
diseased livers (e.g. cirrhotic livers, fatty livers, post chemotherapy). The other 
major issues would be the optimal preconditioning protocol in humans and the time 
interval between RIPC and the beginning of surgery. An additional point of 
contention in liver transplantation would be whether maximal benefits are obtained 
by preconditioning the donor, the recipient, or both. All these issues would require 
well designed randomized clinical trials for worthwhile answers.  
 
Based on the finding of this thesis potential therapeutic pharmacological strategies 
may aim to increase NO availability through the up-regulation of eNOS, an increase 
in endogenous nitrite and nitrate concentrations, up-regulation or decreased 
degradation of sGC-cGMP, or through the use of NO donors. An additional strategy 
may aim at mechanisms to preserve the hepatic microvasculature as MBF 
significantly decreases with liver IR and is preserved with hindlimb RIPC through 
an action involving eNOS and NO. These potential avenues for targeted drug 
development would entail significant scientific research.                
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Many questions have arisen as a result of the research findings in this thesis. The 
findings of this study are applicable to the early phase of IR injury as the 
experiments were performed with a reperfusion period of 2 hours. Future research 
needs to analyse the effects of RIPC during the late phase of IR injury as well as the 
role eNOS-derived NO plays during the late phase. Additionally the exact 
contribution of hindlimb versus liver eNOS to the protection elicited by RIPC needs 
further clarification. The most precise and scientifically-valid method of conquering 
this would be to use tissue-specific knockout mice that selectively lack the eNOS 
gene in the liver or hindlimb. In the present study iNOS expression in the liver and 
hindlimb skeletal muscle was faintly up-regulated at 2 hours of reperfusion. To 
further shed light on the role of iNOS in RIPC future research could utilize iNOS-/- 
animals in both early and late phase IR injury. The effects of RIPC probably 
represent a systemic phenomenon with cross-talk between different organs. For 
example is it possible that hindlimb RIPC up-regulates eNOS and / or iNOS in non-
hepatic organs such as the heart or the kidney, which subsequently amplify the 
protection exhibited by the liver? Could preconditioning the hindlimb act as the 
triggering signal that initiates multi-organ protection with positive feedback loops 
between the organs? These questions remain unanswered.  
 
It is now clear that disturbances to the microvasculature of the liver may represent a 
key mechanism through which IR injury acts to damage the liver. In this study it was 
demonstrated hindlimb RIPC significantly preserves the hepatic microvasculature 
and eNOS-derived NO plays a crucial role in this. Furthermore, preservation of liver 
MBF is associated with a significant reduction in liver IR injury. Previous work 
using intravital microscopy has shown hindlimb RIPC significantly increases liver 
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sinusoidal RBC velocity, sinusoidal blood flow, and the ratio of perfused hepatic 
sinusoids during the early phase (3 hours of reperfusion) of liver IR injury (229). 
The long term benefits or otherwise, of hindlimb RIPC on liver IR injury, may well 
depend on the long term effects of RIPC on hepatic microvascular perfusion. 
Therefore long term recovery studies (e.g. up to 28 days) using wild type and eNOS-
/-
 mice supplemented with NO donors, and using techniques such as LDF and 
intravital microscopy, would be valuable in assessing the hepatic microvasculature. 
 
Finally, RIPC offers a systematic means of protection against liver IR injury. Our 
understanding of the pathways mediating the protective effects of this phenomenon 
is increasing. It is hoped, with the culmination of enough knowledge about RIPC, 
mechanistic and / or pharmacological therapeutic strategies will eventually be 
developed and used in the clinical setting of liver resections and transplantation.    
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